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Abstract 
Maintenance of T cell tolerance to self-antigens is crucial to prevent immune 
responses against our own tissue, which can result in autoimmune pathology. 
Experimentally, the outcome of an immune response can depend on the form in 
which the antigen is administered. Systemic administration of soluble antigen results 
in antigen-specific T cell tolerance, while administration of the same antigen in 
conjunction with an adjuvant leads to T cell immunity. Both tolerance and immunity 
involve some degree of T cell activation, a process in which costimulatory receptor-
ligand pairs on T cells and dendritic cells (DC) are of crucial importance. Tolerance 
induction is thought to be the result of peptide presentation by resting DC, which are 
lacking full costimulatory potential. The precise signals that drive a T cell towards 
tolerance, rather than a productive immune response, are not well defined. This 
project has addressed this issue by asking three questions: 
Can exogenous ligation of defined costimulatory receptors convert a tolerogenic 
signal into an immunogenic one? 
How does expression of CD154, 0X40 and RANKL on T cells, and CD40, 
OX40L and RANK on DC differ during induction of T cell tolerance versus T cell 
immunity? 
Do T cells become tolerant on exposure to antigen-loaded DC lacking CD40? 
- It was found that agonistic antibodies to CD40 and 0X40 overcame a tolerogenic 
signal, and prevented the induction of tolerance. CD154, 0X40 and RANKL were 
expressed on T cells under conditions leading to either tolerance or immunity. Up-
regulationlinduction of CD40, OX40L and RANK on DC, however, was only 
observed during the induction of T cell immunity. The administration of antigen-
loaded CD40-deficient DC mimicked tolerance induced by soluble peptide. 
Collectively, the results suggest that the CD40-CD154 interaction provides an 
important checkpoint in the decision between T cell tolerance and immunity. 
Investigating the process of tolerance induction may provide a rational basis for 
therapeutic targeting of costimulatory pairs in adverse immune reactions in humans. 
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1. CHAPTER 1- Introduction 
1.1. T cell activation 
T cells are a subset of lymphocytes defined by their development in the thymus and 
by heterodimeric receptors on their surface. T cells bearing the a, 13 T cell receptor 
(TCR) can broadly be divided into CD4 and CD8 T cells, according to their 
selective expression of these co-receptors (Davis and Bjorkrnan, 1988). This 
introduction concentrates on CD4, so—called T helper (Th) cells. CD4 T cells 
require three signals for effective activation (Kalinski et al., 1999), which are 
illustrated in Fig. 1 .1. 
1.1.1. Signals 1, 2 and 3 lead to effective T cell activation 
The first signal required for T cell activation consists of TCR binding to peptide-
MHC complexes displayed on the surface on antigen presenting cells (APC). The 
expression of CD4 restricts CD4 T cells to recognition of processed peptides bound 
to MHC class II molecules (Guermonprez et al., 2002). Although B cells and 
macrophages also express MHC class II complexes and are able to activate naïve 
CD4 T cells in vitro (Askew et al., 1995; Cassell and Schwartz, 1994), dendritic 
cells (DC) are the only MHC class II expressing cell type in the T cell areas of the 
lymph node (LN) (Steinman et al., 1997). DC are the initiating APC for primary 
immune response in vivo (Banchereau and Steinman, 1998; Steinman, 1991), and 
they are thus referred to as professional APC (Lassila et al., 1988). They efficiently 
take up protein, which is processed to peptides, and these processed peptides are 
loaded onto MHC class II molecules for recognition by the TCR. 
The second signal required for effective T cell activation is delivered through a 
variety of costimulatory molecules found on DC and T cells. Although costimulation 
can simply promote more efficient engagement of TCR molecules to enhance the 
initial activation, it has become clear that it also serves to provide additional signals 
leading to cell division, augmented cell survival or induction of effector functions In 
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the last decade, an increasing number of costimulatory receptor-ligand pairs have 
been discovered, revealing the complexity of signalling involved in the regulation of 
T cell expansion, contraction, and inactivation. These can be divided into two main 
groups, the immunoglobulin (Ig) superfamily, including CD28, PD-I and ICOS; and 
the TNF receptor (TNFR) superfamily, including CD40, 0X40 and RANK, both of 
which will be introduced in more detail in section 1.2. These receptor-ligand pairs 
are shown in Fig. 1.2, although it is important to emphasize that this is only a 
summary and not an exhaustive list of the molecules with costimulatory activity. 
Finally, signal 3 plays a role in directing the effector functions of T cells. The 
paradigm is that naïve (ThO) cells differentiate predominantly into effector ThI or 
Th2 cells, which are defined by the cytokines secreted during the immune response 
(Mosmann and Coffman, 1989). The Thl-Th2 divergence is influenced by a variety 
of factors, including the cytokine environment present at the initiation of the immune 
response, the antigen (Ag) dose, and the presence of costimulatory molecules 
(Constant and Bottomly, 1997). The presence of interleukin-12 (IL-12) drives 
development of Thi cells that secrete the pro-inflammatory cytokines interferon-y 
(IFN-y) and tumour necrosis factor cX113 (TNF-(x/3), principally in response to 
intracellular pathogens. Th2 cells secrete IL-4, IL-5 and IL-13 and initiate antibody 
production, generally against extracellular pathogens. All three signals are regulated 
through the information DC receive at the site of Ag exposure, via expression of 
'pattern-recognition receptors', such as Toll-like receptors (TLR). In this way, DC 
exert control over the outcome of the immune response. The change from an Ag-
capturing to an Ag-presenting, T-cell-priming mode, coupled with the expression of 
the necessary costimulatory molecules and cytokines, allows DC to initiate, the 
appropriate adaptive immune response. 
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1.1.2. Experimental Autoimmune Encephalomyelitis as a 
model of T cell-driven autoimmunity 
Experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis, 
is an autoimmune disease that is driven by CD4 T cells specific for components of 
the central nervous system (CNS) myelin sheath. These cells traffic to the CNS 
parenchyma, resulting in focal areas of inflammation and demyelination throughout 
the CNS (Martin and McFarland, 1995). EAE can be induced in mice by active 
immunization with complete Freund's adjuvant (CFA) mixed with CNS auto-Ag, 
notably myelin basic protein (MBP) (Anderton and Wraith, 1998; Zamvil et al., 
1985), proteolipid protein (PLP) (Anderton and Wraith, 1998) and myelin 
oligodendrocyte glycoprotein (MOG) (Mendel et al., 1995), or by the adoptive 
transfer of MBP-reactive T cells (Lafaille et al., 1997; Zamvil et al.). Central to the 
aetiology of most experimental autoimmune models is the activation of CD4 T cells 
of the Thi functional phenotype, and the CD4 T cell lines and clones that transfer 
EAE invariably produce IFN-y and/or, TNF-a/13 on antigenic challenge in vitro 
(Ando et al., 1989; Powell et al., 1990). Immunodominant T cell epitopes within 
myelin auto-Ag have been defined, allowing EAE induction with peptide Ag. The 
35-55 peptide of MOG (pMOG) has been shown to cause EAE in H2b  mice (Mendel 
et al., 1995; Mendel et al., 1996). Since a number of knockout mice are available on 
the H2b  background, including CD40- and CD 154-deficient mice, EAE provides a 
good model to study the importance of these costimulatory molecules in a disease 
setting. 
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1.2. The molecular basis of costimulation 
A large number of costimulatory receptor-ligand pairs have been identified, some of 
which are shown in Fig. 1.2. The molecules shown are expressed at various stages 
during the immune response. Although some redundancy exists, the requirements for 
many of these molecular interactions probably reflects a need for different signals at 
different times and stages during the immune response. In addition to allowing 
development of alternative effector functions or creation of long-lasting immunity, 
this provides a number of checkpoints during T cell activation, which may serve to 
control the final outcome of an immune response. 
1.2.1. Members of the immunoglobulin superfamily 
Although a large number of costimulatory molecules are expressed after TCR 
ligation, some are found constitutively expressed on naïve T cells, and are thus 
considered especially important during the early stages of T cell activation. One such 
molecule is CD28, a member of the Ig superfamily, which is constitutively expressed 
on naïve T cells (Linsley and Ledbetter, 1993). CD28 binds to CD80 or CD86, found 
at low levels on resting DC, and upregulated on activated, mature DC (Banchereau et 
al., 2000). CD28 engagement can enhance T cell proliferation (Jenkins et al., 1991), 
cytokine secretion (Jenkins et al., 1991), and expression of anti-apoptotic molecules 
such as Bcl-xL (Boiseet al., 1995). Experiments using CD28-deficient T cells clearly 
show that CD28 is required for initial T cell prolifeation in vivo (Howland et al., 
2000). CD28-deficient mice show reduced Th2 responses with defective 
immunoglobulin class switching, but normal cytotoxic T cell responses, indicating 
differential requirements in the activation of helper or cytotoxic T cells (Shahinian et 
al., 1993). 
Another receptor for CD80 and CD86 is expressed by both CD4 and CD8 T cells 
after activation, namely cytotoxic T lymphocyte Ag-4 (CTLA-4). CTLA-4 is a close 
homologue of CD28, and an important negative regulator of T cell responses. It 
binds CD80 and CD86 with 20-50-fold higher affinity than CD28, and is thought to 
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deliver a negative signal to the T cell (Oosterwegel etal., 1999), thus downregulating 
T cell responses after initial activation. CTLA-4 deficient mice develop fatal 
lymphOproliferative disease with multiorgan tissue destruction, illustrating the 
critical ro!e of CTLA-4 in moderating T cell activation and maintaining peripheral 
self-tolerance (Tivol et al., 1995). 
Other costimulatory molecules with negative effects on T ccll activation have 
recent!y been described, including Programmed Death-I (PD-I), which binds to 
Programmed Death Ligand 1 and 2 (PD-Li and PD-L2), also members of the Ig 
superfamily. PD-I is expressed on activated T and B cells, as well as myeloid cells 
(Agata et al., 1996). PD-Li is constitutively expressed on naïve T cells, B cells, 
macrophages and DC, is upregulated on T cells, macrophages and DC after 
activation (Liang et al., 2003), and has also been found in non-lymphoid organs such 
as heart, placenta, lung and pancreas (Liang et al., 2003). In contrast, PD-L2 was 
only inducible on macrophages and DC after cytokine stimulation (Yamazaki et al., 
2002). Ligation of PD-I by both PD-LI and PD-L2 inhibits T cell activation 
(Khoury and Sayegh, 2004). Blocking PD-i worsens EAE induced by immunisation 
with pMOG in CFA (Salama et al., 2003), and PD-i-deficient mice develop multiple 
autoimmune diseases (Nishimura et al., 1999; Nishimura et al., 2001), suggesting a 
possible role for PD-i in controlling the activation of autoreactive T cells. 
ICOS, a third member of the Ig superfamily family, is expressed on activated but not 
naïve T cell (Hutloff et al., 1999). ICOS binds to 137h, which is constitutively 
expressed on B cells, some macrophages and DC (Sharpe and Freeman, 2002.;. 
Yoshinaga et al., 1999). Experiments with ICOS-deficient T cells indicate that the 
ICOS-B7h interaction plays a role in T cell activation and proliferation in vitro. In 
vivo, it is essential for germinal centre formation (Dong and Nurieva, 2003), and a 
lack of ICOS has an effect on Th2, but not Thi development (Dong and Nurieva, 
2003). ICOS thus appears to be less crucial for in vivo T cell activation, but more 
important for fine-tuning effector T cell differentiation and function. 
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1.2.2. TNF/TNFR family members 
The TNFR-TNF superfamily consists of an increasing number of molecules, many of 
which have been reported to play a role at various stages in the activation of T cells. 
The TNFR family members are type I transmembrane proteins, and are believed to 
exist either as monomers or as self-assembled oligomers, forming trimeric signalling 
complexes when interacting with their ligand. The ligands are members of the TNF 
family, which are type II transmembrane proteins, and thought to be expressed as 
trimers on the cell surface. Although some redundancy exists between members of 
these families, knockout studies show specific functions for most of the molecules, 
which cannot be compensated for by other members of the family. Most accounts of 
TNR and TNFR-family members take the simplistic view that one molecule is 
expressed by T cells, while its molecular partner is expressed by APC. Interestingly, 
in some cases, both receptor and ligand can be expressed by T cells (Croft, 2003). 
Although it is not known whether this occurs generally in vivo, it might indicate a 
potential role for TNFR-TNF-family interactions in communication between T cells, 
amplifying signals that were initiated by APC. However, this project concentrates on 
DC-T cell interactions, and expression of these molecules will be discussed with 
respect to receptor-ligand expression on these two cell types. The three receptor-
ligand pairs of particular relevance to this project are described in further detail 
below. 
The CD40-CD154 interaction 
The CD40-CD 154 interaction has been known to be crucial in the initiation of T cell 
immunity for some time (Grewal and Flavell, 1998). The gene encoding CD154 is 
found on the X chromosome in both humans and mice. Mutations in the CD154 gene 
result in the X-linked hyper-IgM syndrome in humans (Notarangelo and Peitsch, 
1996; Villa et al., 1994). CD40-deficient mice have significant defects in thymus-
dependent T cell responses, failing to form germinal centres and showing defects in 
immunoglobulin class switching (Castigli et al., 1994; Kawabe et al., 1994), while 
CD154-deficient mice similarly fail to form germinal centres and show decreased 
antibody responses (Grewal et al., 1995; Xu et al., 1994). Early reports suggested 
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that CD154' T cells fail to prime in vivo (Grewal et al., 1996), but more recently, it 
was shown that CD 154' T cells become activated, but are unable to sustain a 
response in vivo, and are defective in ThI development in vitro (Howland et at., 
2000). Mice deficient for CD40 or CD154 fail to develop EAE (Grewal et at., 1996; 
Grewal et al., 1995), and mice lacking expression of CD40 in the CNS similarly do 
not develop symptoms of EAE (Becher et al., 2001). Blocking the CD40-CD154 
interaction prevents the induction of EAE (Gerritse et al., 1996; Laman et al., 2002; 
Samoilova et al., 1997), while agonistic anti-CD40 monoclonal antibody (mAb) 
potentiates EAE (Ichikawa et al., 2002), further illustrating the importance of the 
CD40-CD 154 interaction in T cell priming. 
CD40 is found at low levels on resting APC, and is upregulated after APC activation 
(Celia et al., 1997; Inaba et at., 1994; Vremec and Shortman, 1997), whereas CD154 
is transiently induced on naïve T cells after TCR stimulation (Roy et al., 1993). 
Splenic CD4 T cells show CD 154 expression 4 hrs after in vitro anti-CD3 
stimulation, which peaks between 6 and 8 hrs, and returns to resting levels between 
24 and 48 hrs (Roy et al., 1993). The CD40-CD154 interaction primarily signals to 
the APC, resulting in sustained activation of nuclear factor-icB (NF-icB) transcription 
factors (O'Sullivan and Thomas, 2002), which regulate DC differentiation and 
cytokine production. In culture, CD40 signalling results in increased expression of 
CD80 and CD86 (Caux et at., 1994), enhanced Ag presentation (Delamarre et at., 
2003; Machy et at., 2002) and IL-12 production (Celia et al., 1996; Koch et at., 
1996). CD40 signalling also enhances DC survival through upregutation of the 
survival molecule Bcl-2 (Bjorck et at., 1997). Although some evidence for CD154 
signalling into the T cell also exists (van Essen et al., 1995), the significance of this 
remains to be investigated. CD40 ligation on DC is a crucial trigger for IL-12 release 
and priming of a Thi type response (Cella et al., 1996; Koch et at., 1996), and the 
CD40-CD154 interaction synergises with IL-12 in selectively enhancing IFN-y 
production by T cells (Peng et at., 1996). In the absence of IL-12 release, a default 
Th2 type response is observed (Stuber et al., 1996). 
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While CD28 is required for the initiation of the T cell response, CD 154 is required 
for sustaining Thi responses (Howland et al., 2000). A soluble isoform of CD154 
has been found in T cell supernatants after, activation (Graf et al., 1995). Soluble 
CD 154 was also detected in human serum of individuals with systemic lupus 
erythematosus (Kato et al., 1999) and rheumatoid arthritis (Tamura et al., 2001), but 
the significance of soluble CD154 during T cell responses remains to be clarified. 
CD40 ligation delays clonal deletion of Ag-specific T cells and enhanced T cell 
clonal expansion in response to super-Ag (Maxwell et al., 1999). This may be due to 
de novo OX40L expression on DC, which is induced after CD40 ligation, and which 
signals to the T cell through 0X40 (Fillatreau and Gray, 2003). The importance of 
this interaction is further explained in the next section. 
As described above, CD40 and CDI54 are crucial for effective T cell activation in 
lymphoid organs. The CD40-CD154 interaction is however also important in the 
migration of DC from the periphery to the draining lymph node (DLN). The 
paracortical regions in DLN have been shown to be site of Ag-specific DC-T 
interaction (Ingulli et al., 1997). In CD154' mice, Ag-specific DC failed to migrate 
out of the skin and fewer DC accumulated in the DLN after contact sensitisation 
(Moodycliffe et al., 2000). This migratory defect was accompanied by a decrease in 
TNF-a. It appears that CD40 ligation of DC induces their migration out of the 
periphery, but that an important effect of CD40 ligation is TNF-a release by cells in 
the peripheral tissue displaying CD154 (Moodycliffe et al., 2000). These CD154-
displaying cells have not been identified yet, but possible candidates include mast 
cells and keratinocytes (Flores-Romo, 2001). 
Once in the DLN, the CD40-CD154 interaction is essential for DC longevity (Miga 
et al., 2001). Administration of blocking anti-CD154 antibodies accelerated 
disappearance of DC in the DLN, leading to a deficiency in sustaining T cell 
responses over a longer period of time (Miga et al., 2001), fitting with previous data 
that CD28 appeared to be the most important costimulatory molecule for initial T cell 
activation, while CD40 on DC was required for sustained T cell responses (Howland 
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et al., 2000). The CD40-CD154 interaction is, as a result, crucial for DC migration as 
well as T cell activation, and also appears to be important during effector T cell 
activation in the target organs later in the immune response (Becher et al., 2001; 
Grewal and Flavell, 1998). A model for the role of CD40-CD 154 in T cell function is 
shown in Fig. 1.3. 
The 0X40-OX40L interaction 
0X40 and OX40L-deficient mice have reduced primary CD4 T cell responses to 
common protein Ag, some viruses, and in contact-sensitivity reactions (Kopf et al., 
1999; Murata et al., 2000). OX40L-deficient mice also show reduced severity of 
EAE (Ndhlovu et al., 2001), and administration of a neutralising anti-OX40L Ab 
ameliorates EAE (Nohara et al., 2001; Weinberg et al., 1999). As with CD154, 0X40 
is not constitutively expressed on naïve T cells, but peaks in expression 3-4 days 
after initial activation signals. It is rapidly and highly re-expressed on effector T 
cells, and can be induced by TCR signals in the absence of CD28 (Akiba et al., 1999; 
Gramaglia et al., 1998; Nohara et al., 2001). Like CD28, 0X40 ligation promotes 
Bcl-xL and Bcl-2 expression in T cells and thus prolongs T cell survival (Rogers et 
al., 2001). This effect is illustrated in naïve CD4 T cell populations that are deficient 
in 0X40. The early proliferation in these T cells is not impaired, but marked 
apoptotic cell death occurs 4-5 days after T cell activation, resulting in lower 
frequencies of Ag-specific effector T cells being generated late in the primary 
response, and fewer T cells entering the memory pool (Gramaglia et al., 2000). 
Correspondingly, OX40L is expressed on DC many hours or days after DC 
activation (Ohshima et al., 1997; Rogers et al., 2001), and its induction is dependant 
on CD40 ligation (Fillatreau and Gray, 2003). These data indicate that the 0X40-
OX40L interaction is very likely to be important after the CD40-CD 154 interaction 
has taken place. 
Overexpression studies further reinforce the view that the 0X40-OX40L interaction 
provides late-acting signals that allow the survival of newly generated T effector 
cells. Transgenic expression of OX40L by DC (Brocker et al., 1999), or T cells 
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(Murata et al., 2002), increases the number of Ag-specific T cells and produces 
autoimmune-like symptoms, normally associated with aberrant T cell activation. 
Similarly, administration of agonistic antibodies for 0X40 after immunisation results 
in increased numbers of Ag-specific T cells, and an increased memory T cell 
population (Gramaglia et al., 2000). Although 0X40-deficiency had similar reducing 
effects on both CD4 and CD8 T cell responses, the primary effect of 0X40-
deficiency may be on CD4 T cells, which need to be "conditioned" in order to 
activate CD8 T cells (Bennett et al., 1998; Ridge et al., 1998). Analogous results in 
CD8 cells have been obtained in studies looking at the role of a different TNFR 
superfamily member in CD8 T cells, namely 4-IBB, suggesting a possible role for 
0X40 in CD4 T cells, and 4-1BB in CD8 T cells in some systems (Croft, 2003). 
However, some research also reports distinct roles for OX4OL, such as a requirement 
for OX40L on B cells for the induction of primary Th2 responses (Linton et al., 
2003), and expression of OX40L on a unique APC population, found at the T cell-B 
cell interface and in B cell follicles (Kim et al., 2003), which might provide co-
stimulatory signals to memory T cells over extended periods of time. A model for the 
role of 0X40-OX40L in T cell function is shown in Fig. 1.4. 
The RANK-RANKL interaction 
RANKL (receptor activator of NFiB ligand, also known as TRANCE, 
osteoprotegerin ligand, or osteoclast differentiation factor), is a recently described 
member of the TNF superfamily, that was discovered during attempts to clone novel 
genes involved in regulation of apoptosis and function of DC (Anderson et al., 1997; 
Wong et al., 1997) Its receptor is RANK, and this receptor-ligand pair displays 
remarkable sequence homology with CD154 and CD40 respectively (Anderson et al., 
1997). However, both RANK and RANKL-deficient mice have impaired lymph node 
organogenesis and increased bone density (Dougall et al., 1999; Kong et al., 1999), 
indicating these molecules have additional functions in organ development, as well 
as in the mature immune system. So far, no data exists with respect to RANK- or 
RANKL-deficient mice and their susceptibility to EAE. 
29 
Similar to CD 154, RANKL is expressed on T cells in a TCR-dependent manner after 
in vitro activation. It is detected as soon as 4 hours after T cell stimulation, but its 
expression peaks at 48 hours, and remains high until at least 96 hours (Josien et al., 
1999). This expression is strongly enhanced by CD28 stimulation (Josien et al., 
1999). RANKL is additionally found on immature DC in the skin, where it may play 
a role in regulating long-term survival of interstitial DC (Cremer et al., 2002). RANK 
is also expressed on these cells, but while RANKL is lost during maturation and 
migration to DLN, mature DC retain expression of RANK, becoming dependent on 
RANKL expression by other cell types in DLN, e.g. T cells, for survival (Cremer et 
al., 2002). In vitro treatment of these mature DC with soluble RANKL induces Bc!-
xL expression in DC and thus promotes DC survival, as well as cytokine production 
(IL-i, IL-6 and IL-12) by DC (Josien et al., 1999). Treatment of Ag-loaded, mature 
DC with soluble RANKL before subcutaneous injection also affects immune 
responses, resulting in prolonged DC survival in the DLN as well as increased 
primary and secondary T cell responses (Josien et al., 2000). Although T and B 
express low levels of RANK, soluble RANKL has no effect on these cells (Josien et 
al., 1999). 
The CD40-CD154 and the RANK-RANKL interactions appear to show some 
redundancy, both leading to IL-12 production and promoting ThI type responses. 
This is further evident in that RANK-RANKL can compensate for CD40-deficiency 
in response to a number of viruses (Bachmann et al., 1999). However, their functions 
do not completely overlap, exemplified by the fact that RANKL exerts its effects 
mainly on DC, while the CD40-CD154 is also crucial during T-B cell interactions 
and subsequent antibody isotype switching (Banchereau et al., 1994). RANKL 
expression on anti-CD3 activated T cells in vitro peaks at 48hrs (Josien et al., 1999). 
CD154 on the other hand is more rapidly expressed, and expression wanes within 24-
48 hrs (Roy et al., 1993). CD40 ligation of cultured human DC in vitro also greatly 
increases RANK expression (Anderson et al., 1997), suggesting that RANKL may 
act at a later time-point than CD 154 during T cell activation to regulate DC function 
and survival, providing an additional checkpoint during T cell activation by DC. 
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1.2.3. Dendritic cells as the initiators of CD4 T cell 
responses 
The DC located in most peripheral non-lymphoid tissues are in an immature, or 
quiescent, state. Here, they sample their environment for Ag. Upon exposure to 
inflammatory signals or mediators, DC undergo migratory, phenotypic, and 
functional changes (Flores-Romo, 2001). They migrate from the periphery via 
afferent lymphatics to DLN, lose their high endocytic and phagocytic activity, up-
regulate their levels of costimulatory molecules, such as CD40, CD80 and CD86, and 
concentrate peptide-loaded MHC class H molecules at their cell surface (Flores-
Romo, 2001). On arrival in the LN, these mature, activated DC are capable of 
stimulating naïve Ag-specific T cells. 
DC subsets 
A number of DC subsets can be identified in humans and mice. The correspondence 
between these subsets remains unclear, possibly because human DC are generally 
isolated from peripheral blood, while murine DC are purified from secondary 
lymphoid organs. CD11c is a surface molecule used as a DC marker, although it is 
also expressed on other cells of myeloid origin. Expression of CD4 and CD8a is 
generally used to distinguish different DC subsets, and it is thought that CD8ci. DC 
are of myeloid origin, while CD8a are of lymphoid origin (Celia et at., 1997). 
Mouse spleen contains three distinct mature DC populations, CD4, CD8c(; CD4, 
CD8a; and CD4, CD8a (Kamath et al., 2000; Vremec et al., 2000). CD8c DC are 
primarily found in the T cell rich paracortex, and CD8a DC (CD11b) reside in the 
outer edges of the paracortex, near B cell rich follicles (parafollicular region) (Pooley 
et al., 2001). DEC-205 is another phenotypic marker for DC, which has been 
investigated to segregate DC subset function. In the spleen, the expression of CD8a 
correlates with DEC-205 expression (Kronin et al., 2000). In the LN on the other 
hand, an additional CD8I, DEC-205subset, can be located (Kronin et al., 2000). 
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A further subset of DC, which is CD1 1cim0w,  has been identified, and is called 
plasmacytoid DC. These plasmacytoid DC are found in all lymphoid tissue as large, 
round cells, which change to DC morphology after stimulation with viral products, 
CpG (further described below) or IL-2 in vitro. They then become potent producers 
of interferon (IFN)-cx and IFN-13 (O'Keeffe et al., 2002), and are thus thought to be 
important in the defence against viral pathogens. 
Ever since the identification of DC subsets, attempts have been made to link DC 
ontogeny to DC function. Conflicting data exists with respect to the induction of Thi 
versus Th2 type responses by CD8a or CD8cI DC. Both CD8a and CD8c DC 
have been shown to efficiently prime Ag-specific T cells in vivo, inducing Th 1 and 
Th2 responses respectively when transferred into naïve hosts (Maldonado Lopez et 
al., 1999b). In this system, it is suggested that CD8c DC selectively express IL-12 
and prime Thi type responses (Maldonado Lopez et al., 1999a). However, the 
maintenance of peripheral tolerance is also attributed to these DC (Belz et al., 2002). 
Others reported that both DC subtypes can induce either type of immune response,. 
and that the microbial signals, which the DC receive, directs the outcome of the Th 
response (Manickasingham et al., 2003). Additionally, evidence suggesting that 
CD8c cells mature from CD8I precursors clearly exists (Martinez del Hoyo et al., 
2002), and thus both DC subtypes can be derived from clonogenic myeloid 
precursors (Traver et al., 2000). CD8ci and CD8c DC may represent different 
maturation stages of the same DC population. The most recent research suggests that 
both DC subsets receive signals from the surrounding environment at the time of Ag 
exposure through for example TLR, described below. These signals mature the DC 
in the appropriate way to ensure that the type of immune response, which most 
effectively deals with the .pathogen at hand, will be initiated. Interestingly, different 
DC subsets express different repertoires of TLR (Boonstra et al., 2003; Reis e Sousa, 
2004). At present, the role and significance of DC subsets for the type of T cell 
response remains to be clarified. 
Toll-Like receptor expression on DC 
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Mammalian TLR are part of a family of 'pattern-recognition receptors', a term first 
coined over 15 years ago (Janeway, 1989). They recognise conserved microbial 
structures, including unmethylated CpG sequences on bacterial DNA (TLR9) 
(Hemmi et al., 2000), lipopolysaccharide (LPS) from Gram-negative bacteria (TLR4) 
(Hoshino et al., 1999) or double-stranded RNA (TLR3) (Alexopoulou et al., 2001). 
DC express a range of TLR, and different subtypes of DC express varying levels of 
the nine murine TLR identified so far (Kapsenberg, 2003). TLR triggering has 
pleiotropic effects on DC, for example promoting survival, chemokine and cytokine 
secretion, expression of chemokine receptors, or migration (Akira, 2003). The 
adaptive immune response generally starts with T cell recognition of peptides on DC, 
which have matured after previous TLR ligation. TLR are therefore crucial proteins 
linking the innate and adaptive immunity (Akira et al., 2001), and additionally, the 
cytokines and chemokines secreted in response to TLR ligation influences the 
outcome of adaptive immune responses. There follows a brief summary of the main 
effects of LPS and CpG, which signal through TLR4 and TLR9 respectively, and 
which are used as adjuvants in this project (also see Fig. 1.5). Both TLR4 and TLR9 
signal through MyD88, an adaptor protein resulting in the activation of the 
transcription factor NF-KB, which controls expression of a number of pro-
inflammatory cytokines. 
LPS as an adjuvant 
LPS is an integral component of the outer membrane of Gram-negative bacteria and 
can provoke a life threatening condition called endotoxic shock (Ulevitch and 
Tobias, 1995). LPS is a ligand for TLR4, but the LPS recognition complex may 
variably contain other components such as CDI4, MD2, heat shock proteins 70 and 
90, and the chemokine receptor CXCR4 (Triantafilou et al., 2001; Underhill, 2003). 
Both TLR4 and MD2 are required for responsiveness to LPS, since MD2 is 
physically associated with the extracellular domain of TLR4 on the cell surface 
(Underhill, 2003). LPS induces release of inflammatory cytokines as well as IFN-13. 
The induction of inflammatory cytokines, such as Th-i3 or IL-12, is dependent on 
the intracellular adaptor molecules MyD88 and TIRAP, which lead to NFiB 
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activation and subsequent induction of cytokine gene transcription in DC (Akira et 
al., 2001). IFN-13 (a type I IFN) release and subsequent upregulation of CD40, CD80 
and CD86 through autocrine and paracrine signalling is MyD88 independent, but 
regulated through IFN regulatory factor 3 (IRF-3) (Kaisho and Akira, 2003). 
However, additional MyD88-independent pathways of LPS activation of DC also. 
exist, which remain to be investigated. 
LPS has been shown to fully activate DC, and its adjuvant effect has been used in 
numerous systems to enhance the T cell response in vivo and in vitro (Khoruts et al., 
1998; Maxwell et al., 2002). In vitro treatment of mouse DC with LPS greatly 
enhances Ag loading onto MHC class II, and display of these MHC class II:peptide 
complexes on the cell surface (Inaba et al., 2000). LPS co-administration in vivo 
similarly improves presentation of protein Ag by both CD8f and CD8a DC (Reis e 
Sousa and Germain, 1999), which may be an indirect effect of the inflammatory 
properties of LPS (Manickasingham and Reis e Sousa, 2000). It also induces splenic 
CD8cx DC migration, from the marginal zone to the T cell areas of the white pulp 
(De Smedt et al., 1996; Reis e Sousa et al., 1997). LPS thus enhances both the T cell 
priming abilities of DC, as well as causing their migration into the T cell areas where 
that priming can occur. LPS stimulation results in IL-12 release by DC, and the 
subsequent induction of a Thi type response under most experimental conditions 
(Langenkamp et al., 2000). However, Th2 type responses after LPS stimulation have 
also been described (Boonstra et al., 2003; Pulendran et al., 2001). Interestingly, the 
IL-12 production after LPS stimulation is a transient effect, and the DC subsequently 
becomes refractory to further stimulation, an effect described as exhaustion. 
CpG as an adjuvant 
CpG-rich motifs are found in microbial DNA, and they are ligands for TLR9 
(Hemmi et al., 2000), which is found on endosomes inside the cells. Three different 
types of CpG have been identified so far, CpG A, which induces IFN-o release by 
DC, but is a poor stimulator of B cell proliferation; CpG B, which conversely 
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stimulates B cell proliferation, but does not induce lEN-a release by DC, and CpG C, 
which stimulates both B cells and DC (Reis e Sousa, 2004). Similar to LPS, CpG has 
been used as an adjuvant in a number of experimental systems, and induces a Thl 
type response (Jakob et al., 1999). DC activation by CpG at the time of T cell 
activation enhances immune responses (Boonstra et al., 2003), and enhances T cell 
responsiveness even after previous tolerance induction (Ichikawa et al., 2002). TLR9 
signals exclusively via MyD88, inducing production of pro-inflammatory cytokines, 
and augmentation of CD40, CD80 and CD86 levels on DC (Hemmi et al., 2000). 
Release of type I IFN is also stimulated, although the exact pathway leading to IFN -
gene induction is unknown (Reis e Sousa, 2004). Additionally, CpG provides a 
survival signal to DC, inducing upregulation of survival molecules Bcl-2 and Bcl-xL 
(Park et al., 2002). CpG thus increases DC survival as well as inducing DC 
maturation, leading to the initiation of effective T cell immunity. 
35 
1.3. T cell tolerance 
TCR diversity coupled with flexible Ag recognition allows T cells to respond to 
peptides from virtually all molecules andlor cells, including our own tissue (Mason, 
1998). However, the immune system is able to distinguish between harmless self-
molecules, and molecules or cells that might be dangerous to us. An immune 
response should only be initiated in the latter case, whereas a tolerant state to self-
molecules is maintained in healthy individuals by a variety of mechanisms. 
1.3.1. Central tolerance 
Tolerance is usually defined as the failure to respond to Ag, resulting in avoidance of 
autoimmunity and pathology. Intrathymic deletion of T cells with high affinity for 
self-Ag plays a crucial role in limiting the autoreactive T cell repertoire (Kappler et 
al., 1987). The thymus contains a variety of professional APC, which express both 
MHC class I and II molecules. These APC include DC, macrophages, B cells and 
thymic epithelial cells (TEC) (Derbinski et al., 2001), which can all express a large 
array of self-Ag. Immature T cells that bind their specific Ag with high affinity in the 
thymus, are deleted at the CD4, CD8 double-positive stage. This process is termed 
central tolerance. In recent years, it has become evident that even "tissue specific" 
Ag are expressed in the thymus. In particular medullary TEC express a vast range of 
Ag which are known to be putative targets in autoimmune diseases, for example 
insulin and MOG (Derbinski et al., 2001). The transcription factor AIRE, which is 
primarily expressed in the TEC and DC in the thymus, may be responsible for 
expression of these "tissue specific" Ag (Mathis and Benoist, 2004). Since immature 
T cellg recognising these auto-Ag become deleted or possibly become regulatory T 
cells (T reg, see below), expression of tissue specific Ag in the thymus greatly limits 
the number of potentially autoreactive T cells in the periphery. 
1.3.2. Peripheral tolerance 
Nevertheless, it is unlikely that all self-peptides can be displayed in the thymus. 
Central tolerance is inevitably an incomplete process, and autoreactive T cells are 
consequently found in the periphery, requiring mechanisms of peripheral tolerance to 
avoid autoimmune pathology (Anderton and Wraith, 2002). Three major mechanisms 
have been proposed to be relevant for the maintenance of peripheral tolerance to self-
Ag, as well as for the induction of tolerance to administered Ag, namely T cell 
deletion, anergy, and suppression by T reg. T cells go through a number of stages 
through their life span and during an immune response, and these different 
mechanisms may all be necessary to avoid detrimental autoimmune responses at 
these various stages. 
Deletion by activation induced cell death 
Activation induced cell death (AICD) is a process of apoptosis induced by repeated 
activation of T lymphocytes by their specific Ag. The principal mechanism of AICD 
in CD4 T cells is the co-expression of Fas (CD95) and Fas ligand (FasL), which has 
been shown to occur after repeated Ag stimulation, and is important in limiting the 
immune response to foreign Ag to avoid damage to the host (Lenardo et al., 1999). 
Resting naïve T cells express little surface Fas, while TCR stimulation in the 
presence of IL-2, a cytokine important for T cell proliferation, enhance Fas 
expression. The activated T cell becomes sensitive to FasL induced apoptosis, which 
is triggered through endogenously produced FasL and signalling through Fas 
(Refaeli et al., 1998). AICD is important to limit the numbers of Ag-specific cells 
towards the end of a normal immune response. Similarly, if an Ag is presented 
chronically, inhibitory genes such as FasL are activated, rendering the T cell 
susceptible to Fas-induced apoptosis (Goodnow, 2001). AICD may thus limit early 
activation and expansion of self-reactive T cells, which consistently see their specific 
Ag, and has a supplementary role in maintenance of peripheral tolerance. The 
significance of Fas and its ligand for peripheral T cell tolerance is underlined by the 
fact that mice deficient for either of these molecules show lymphoproliferative 
disease and systemic autoimmunity (Cohen and Eisenberg, 1991). 
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Anergy 
Anergy can be described as a state of lasting T cell unresponsiveness. Two broad 
categories of anergy are distinguished, namely clonal anergy and adaptive anergy 
(Schwartz, 2003). The former is mostly observed in previously activated T cells, and 
is characterised by growth arrest of the T cell, with lack of proliferation and a block 
in IL-2 production, but little loss of effector function and other cytokine production. 
The latter is initiated in naïve T cells, and consists of a more generalised inhibition of 
proliferation and effector functions (Schwartz, 2003). Clonal anergy does not require 
T cell proliferation or persistence of Ag, in contrast to adaptive anergy, which 
requires persistency of Ag to maintain the unresponsive state. Also, clonal anergy 
can be reversed by addition of IL-2, while adaptive anergy is maintained even after 
addition of IL-2 (Schwartz, 2003). 
Both types of anergy can be induced by a number of circumstances in vitro and in 
vivo. Clonal anergy has primarily been studies in vitro, and induction of clonal 
anergy in CD4 T cell clones is induced through strong TCR signalling in the 
absence of costimulation (i.e. provision of signal I without signal 2) (Jenkins and 
Schwartz, 1987) or by stimulation with a low affinity ligand in the presence of 
costimulation (i.e. a low signal 1 with signal 2) (Sloan-Lancaster et al., 1993). 
Clonally anergised T cells remain viable and provision of IL-2 reverses anergy 
induction (Beverly et al., 1992). The CD28-CD80/CD86 interaction is critical in the 
prevention of clonal anergy, possibly by having an, inhibitory effect on the 
production or function of anergic factors (Becker et al., 1995), or through stimulation 
of IL-2 (Beverly et al., 1992; Jenkins, 1992). The involvement of CTLA-4 on the 
other hand is less clear. Blocking antibodies to CTLA-4 or genetic CTLA-4 
deficiency did not influence the induction of clonal anergy in vitro in some systems 
(Frauwirth et al., 2000), but did have a role in others (Wells et al., 2001). All the 
same, it is debatable how important results from in vitro studies are, and although 
some transfer studies looking at clonal anergy in vivo have been carried out 
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(Schwartz, 2003), it is adaptive anergy which has been studied more extensively in 
vivo. 
Adaptive anergy is often initiated in naïve T cells in vivo by TCR stimulation without 
provision of costimulatory molecules, which is thought to be the case during peptide-
induced tolerance. T cells go through a significant phase of proliferation before 
becoming anergic (Pape et al., 1998), see section 1.3.4. The role of the CD28/CTLA-
4-CD80/CD86 interaction for adaptive anergy is debatable. The importance of CD28 
is difficult to investigate, since CD28' T cells fail to proliferate in response to Ag 
(Howland et al., 2000), while the role for CTLA-4 is controversial. Some groups 
report that the induction of anergy in vivo was only possible through engagement of 
CTLA-4, illustrated by a lack of anergy induction when CTLA-4 was blocked (Perez 
et al., 1997), and inability to induce anergy in CTLA-4-deficient T cells (Greenwald 
et al., 2001). Others suggest anergy of CD8 T cell in vivo was possible in the 
absence of CTLA-4 (Frauwirth et al., 2001). The exact role of CTLA-4 in T cell 
activation, anergy and tolerance remains open to discussion, and requires further 
investigation. 
In addition to an increasing number of molecules being identified as positive 
regulators of T cell responses, negative regulators of T cell activation, such as PD-I 
and its ligands PD-LI and PD-L2 (Greenwald et al., 2002) are becoming apparent. It 
seems plausible, that rather than anergy being the result of a simple lack of 
costimulation, it is determined by a balance of positive and negative signals that the 
T cell receives after TCR recognition. 
The molecular mechanisms responsible for anergy induction and maintenance are a 
subject of intense investigation. A number of signalling pathways are activated after 
ligation of TCR and costimulatory molecules. Recently, it was shown that during the 
induction of clonal anergy, a specific set of genes became activated (Macian et al., 
2002), including genes encoding Cbl-1, Itch and GRAIL, three ubiquitin ligases (E3s) 
Ml 
(Heissmeyer et al., 2004). E3s confer substrate specificity to the ubiquitin system 
(Schnell and Hicke, 2003), which targets proteins for degradation. It is suggested that 
degradation of signalling proteins leads to disruption of the signalling synapse 
between the APC and the T cell, which ultimately results in T cell anergy 
(Heissmeyer et al., 2004). Other molecules that may influence tolerance induction 
are signal transducers and activators of transcription (Stats), which are cytoplasmic 
transcription factors, playing important roles as mediators in cytokine and growth 
factor signalling (Daniel!, 1997). Stat 3 has recently been described as a negative 
regulator of inflammatory responses, and CD4 T cells from mice with disrupted Stat 
3 function in macrophages cannot be tolerised through a known tolerogenic protocol 
(i.v. administration of soluble peptide) (Cheng et al., 2003; Kearney et al., 1994). 
Stat 3 is thus a signalling molecule that has been identified to specifically be required 
for tolerance induction. Identification of molecules such as..Cbl-1, Itch, GRAIL and 
Stat3 gives new insight into the molecular events during tolerance induction, and 
allows identification of new potential targets for immunotherapy. 
Regulatory T cells 
The idea of a specialised subset of T cells, which limits the outcome of an immune 
response, was first described in the 1970s (Gershon, 1975). After a long period 
during which this concept was in disrepute, regulatory T cells (T reg) have regained 
acceptance as a specialised subset of T cells, which have suppressive or regulatory 
properties, aiding in the prevention of autoaggressive immune responses. Two 
different T reg subsets can be distinguished through their mode of action. Naturally 
occurring T reg are thought to arise in the thymus, perhaps via an altered negative 
selection by self-Ag (Caton, 2003), but they may have to re-encounter Ag in the 
periphery to become fully mature (Shevach, 2000). They constitute 5-10% of all 
peripheral CD4 T cells and display characteristic surface markers such as CD25 
(Sakaguchi et al., 1995), CTLA-4 (Read et al., 2000) and GITR (McHugh et al., 
2002; Shimizu et al., 2002). Their importance in peripheral tolerance is demonstrated 
by the development of autoimmune diseases such as gastritis and thyroiditis when T 
reg are eradicated (Sakaguchi et al., 1995). Although T reg need to be triggered 
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through their TCR (Shevach, 2002), once activated, they suppress effector T cells 
(CD25) in an Ag-nonspecific fashion (Thornton and Shevach, 2000). In vitro, this 
inhibitory action is dependent on cell-cell contact with the CD25 cells to be 
suppressed, and can be overcome by addition of exogenous IL-2 and IL-15 
(Dieckmann et al., 2001; Jonuleit etal., 2001; Thornton and Shevach, 1998). In vivo, 
roles for IIL-10 and TGF-P have been described (Belkaid et al., 2002; Sun-Payer and 
Cantor, 2001). However, their target Ag and mechanisms of action remain poorly 
defined, and their exact role in autoimmune diseases continues to be a topic of 
intense investigation. 
The second type of suppressive CD4 T cells is induced from conventional 
CD4CD25 T cells in the periphery. In contrast to the naturally occurring 
CD4CD25 subset, these T cells carry out their in vitro suppressive effects via cell 
contact independent mechanisms, mainly through secretion of immunomodulatory 
cytokines such as IL-lO andlor TGF-13 (Jonuleit and Schmitt, 2003). Two subsets of 
induced T reg have been described as Trl and Th3 cells (Roncarolo et al., 2001 a; 
Weiner, 2001). TrI cells produce large amounts of IL-lO and little TGF-f3, while Th3 
produce preferentially TGF-. Trl cells were first induced by repeated stimulation of 
T cells in the presence of IL-lO (Groux et al., 1997). The resulting T cell population 
controls activation of naïve and memory T cells in vivo and in vitro, and suppresses 
Thi- and Th2-mediated responses to pathogens, tumours and allo-Ag (Groux, 2003). 
The inhibitory effect is mainly through production of IL-b, as shown by the reversal 
of this effect after administration of blocking antibodies against IL-b (Groux et al., 
1997). Th3 cells producing TGF-P were identified in mice after oral tolerance 
induction using myelin basic protein (MBP) (Chen et al., 1994), and have similarly 
been described in humans after oral administration of MBP (Fukaura et al., 1996). 
TGF-13 influences the activity of multiple cell types, and Th3 cells may therefore 
have a major role in many aspects of immune regulation and T cell homeostasis 
(Weiner, 2001). 
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1.3.3. Dendritic cells as tolerogenic APC 
It is clear from the existing data that Ag presentation by APC, including DC, plays a 
major role in the induction and maintenance of tolerance. There are two separate 
ideas about DC and their role in tolerance. Firstly, a subset of regulatory DC may 
specialise in inducing tolerance in the T cells to which they present, or secondly, the 
activation status of the DC regulates their ability to induce tolerance or immunity. 
Some evidence exists for specialised regulatory DC (Fazekas de St Groth, 1998; Suss 
and Shortman, 1996), in that CD8u DC of lymphoid origin (LDC) have been 
proposed to negatively regulate CD8 T cell responses (Belz et al., 2002; Kronin et 
al., 1996; Kronin et al., 2000). These LDC are the predominant DC population found 
in the spleen and in the T cell zones of non-immunised mice (Fazekas de St Groth, 
1998), and have been found to express high levels of seif-peptides (Inaba et al., 
1997), making them an ideal candidate for tolerance induction (Fazekas de St Groth, 
1998). However, since they may be derived from the same precursors as CD8c( DC, 
(Roncarolo et al., 2001b; Traver et al., 2000), and taking into account the 
accumulating evidence that tolerance is a result of the activation status of the DC 
(described below), it remains to be seen whether there truly is a subtype of DC 
specialised for tolerance induction. 
It has been shown that T cell tolerance to self-Ag is an active choice of the immune 
system. The (self-) reactive T cell goes through a phase of activation (Kurts et al., 
1997), and evidence exists that the T cell acquires significant effector functions on its 
way to becoming tolerant (Huang et al., 2003). Originally, it was thought that 
immature, resting DC, which display MHC/self-peptide complexes and low levels of 
costimulatory molecules in the absence of inflammatory stimuli, induce peripheral T 
cell tolerance in vivo (Dhodapkar et al., 2001; Steinman et al., 2000). This idea has 
now been revised to suggest that peripheral tolerance in the steady state is induced by 
mature, but quiescent DC, displaying high levels of self-Ag in their surface (Inaba et 
al., 1997), while immunity is initiated by DC that are fully activated through the 
presence of "danger", such as microbial molecules, which activate DC through TLR 
ligation as described in section 1.2.3 (Albert et al., 2001; Shortman and Heath, 2001). 
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The activated DC provide the T cells with much stronger versions of the same 
signals and/or additional signals to induce immunity. One might therefore suggest 
that the induction of tolerance versus immunity could be determined by the ratio of 
quiescent DC to activated/mature DC (Roncarolo et al., 2001b). The emerging 
consensus is that quiescent DC, which display self-Ag and low levels of 
costimulatory molecules, and which continuously travel from peripheral sites to 
DLN, are required for continual induction of tolerance to self-Ag. However, if DC 
become activated in the presence of "danger" or through maturation signals such as 
agonistic anti-CD40 antibody, they increase expression of costimulatory molecules. 
This in turn allows initiation of an effective immune response in the DLN. Although 
the DC still express self-Ag, the prior establishment of self-tolerance will prevent 
detrimental immune responses against those self-Ag. 
Quiescent DC can induce T cell deletion as well as T cell anergy to foreign and self-
Ag, and DC also play a role in the induction and modulation of T reg in vitro and in 
vivo. Targeting ovalbumin peptide (pOVA), or hen egg lysozyme (HEL) to resting 
DC via DEC-205 results in deletion of both Ag-specific CD4 and CD8 T cells 
(Bonifaz et al., 2002; Hawiger et al., 2001), while targeting pMOG to resting DC via 
DEC-205 causes CD4 T cell anergy (Hawiger et al., 2004). In both cases, T cells go 
through a phase of proliferation and activation before becoming anergic or deleted. 
IL-lO producing T reg may be induced in vitro by repetitive stimulation through 
untreated immature DC (Jonuleit et al., 2000). In vivo, steady-state DC present 
soluble protein to CD4 CD25 T cells, and induce their expansion (Yamazaki et al., 
2003). At least in humans, T reg themselves can also reduce the capacity of DC to 
induce T cell proliferation, indicating a feedback loop resulting in maintenance of 
tolerance (Roncarolo et al., 2001b). Similarly, CD4 CD25 T reg are able to directly 
induce the development of other T reg subsets (Dieckmann et al., 2002; Jonuleit et 
al., 2002), to elicit a form of infectious tolerance. The ability to induce T reg using 
modified DC has enormous therapeutic potential, but more research needs to be 
carried out to fully understand the mechanisms involved. 
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1.3.4. Peptide-induced tolerance 
It has been known for a long time that the form in which the Ag is administered plays 
a crucial role in the outcome of the immune response (Weigle, 1973). Ag in 
aggregated form, or administered with appropriate "danger" signals, such as 
adjuvant, leads to T cell activation and expansion and the generation of a productive 
immune response. The same Ag administered in soluble, monomeric form (in the 
absence of "danger"), however, leads to T cell tolerance, as illustrated by the absence 
of T cell activation when rechallenged with Ag in adjuvant. Administration of 
soluble Ag via the oral/mucosal, intravenous (i.v.), intraperitoneal (i.p.), or intranasal 
(i.n.) routes have all been shown to successfully induce tolerance (a! Sabbagh et al., 
1994; Burkhart et al., 1999; Chen et al., 1995; Liblau et al., 1996; Liu and Wraith, 
1995). With the identification of immunodominant epitopes within proteins, it has 
been possible to move from tolerisation using whole proteins to induction of 
tolerance through administration of soluble peptides. This approach is very effective 
in preventing autoimmunity, and inhibits the onset of autoimmunity in EAE 
(Anderton and Wraith, 1998), as well as in experimental models of arthritis and 
myasthenia gravis (Paas-Rozner et al., 2000). The therapeutic potential for treatments 
of allergies and human autoimmune diseases is described further at the end of this 
section. 
The exact mechanisms leading to induction of tolerance after administration of 
soluble peptide remain an issue of debate. It has been suggested that tolerance is 
simply due to immune deviation from a Thi phenotype, which causes autoimmune 
damage, to a less pathological Th2 cytokine profile (Tian et al., 1996). However, it 
has been shown that in most systems, induction of peptide-induced tolerance 
involves the same mechanisms responsible for induction of peripheral tolerance; 
anergy, apoptosis and induction of T reg. Each has been shown to play a role, 
depending on the exact dose and route of Ag administration, and in a number of 
systems, a combination of these mechanisms was responsible for the resulting 
tolerance. High doses of orally administered Ag may cause deletion of specific T 
cells (probably through Fas-mediated apoptosis after initial T cell activation, i.e. 
AICD) (Chen et al., 1995), or anergy (Friedman and Weiner, 1994). Low doses on 
the other hand appear to induce Ag-specific T reg of the Th3 subtype (Chen et al., 
1994; Friedman and Weiner, 1994). Similarly, i.v. administration of high doses of 
soluble peptide causes apoptosis of Ag-specific T cells (Liblau et at., 1996), and in 
some systems it was shown that most Ag-specific T cells are deleted, leaving the 
remaining Ag-specific T cells functionally impaired, i.e. anergic, and resulting in T 
cell tolerance (Kearney et al., 1994; Pape et al., 1998). In most experimental systems, 
tolerance is thus likely to result from several mechanisms collectively acting to 
maintain tolerance. 
Induction of T cell tolerance is an active process 
Earlier studies showed that systemic T cell tolerance takes 3 days to become 
established (Liu and Wraith, 1995). Because only a fraction of T cells are specific for 
a certain Ag, the number of Ag-reactive T cells during an immune response is small, 
and impossible to trace. By generating TCR transgenic mice, in which all T cells 
specifically recognise a certain peptide-MHC complex, and transferring T cells from 
the TCR transgenic mouse into naïve syngeneic recipients, it became possible to 
trace a definite population of T cells during the induction of tolerance (Kearney et 
al., 1994). Initial experiments compared T cell expansion after i.v. administration of 
soluble Ag to sc injections of Ag in CFA. While in both cases, Ag-reactive T cells 
proliferated in response to the Ag, T cells only entered B cell follicles and remained 
Ag responsive upon in vitro challenge when Ag was administered with an adjuvant. 
When T cells encountered their Ag without the presence of adjuvant, they 
proliferated for some time, but never entered B cell follicles, and the cells that 
remained were hyporesponsive to antigenic challenge (Kearney et al., 1994). 
It has since been shown in a number of systems that although tolerant T cells are 
ultimately unresponsive to their Ag, they go through a significant phase of activation 
en route to tolerance induction. The kinetics of T cell activation during the induction 
of tolerance show transient T cell activation with expression of costimulatory 
molecules, followed by T cell unresponsiveness to Ag (Kearney et al., 1994). 
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Similarly, expression of a neo-self-Ag results in initial activation and gain of effector 
functions, before finally resulting in anergy of the adoptively transferred Ag-specific 
T cells (Huang et al., 2003). In both systei-ns, T cells undergo significant activation 
and proliferate in response to Ag-encounter, before becoming anergic. In 
experimental settings where Ag are targeted to quiescent DC, T cells similarly go 
through a phase of activation and proliferation, before becoming anergic or deleted 
(Bonifaz et al., 2002; Hawiger et al., 2001; Hawiger et al., 2004). Since 
costimulatory molecules are crucial for effective T cell activation, their possible 
importance during the induction of tolerance is evident and discussed further in 
section 1.3.5. 
DC versus B cells in the induction of T cell tolerance 
The APC that is responsible for displaying peptide to tolerise T cells, has been 
debated for some time. Early data shows that not only DC, but also B cells present 
processed peptides 4 hours after i.v. administration of soluble protein in vivo (Zhong 
et al., 1997). Nevertheless, it has been shown that CD8a DC present to CD8 T 
cells, while CD8oC DC present to CD4 T cells after i.v. administration of Ag 
(Pooley et al., 2001). Also, T cell-DC interactions, rather than T cell-B cell 
interactions, were observed in the parafollicular regions of the DLN after s.c. 
administration of soluble protein (Ingulli et al., 1997). More recently, it was shown 
that 4 hours after s.c. administration of soluble protein, most protein was found on 
the CD8ot DC subset, in the parafollicular regions of the DLN, to which Ag-specific 
T cells home after administration of Ag (Ingulli et al., 2002). Additionally, it was 
shown that protein administered s.c. was presented to T cells in the DLN in two 
temporally distinct waves. Even though processed protein was found on B cells 
throughout the 24 hours period examined, the peptide-expressing cells in T cell areas 
were found to be DC (Itano et al., 2003). Finally, DC display peptide for several days 
longer on their surface compared to B cells after i.v. administration of peptide (S. 
Anderton, personal communication), and B cell-deficient p.MT mice can be tolerised 
to induction of EAE (Vella et al., 1996). Collectively, these data suggest that it is 
DC that present processed peptides to T cells and tolerise them, rather than B cells. 
Further supporting this argument is the notion that T cells need signals different from 
TCR stimulation to enter B cell areas. In the presence of "danger", such as of LPS or 
the proinflammatory cytokines IL-i and TNF-a, T cells migrate into B cell follicles 
(Pape et al., 1997). It was similarly shown in an oral tolerance model that T cells do 
not enter B cell follicles after a tolerogenic stimulus, while they do after 
administration of an immunogenic one (Smith et al., 2002), and that T cells need to 
receive costimulatory signals from DC before they can enter B cell areas (Fillatreau 
and Gray, 2003). It appears that although B cells may present peptide on their surface 
after administration of soluble Ag, T cells will home to T cell areas and first need to 
interact with DC before being able to enter B cell areas and possibly re-encounter 
their Ag. 
Tolerance to EAE 
All three mechanisms of tolerance described above are thought to play a role in 
therapeutically-induced tolerance to myelin Ag. FasL-mediated apoptosis is 
important in some mouse strains in the recovery from EAE, however, it also 
functions in T cell-mediated killing of oligodendrocytes (Sabelko Downes et al., 
1999). Direct induction of T cell apoptosis with high-dose Ag can similarly induce 
remission of EAE (Critchfield et al., 1994). Administration of soluble peptides from 
PLP or MBP result in protection from subsequent EAE induction (Anderton and 
Wraith, 1998). At the population level, tolerant T cells are similar to anergic T cells 
described above, since this tolerance is characterised by reduced T cell proliferation 
and cytokine production upon rechallenge with Ag in adjuvant. Immune deviation 
towards a Th2 phenotype has not proved to be successful in suppressing on-going 
EAE (Khoruts et al., 1995), but EAE could be prevented if Th2 cells were present 
during the initiation of the Thi response (Kuchroo et al., 1995). 
Several tolerisation protocols result in the induction of a suppressor T cell 
population. Th3 cells described in section 1.3.2, producing large amounts of TGF-f3, 
and some IL-10 and IL-4 in an Ag-specific fashion, were first isolated after oral 
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administration of lower doses of MBP (Chen et at., 1994). These cells successfully 
suppressed EAE after transfer into naïve recipients. Intranasally-induced peptide 
tolerance to EAE induces T cell populations that produce IL-b (Burkhart et al., 
1999; Massey et al., 2002). When IL-lO was neutralised, or IL-JO-deficient mice 
were used, mice were no longer protected from EAE after i.n. administration of Ag, 
further showing the importance of IL-10 in this process (Burkhart et at., 1999; 
Massey et al., 2002). The search for Ag-specific T reg cells is still ongoing, and their 
isolation may allow exploitation of novel therapeutic possibilities for the treatment of 
autoimmune diseases. 
Peptide therapy in humans 
Over the last years, the findings from peptide-induced tolerance in animal models 
have been translated into peptide-based therapeutic trials to treat autoimmunity in 
humans. However, the majority of data has been generated from attempts to treat 
allergy. A variety of methods, including administration of soluble whole allergenic 
proteins, or peptides from allergens, have been tested. Results have however been 
mixed, and most trials showed some adverse side effects of treatment with peptide, 
such as symptoms of breathlessness and wheeze with onset several hours after 
peptide administration. Improvements in allergic reactions of patients were found 
after high dose peptide therapy with Fel d I peptides (a cat allergen) (Norman et al., 
1996), and promising results indicating induction of T cell hyporesponsiveness after 
peptide administration have also been reported (Oldfield et al., 2001). Even more 
encouraging results were found when patients, who previously had severe systemic 
reactions following bee stings, were treated with a mixture of three peptides from the 
major bee venom allergen, and all five patients experienced no, or greatly reduced, 
reactivity to bee stings (Muller et al., 1998). Unfortunately, other trials showed less 
promising results (Simons et al., 1996). Nevertheless a number of studies indicate a 
role for IL-10 in successful treatment using soluble peptide or protein (Akdis et at., 
2001; Oldfield et al., 2002), indicating that human peptide therapy may work through 
induction of enhanced IL-lO production which down-regulates pro-inflammatory 
responses. Hopefully, ongoing studies will further elucidate the relevant 
mechanisms, and will brighten the prospects of developing peptide-based vaccines 
for human diseases. 
1.3.5. The CD40-CD154 interaction in the decision between 
tolerance and immunity 
As described above, T cells go through a significant phase of activation and 
proliferation on their way to becoming tolerant. The importance of costimulatory 
molecules such as CD40 and 0X40 during the induction of T cell immunity is 
described above, and is well-documented in the literature. The importance of some 
costimulatory molecules during the induction of tolerance has been investigated, but 
this has by no means been extensive. Conflicting evidence exists with respect to the 
requirements of CD40-CD154 in tolerance. Mucosally induced tolerance to 
ovalbumin appears to require the presence of CD 154 in some systems (Kweon et al., 
1999), but not others (Hanninen et al., 2002), while tolerisation via the Lv. route was 
possible in the absence of CD154 (Howland et al., 2000). The requirements for 
0X40-OX40L interactions during tolerance induction had not yet been investigated 
prior to this project. 
Exogenous ligation of CD40 has been used extensively to activate APC in vitro 
(Caux et al., 1994; CelIa et al., 1996), and more recently, is has been shown that 
administration of agonistic anti-CD40 mAb in vivo boosts T cell immunity in 
response to a super-Ag (Maxwell et al., 1999). Other experimental systems further 
support this, in that anti-CD40 administration also prevents tolerance to tumours 
(Diehi et al., 1999; Grohmann et al., 2001; Sotomayor et al., 1999). Similarly, ex vivo 
blockade of CD40-CD 154 has also been reported to result in the induction of potent 
T reg (Taylor et al., 2002) after transfer of tolerised T cells, and in vivo blockade of 
CD40-CD154 interaction induces T cell tolerance (Tang et al., 1997), and prolongs 
allograft survival (Honey et al., 1999). CD40-deficient DC have been shown to 
produce IL-b, but not IL-12, which induced T cell hyporesponsiveness in vitro (Gao 
et al., 1999), again illustrating the importance of CD40 on DC for effective 
immunity. Similar to the conflicting evidence for the requirements of CD40-CD154 
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in mucosal tolerance however, there is some evidence that administration of 
agonistic anti-CD40 does not prevent mucosally induced tolerance (Chung et al., 
2004; Sun and Van Houten, 2002), suggesting that T cell tolerance is differentially 
regulated in different peripheral sites. Nevertheless, the CD40-CD154 interaction is 
an important candidate as a checkpoint determining between tolerance and immunity. 
The interactions of CD28 and CTLA-4 with CD80 and CD86 have been suggested to 
determine tolerance versus immunity. However, initial T cell activation in T cells 
lacking CD28 is greatly impaired (Howland et al., 2000). Since T cells undergo a 
significant phase of activation and proliferation on their way to becoming tolerant, 
this suggests that the CD28-CD80/CD86 interaction is not disrupted during tolerance 
induction. In contrast, when T cells lacking CD154 are stimulated by an Ag in 
adjuvant, they initially become activated, and although they are unable to sustain this 
activation, they are not rendered tolerant by this initial activation in the absence of 
CD154 (Howland et al., 2000). Nevertheless, CD154 T cells can be tolerised by 
administration of soluble Ag. CD154 is thus neither required for tolerance induction, 
nor for initial T cell activation. The main role identified for CD154 is ligation of 
CD40 on DC, which leads to the induction of OX40L expression on the surface of 
DC (Fillatreau and Gray, 2003;Ohshima et al., 1997). OX40L is then thought to bind 
0X40 on activated T cells, resulting in the expression of the survival molecules Bcl-
2 and Bcl-xL (Rogers et al., 2001) (also see section 1.1.4). The main effect when the 
CD40-CD 154 interaction is missing, either through a lack of CD 154, or by blocking 
with antibodies, may thus be the subsequent lack of up-regulation of OX40L on DC. 
This will result in a shortage of survival signals to the activated T cell, and 
subsequent T cell tolerance. In contrast, provision of anti-CD40 activates the DC and 
results in OX40L expression, allowing T cell immunity. The CD40-CD 154 
interaction may therefore be a crucial switch deciding between T cell tolerance and T 
cell immunity. 
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1.4. Central Hypothesis 
The CD40-CD 154 and 0X40-OX40L interactions have previously been shown to be 
of crucial importance during T cell responses, giving a costimulatory signal, i.e. 
signal 2, resulting in effective T cell activation. The timing of expression of CD154 
and 0X40 on T cells fits with the timing of tolerance induction. This thesis proposed 
that the chief defect driving a T cell towards tolerance is the lack of CD40 ligation, 
subsequently resulting in a lack of the 0X40-OX40L interaction. The CD40-CD154 




The above hypothesis was investigated by asking three main questions: 
Can exogenous ligation of defined costimulatory receptors convert a 
tolerogenic signal into an immunogenic one? 
If the CD40-CD 154 and 0X40-OX40L interactions are checkpoints determining the 
outcome of T cell immunity, agonistic antibodies to CD40 or 0X40 should prevent 
the induction of T cell tolerance after administration of a tolerogenic stimulus. 
How does expression of CD 154 and 0X40 on T cells, and CD40 and OX40L 
on DC differ during induction of T cell tolerance versus T cell immunity? 
If the presence or absence of costimulatory molecules on DC is responsible for the 
induction of T cell immunity versus tolerance, DC will upregulate expression of 
CD40 and OX40L during the induction of T cell immunity, but not T cell tolerance. 
Since T cells go through a phase of activation during tolerance induction, T cells are 
likely to express CD 154 and 0X40 during both immunity and tolerance. 
Do T cells become tolerant on exposure to Ag-loaded DC lacking CD40? 
The lack of CD40 on Ag-loaded DC should not result in T cell priming, but 
conversly induce T cell tolerance. 
These three questions will be addressed in turn in Chapters 3, 4, and 5, respectively. 
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Signals 1, 2 and 3 lead to effective T cell activation 
Signal 1 is the Ag-specific signal that is mediated through the TCR-
MHC-peptide complex interaction. Signal 2 can be provided by a 
variety of costimulatory molecules. Shown here are CD80/CD86-
CD28, and CD40-CD 154. Other costimulatory molecules shown to 
be important for effective T cell activation are 0X40 and RANKL, 
binding to their receptors OX40L and RANK, respectively. Signal 
3 induces release of the polarising signals that promote the 
development of Th 1 or Th2 cells. Signal 3 also activates DC, 
resulting in increased expression of costimulatory molecules, i.e 
signal 2. 




















Summary of some of the costimulatory molecules known to be 
important in T cell activation 
The TCR-MHC-peptide complex interaction induces expression of 
CD154, 0X40, RANKL (as well as CTLA-4, ICOS and PD-i). 
CD 154 expression peaks between 6 and 8 hours, while 0X40 and 
RANKL expression peak 2-3 days after initial T cell activation. 
CD40 is expressed constitutively at low levels on DC, and becomes 
upregulated early after DC activation. OX40L is induced (and 
CD80 and CD86 are upregulated) through CD40 ligation, while 
RANK has been found to be expressed on mature DC. Expression 
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Fig. 1.3: 
The role of CD40-CD 154 in T cell function 
The CD40-CD 154 interaction is involved in DC migration to 
lymphoid organs 0. and DC maturation, allowing effective T cell 
activation. CD40 signalling induces up-regulation of a number of 
costimulatory molecules, such as CD80. CD86. OX40L. enhancing 
DC survival in the lymph node 0. Ligation of these niolecules by 
their receptors on T cells results in effective T cell activation and 
survival 0. inducing T cell migration into B cell follicles. Once the 
T cell has become activated. CD40-CD 154 is important in B-T cell 
interactions, allowing isotype class switching 0. Finally, CD40-
CD 154 allows entry of effector T cells into peripheral sites. e.g. 
CD40 expression in the CNS is required for entry of T cells into the 
CNS 0. However, it does not appear to play a role in memory 
formation and is not required for reactivation of memory cells. 
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The role of OX4OL-0X40 in T cell function 
0X40 is up-regulated after TCR Ag recognition in lymphoid 
organs. Binding to OX40L on activated DC induces expression of 
survival molecules in effector T cells 0. 0X4() ligation also allows 
effective entry into the memory T cell pool 0. Binding of OX40L 
on B cells may play a role in induction of Th2 type responses 0. 
Finally, OX40L-0X40 is involved in entry of effector T cell into 
peripheral sites 0. and reactivation of memory cells 0. 
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Fig. 1.5: 
Possible signalling pathways coupling TLR4 and T1,119 to DC 
activation 
TLR-4 can signal via both MyD88 and TRIF. TIRAP couples 
MyD88 to TLR4. MyD88 and TRIF promote activation of NFiB 
and MAPKs, allowing transcription of inflammatory cytokines, 
such as IL-6, IL-12 and TNF-a. TRIF also activates IRF3, leading 
to synthesis of type I IFN. TLR9 signals exclusively through 
MyD88, which does not activate IRF3, but nevertheless results in 
WN-13 release (a type I IFN). IFN- P then signals in autocrine and 
paracrine manner, resulting in increased upregulation of CD80. 
CD86 and CD40. 
(Adapted from Reis e Sousa. 2004) 
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2. CHAPTER 2 - Materials and Methods 
2.1. Mice 
All mice used were on the C57BL/6 (H2b)  background and were bred at the Institute 
of Infection and Immunology Research, University of Edinburgh. C57BL/6 (136), 
CD40' (Kawabe et al., 1994), CD154' (Xii et al., 1994), jiMT (Kitamura and 
Rajewsky, 1992) and B6 Ly5.1 congenic mice were used extensively. OT-Il mice 
expressing an Abrestricted,  transgenic pOVA-reactive TCR (Barnden et al., 1998) 
were crossed with the respective strains to generate OT-IIxCD40' mice, OT-
IIxCD154 1 mice, and OT-llxLy5.1 mice. Sex-matched, 6-8 week old mice were 
used for all experiments. 
2.2. Reagents 
2.2.1. Antigens 
Peptides (ovalbumin 323-339, hereafter referred to as pOVA, and myelin 
oligodendrocyte glycoprotein peptide 35-55, hereafter referred to as pMOG) were 
synthesized by the Advanced Biotechnology Centre, Imperial College London, using 
standard F moc chemistry. 
2.2.2. Antibodies 
The OX-86 hybridoma that produces anti-0X40 and the MAC-49 isotype control 
hybridoma (anti-phytochrome, rat IgGI isotype), as well as the MAC-i control 
hybridoma (anti-glycoprotein of Chlamydomonas reinhardii, rat IgG2a isotype), 
were obtained from the European Collection of Cell Culture (ECACC, Wiltshire, 
GB). The FGK-45 hybridoma that produces anti-CD40 was kindly provided by Prof 
D. Gray, IIIR, Edinburgh. Antibodies were purified using an AktaPrime (Amersham 
Biosciences) automated chromatography system using a High Trap protein G HP 
(Amersham Biosciences). 
2.2.3.Adjuvants 
Complete Freud's Adjuvant (CFA) and LPS were obtained from Sigma (Poole, GB). 
CpG1668 (TCCATGACGTTCCTGATGCT) was produced by MWG. 
Various doses of LPS have previously been shown to induce immunity (Khoruts et 
al., 1998; Maxwell et al., 2002), and 30p.g LPS was tested here, found to work 
efficiently to prevent tolerance, and thus used in subsequent experiments to induce 
immunity. 
5.tg CpG has been used by others to induce immunity (Vicari et al., 2002), and was 
thus initially tested in the system used here. When it was unsuccessful in inducing 
immunity, higher doses (lOp.g and 30p.g) were also tested, but similarly did not 
induce immunity. 
2.2.4. Tissue culture media 
The following media were used unless indicated otherwise. 
Tissue wash medium: RPM! 1640 medium containing 2mM L-Glutamine, 5x10 5 M 
2-ME, 100U/ml penicillin, lOOp.g/ml streptomycin (all from Gibco, Life 
Technologies, Paisley, UK Gibco, hereafter referred to as Gibco). 
Tissue culture medium: X-VIV0I5 serum free medium (BioWhittaker, Maidenhead, 
GB) supplemented with 2mM L-glutamine and 5x10 5 M 2-ME. 
2.2.5. General reagents 
MACS buffer: Hanks medium, supplemented with 5x10 5 M 2-ME, 100g/ml 
penicillin, 100 U/mI streptomycin, and 2% FCS (all from Gibco). 
FACS buffer: PBS supplemented with 2% FCS (Gibco) and 0.05% NaN3. 
The PBS used for i.v. administration of cells and antigens was calcium- and 
magnesium-free sterile PBS (Gibco). 
PTX: Pertussis toxin for induction of EAE was obtained from the ECACC, and 
diluted in PBS (above) for i.p. administration. 
2.3. Cell purification 
2.3.1. Isolation of naïve CD4 T cells 
Peripheral lymph nodes and spleens were removed, disaggregated, and resuspended 
in MACS buffer. Cells were depleted of red blood cells (RBC) using RBC lysis 
buffer (Sigma). CD4 T cells were isolated by positive selection using CD4-
conjugated MACS beads and MS or LS columns (all Miltenyi Biotec), according to 
the manufacturer's instructions. Cells were incubated at 90111 MACS buffer/10 7 total 
cells, with 10il beads/10 7 total cells for 15min at 4°C, before purification on a 
MACS magnet (Vario MACS, Miltenyi Biotec). A consistent purity of >95% CD4 
was confirmed by flow cytometry. 
2.3.2. Isolation of splenic DC for phenotyping 
Spleens were removed and experimental groups of mice were pooled (2 mice/group 
for each time point). Spleens were disaggregated, and resuspended in MACS buffer. 
Cells were depleted of RBC using RBC lysis buffer. CD11c cells were isolated from 
the spleen by positive selection using anti-CD1Ic-conjugated MACS beads (Miltenyi 
Biotec), according to the manufacturer's instructions (with a consistent purity of 
>80% CD11c as confirmed by flow cytometry). Cells were incubated at 4001i1 
MACS buffer/10 8 total cells, with 100111 beads/10 8 total cells, for l5min at 4°C, 
before purification on a MACS magnet using MS or LS columns. CD1 ic-purified 
cells were resuspended in FACS buffer for FACS analysis. 
2.3.3. Isolation of splenic DC from naïve mice 
Splenic DC were isolated from naive B6 or CD40' mice by initial digestion of. 
spleens in lOmi RPMI without serum, supplemented with 2.4mg/nil collagenase D 
(Worthington Biochemical) and lmg/ml DNAse (Sigma, final concentrations) for 30 
minutes at 37°C. Cells were depleted of RBC using RBC lysis buffer. CDI lc cells 
were then isolated by positive selection using anti-CD 1 Ic-conjugated MACS beads 
as described in section 2.3.2. CDI 1c cells were then resuspended in wash medium 
for further experiments. 
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Because the simple process of DC purification can induce DC maturationlactivation, 
and upregulation of costimulatory molecules, different purification methods were 
tested, to ensure the above method was comparable to others with respect to the 
levels of costimulatory molecules found on DC from naïve mice after purification. 
Alternatively, DC were isolated using an adaptation of a previously described 
protocol (Vremec et al., 1992). Spleens were divided into two groups, and one group 
was digested as above, while the other group was digested as above in the presence 
of 100U/ml polymyxin B (Sigma). EDTA (Imi, 0.IM, pH 7.2) was added to both 
groups for the last 5 minutes of incubation, The cells were removed from the digest 
by centrifugation, prior to depletion of RBC using RBC lysis buffer, and the pellet 
was resuspended 4 ml of wash medium, and underlayed with I .077g/cm 3 NycoPrep 
(Axis-Shield diagnostics), and a low density fraction was collected after 
centrifugation at 610xg for 15 minutes at 4°C. This fraction was incubated for 30 
minutes at 4°C with anti-CD3 (KT-3), anti-Thy.1 (30-1412) and anti-Gri (RB68C5). 
These are all antibodies raised in rats, and DC were purified by depletion of 
antibody-bound cells using anti-rat Ig-coupied dynabeads (5:1 ratio) (Dynal, Milan 
Analytica). Dynabead purification was carried out under continuous rotation for 20 
minutes at 4°C. The resulting population was >80% CDI 1c as confirmed by flow 
cytometry. Expression of costimulatory molecules on DC was analysed by FACS 
analyses as described in section 2.7.1. 
2.3.4. Preparation of bone marrow-derived DC 
"Myeioid-like" DC were obtained using an adaptation of a previously used protocol 
(Inaba et al., 1992). Bone marrow cells were flushed from femurs and tibias, depleted 
of RBC using RBC lysis buffer and cultured in 24-well flat-bottom plates at 3.75x l0 
cells/mi, in imi wash medium/well (supplemented with 1% normal mouse serum, 
Gibco) and 5% GM-CSF supernatant (GM-CSF supernatant from cell cultures of an 
GMCSF-producing cell line; X-86, kindly provided by Dr A. Knight, IIIR, 
Edinburgh). The cells are washed with this medium at day 3 and day 6, before 
collection at day 7 for further experiments. The resulting population was >75% 
CD1 lc+ as confirmed by FACS analysis as described in section 2.7. 1. 
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To test the ability of CpG1668  to activate DC, DC were incubated with 6jig/ml 
CpG1668 overnight before FACS analysis as described in section 2.7.1. 
2.4. In vivo antigen administration 
2.4.1. Immunisations 
Mice received 20j.tg pOVA or 100ig pMOG emulsified in CFA (Sigma, Poole, GB) 
s.c. in the hind legs, on day 0. Varying doses of pOVA (ranging from 20-100.tg) 
were originally tested, and 20p.g found to give efficient recall responses upon ex vivo 
recall challenge. Similarly, varying doses of pMOG had previously been tested in the 
lab, and lOOjig gave optimal recall responses in the system used. After ten days, 
spleens and draining inguinal and popliteal LN were removed, disaggregated and 
used as a source of primed lymphoid populations. Cells were cultured as described in 
section 2.5.1. 
2.4.2. Induction of tolerance with soluble peptides 
For experiments investigating the induction of T cell tolerance, mice received a 
single i.v. dose of 500p.g pOVA or pMOG on day -7, or 3 doses of 200ig pOVA or 
pMOG on days -8, -6 and -4. Some mice then received pOVA/CFA or pMOG/CFA 
as described above. Three doses of 200jig peptide administered i.p. two days apart 
had previously been established in the lab to successfully induce tolerance. Vary.ing 
doses of peptide to induce tolerance i.v. were tested (ranging from 200ig-500jig), 
and 500.tg were required to successfully induce tolerance after adoptive transfer of 
Ag-specific T cells. In order to keep the dose of peptide consistent, 500 jig were used 
in subsequent experiments to induce tolerance whether or not the adoptive transfer 
system was used. This dose has also been used by others to induce tolerance after 
adoptive transfer of Ag-specific T cells (Bansal-Pakala et al., 2001). 
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2.4.3. Administration of LPS to induce T cell immunity 
For experiments using LPS as an adjuvant to prevent tolerance induction, mice 
received 500.tg pOVA and 30p.g LPS in PBS i.v. 
2.4.4. Administration of antibodies to prevent tolerance 
induction 
Mice received 200j.tg of anti-CD40, anti-0X40, MAC-I, or MAC49 as indicated on 
day -7 (at the same time as soluble peptide), and in some cases a second dose on day 
-5 as indicated. Different doses (ranging from 5Oig-200.Lg) were tested, and 200ig 
was found to have the most profound effects in vivo. 
24.5. In vivo administration of antigen-loaded DC 
DC were purified (in the case of splenic DC) or grown (in the case of bm-derived 
DC) from naïve B6 or CD40' mice as described above. DC were resuspended at 
2.5x106 cells/ml in wash medium supplemented with 1% normal mouse serum and 
pulsed with either pOVA or pMOG (53tg/ml, 1:75 of 4mg/ml stock solution; this 
concentration had been optimised by Georgia Perona Wright) as indicated, in the 
presence of LPS (0.1 j.tg/ml, Sigma) for 2 hours. 5x10 5 DC were injected i.v. into B6 
recipients on day 0. Varying numbers of DC (5x10 5-2x106) were originally tested, 
and 5x105 DC gave efficient recall responses. Some mice also received 200.tg anti-
0X40 or isotype control antibody MAC 49 on the day of DC injection and 2 days 
later, as indicated. 
2.5. In vitro assessment of T cell function 
2.5.1. Recall proliferation assays 
Lymphoid cell suspensions were cultured in 96-well flat-bottom microtitre plates 
(Becton Dickinson) at 6x10 5 LN cells/well or 8x10 5 spleen cells/well using tissue 
culture medium. Cultures were stimulated with a dose range of pOVA or pMOG for 
48 hours prior to addition of tritiated thymidine (3H-dThd, Amersham) at 0.5 
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p.Ci/well. The dose ranges (ranging from pMOG: 0.03-30!iM, or —0.06-60igIml, 
pOVA: 0.001-100l.LM or —0.0018-180jig/ml) and cell numbers used were previously 
optimised in the lab. After a further 18 hours, cultures were harvested and dThd 
incorporation measured using a liquid scintillation 13-counter (Wallac). Results are 
expressed as mean cpm of triplicate cultures. 
2.5.2. Cytokines production assays (ELISA) 
Production of some cytokines is difficult to detect by standard ELISA techniques, 
and cell-based ELISAs were thus adapted from a previously described protocol 
(Beech et al., 1997) in order to quantify Ag-specific production of cytokines. 
Cultures were set up with Ag as described above for T cell proliferation assays. After 
48 hours, lOOjJ.l aliquots of cells were removed from each well, and tested for 
production of IL-2, IL-4, and IFNy by ELISA. Miérotitre plates (NUNC) were coated 
with the cytokine-specific capture antibodies JES6-1Al2 (anti-IL-2), IIBI1 (anti-IL-
4) or R4-6A2 (anti-IFNy) using bicarbonate coating buffer (pH 9.6) at 4°C overnight 
prior to transfer of cells. After a further 24 hours culture, specifically bound 
cytokines were quantified using biotinylated secondary antibodies E56-5H4 (anti-IL-
2), BVD6-24G2 (anti-IL-4) or XMGI .2 (anti-IFNy) followed by extravidin 
peroxidase (Sigma). Cytokines were detected using phosphate citrate buffer, with 
added hydrogen peroxide and 3,3',5,5'-tetramethyl-benzidine (TMB) (both Sigma). 
Reactions were stopped using 2M sulphuric acid. All cytokines were quantified with 
standard curves obtained with known amounts of recombinant mouse cytokines. All 
monoclonal antibodies and recombinant mouse cytokine standards were purchased 
from BD PharMingen. The lower and upper limits of detections were as follows: IL-
2 and IL-4: 4-1000pgIml, IL-lO and IFN-y: 0.4-10ng/mI. 
2.5.3. In vitro assays of primary T cell activation 
Ag-loaded DC were prepared by incubation with 53tg/ml pOVA (1:75 of 4mg/ml 
stock solution) in wash medium supplemented with I % normal mouse serum at 37°C 
for 2 hours in the presence of 0.1 p.g/ml LPS (Sigma). Naïve CD4-purified UT- 
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llxCD40 T cells were labelled with 51.tM CFSE (Molecular Probes). Cells were 
labelled at 107/ml in wash medium for 15 minutes at 37°C (continuous shaking). 
CFSE was quenched with wash medium supplemented with 5% FCS (Gibco), prior 
to culture with pOVA-loaded DC (4x10 4 T cells + 4xI03 DC, 8xIO2 DC, or 4x102 
DC/well) in 96-well flat-bottom plates (Becton Dickinson) using wash medium 
supplemented with 5% FCS. These numbers of T cells with these ranges of DC 
numbers gave good T cell proliferation in preliminary experiments testing the ability 
of DC to activate transgenic T cells in vitro (see Fig. 5.2). Cells were harvested for 
FACS analysis at various time-points. 
2.6. Adoptive transfer model for T cell tolerance or 
immunity 
In order to phenotype T cells during the induction of tolerance or immunity, CD4 T 
cells were purified as described above from OT-Il, OT-IIxLy5.1 or OT-IIxCDI54' 
mice as indicated. 2-4x106 cells/mouse were transferred i.v. into syngeneic, naïve 
recipients on day -1. In some cases, CD4-purified T cells were fluorescently labelled 
with CFSE (see section 2.5.3) prior to adoptive transfer. 
Mice received i.v. injections of 200p1 PBS, 50Otg pOVA in PBS, 50Otg 
pOVA+30p.g LPS in PBS, or 500tg pOVA+30jig CpG one day after adoptive 
transfer of pOVA-reactive T cells, i.e. day 0. In some experiments, some mice also 
received 200tg anti-CD40 or 200 jig MAC-I as indicated on the same day. 
Mice were sacrificed at various time-points after Ag-administration, and 
splenic DC were isolated for phenotyping as described in section 2.3.4. The 
flowthrough of the purification procedure contained the transferred T cells, and their 
phenotype was assessed as described below. 
102 
2.7. Phenotypic analysis of T cell and DC populations 
after induction of tolerance or immunity 
2.7.1. Flow cytometric analysis 
Samples were washed with FACS buffer prior to incubations with antibodies. All 
samples were incubated with the 2.4.G2 anti-Fc receptor antibody to prevent non-
specific binding via Fc receptors, prior to incubations with other antibodies. 
Antibodies were diluted in FACS buffer supplemented with anti-Fc receptor 
antibody (final concentration of 2OIg/ml). FACS buffer used for staining of DC was 
also supplemented with 2% normal rat serum (Caltag) and 2% normal goat serum 
(Caltag) to prevent non-specific binding. All samples were collected on a Becton 
Dickinson FACScan (Mountain View, CA) flow cytometer and analysed using 
FlowJo Software (TreeStar, USA). All antibodies were obtained from BD 
Pharmingen (Oxford, GB) unless stated otherwise. 
DC purity was assessed with FITC-conjugated anti-CD 1 ic. Costimulatory molecules 
on DC were identified using biotinylated primary antibodies specific for CD80, 
CD86, CD40, OX40L or RANK (R&D systems), followed by streptavidin-APC 
conjugate. The following biotinylated isotype control antibodies were used: IgG2a, 
IgG2b and IgGi. 
In experiments involving transfer of OT-Il cells, the T cells were identified using 
biotinylated anti-V5 followed by APC- or FITC-conjugated streptavidin and PE-
conjugated anti-Vct2. Transferred OT-IIxLy5. 1 cells were identified using APC-
conjugated anti-CD4 together with FITC-conjugated anti-Ly5.1. In the case of 
transfer of previously CFSE-labelled cells, identification used biotinylated anti-Ly5. 1 
followed by APC-conjugated streptavidin and PE-conjugated CD4. T cell activation 
was assessed using biotinylated anti-CD69, anti-0X40, or anti-RANKL (R&D 
Systems), all followed by APC-conjugated streptavidin. Control samples were 
stained with APC-conjugated streptavidin alone. Once CD154 reaches the cell 
surface,. it is rapidly cleaved off. Intracellular staining was thus carried out to 
investigate CD 154 expression (see below). 
Intracellular cytokine production was measured ex vivo in splenocytes by flow 
cytrometric staining as described (Openshaw et al., 1995). Briefly, splenocytes (at 
5x106/ml) were stimulated with PMAlionomycin (Sigma, 1IgIml and l5ng/ml final 
concentration) in the presence of GolgiStop (diluted 1:1000) (BD Pharmingen) for 4 
hours at 37°C, before staining with biotinylated anti-V35 followed by APC-
conjugated streptavidin, and FITC-conjugated anti-Va2, or APC-conjugated anti-
CD4 together with FITC-conjugated anti-Ly5.1, as indicated. Cells were then fixed 
for 20 minutes on ice, washed with cytoperm wash buffer (BD Pharmingen) and 
stained with PE-conjugated anti-IL-2, anti-IL-4, anti-IL-lO or anti-IFNy for 30 
minutes on ice. To look for CD 154 expression, cells were first stained with APC-
conjugated anti-CD4 together with FITC-conjugated anti-Ly5. 1, before fixing, and 
stained with biotinylated anti-CD 154, followed by APC-conj ugated streptavidin, 
both diluted in Cytoperm wash buffer (BD Pharmingen). 
2.7.2. Immunofluorescence 
For experiments analysing costimulatory molecules by immunofluorescence, purified 
CD4 Ly5.1 OT-Il T cells were fluorescently labelled using Cell Tracker Orange 
CMTMR (CT orange, Molecular Probes). Since cells stained with CT orange stay 
fluorescent for up to 3 cell divisions according to the manufacturer, compared to 
CFSE labelled cells, which loose fluoerescence upon cell division, labelling the cells 
using CT orange was more likely to allow tracking of T cells using 
immunofluorescence microscopy. Cells were labelled at 10 7 cells/ml with 25..tM CT 
orange for 15 minutes at 37°C, before adoptive transfer into naïve B6 recipients on 
day -1. As before, mice received SOOjig pOVA in PBS, 500ig pOVA+30g LPS in 
PBS, or PBS alone on day 0, Mice were sacrificed 12 and 36 hours after 
administration of Ag. FACS analysis of spleen cells was carried out as described in 
section 2.7.1. Spleen tissue sections were also snap-frozen in liquid nitrogen, and 5- 
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.tm cryosections were cut on a cryostat (Meica microsystems). Sections were dried 
overright, prior to fixing for 10 minutes in cold acetone, and rehydration for 15 
minutes in PBS. Sections were kept in the dark. All washes were carried out for 2 x 3 
minutes using TBST buffer (0.05M Tris-Hcl pH 7.6, 0.3M NaCI, .01% Tween 20), 
and all incubations were carried out at room temperature in a dark, humidified 
staining chamber. 
Sections were blocked with 3% H202 for 5 minutes, and blocked with avidin-biotin-
blocking reagents (Vector) according to the manufacturers instructions for 15 
minutes each. Sections were then blocked and stained using the DAKO Catalysed 
Signal Amplification (CSA) kit. The kit was used according to the manufacturers 
instructions, but adapted in the final steps for immunofluorescence. Briefly, sections 
were blocked with protein block (DAKO kit) for 15 minutes, before addition of 
primary biotinylated antibody for 15 minutes (CD69, CD 154, 0X40 or OX40L, all 
from Pharmingen as used above for FACS analysis, used at a 1:100 dilution). 
Sections were then incubated with streptavidin-biotin-complex from the DAKO kit 
for 15 minutes, before incubation with amplification reagent for l5minutes. Finally, 
the sections were ihcubated with streptavidin-conjugated Alexa Fluoro 647 
(Molecular Probes), before two final 3-minute washes in . PBS, and mounting with 
Vectashield mounting medium for fluorescence (Vector). Pictures were taken with 
3CCD colour vision camera (controlled by Hamamatsu and Orbit controllers) and 
evaluated with Openlab version 3.0.9 digital imaging programme (Improvision, 
Warwick, UK). This work was carried out in collaboration with Dr Paul Garside and 
Angela Grierson (Department of Immunology, Western Infirmary, University of 
Glasgow). 
2.8. Induction and assessment of EAE 
EAE was induced with s.c. injection of 100.Lg p35-55 in a total of lOOjil CFA 
containing 0.5 mg heat-killed Mycobacterium tuberculosis (50 tl into each hind leg). 
Mice also received 200ng pertussis toxin (ECACC) i.p. in 0.5 ml PBS on the same 
day and 2 days later. This protocol has previously been shown to induce EAE in H2b 
mice (Mendel et al., 1995). Clinical signs of EAE were assessed daily using the 
following scoring index: 0, no signs; 1, flaccid tail: 2, impaired righting reflex andlor 
impaired gait; 3, partial hind leg paralysis; 4, total hind leg paralysis; 5, hind and fore 
leg paralysis; 6, moribound or dead. Differences in total disease burden between 
groups were determined using the Mann-Whitney U test. This statistical test is 
accepted for comparison of data obtained from EAE experiments, and consistenly 
used in the scientific community. A different test, namely calculating the area under 
the curve (of EAE scores plotted against days for each experimental group) and using 
the Kruskal-Wallis test, another rank sum test similar to the Mann-Whitney U test, 
can also be used, and may arguably be more accurate. However, the Mann-Whitney 
U test is the standard test used, and we thus chose to analyse out data using this 
widely accepted statistical test. 
2.9. Generation of bone marrow-chimeric mice 
Recipient mice received 1150 cGy of ny-irradiation via a cesium isotope ( 127Cs) 
source. One day later, recipients received 5x10 6 donor bone marrow cells. Bone 
marrow cells were flushed from femurs and tibias of CD40' mice, depleted of RBC 
using RBC lysis buffer, and depleted of T cells by labelling with a biotinylated anti-
Thyl (clone T24) before incubation with streptavidin-microbeads (Miltenyi Biotec) 
and negative selection with a MACS CS magnetic column. Chimeras were left to 
fully reconstitute their peripheral lymphoid system over at least 8 weeks before use 
in EAE experiments. 
2.10. Generation of T cell lines 
pOVA and pMOG-specific T cell lines (TCL) were generated from B6, CD40' mice 
and CD 154" mice. Mice were immunised with 20tg pOVA/CFA or 100ig 
pMOG/CFA, and DLN were taken 10 days later. TCL were then generated by in 
vitro stimulation of LNC with pOVA or pMOG, and were maintained using a 
standard 7-day restimulation/expansion cycle. TCL were restimulated for 3 days with 
pOVA or pMOG (1st  10tM, then I tM peptide) in the presence of irradiated (30 Gy) 
syngeneic B6 spleen APC. T cell blasts were isolated using a NycoPrep 1.077 animal 
density gradient (Nycomed Pharma, Oslo, Norway) and expanded in wash medium 
supplemented with 5% FCS and 5% Con A-activated rat spleen supernatant as a 
source of T cell growth factors. 
For proliferation and cytokine production assays, T cells were cultured in 96-well 
flat-bottom microtitre plates (Becton Dickinson) at 4x10 4 T cells/well with 5x10 5 
APC/well using tissue culture medium. Both assays were carried out as described in 
sections 2.5.1 and 2.5.2. This method had been optimised prior to my arrival in the 
lab. 
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3. CHAPTER 3 - Exogenous ligation of either CD40 or 
0X40 overcomes a tolerogenic signal 
3.1. Introduction 
Conflicting evidence exists with respect to the requirement of CD154 in the 
induction of T cell immunity as well as T cell tolerance. Early reports showed that 
CD154 T cells fail to prime in vivo, and that CD154 is needed for induction of EAE 
(Grewal et al., 1996; Grewal et al., 1995). More recently, it has been shown that 
CD154' T cells are unable to sustain a response in vivo, and are defective in Thi 
development in vitro (Howiand et al., 2000). Regarding tolerance induction, it has 
been reported that mucosal tolerance via the oral route requires the CD40-CD 154 
interaction (Kweon et al., 1.999). Other groups however reported that CD154' mice 
could successfully be tolerised via i.v. administration of soluble peptide (Howland et 
al., 2000). 
Exogenous ligation of CD40 on APC through administration of agonistic anti-CD40 
monoclonal antibodies has been used extensively to activate APC in vitro (Caux et 
al., 1994; Celia et al., 1996) and in vivo (Chung et al., 2004). It has also been shown 
that administration of agonistic anti-CD40 abrogates tolerogenic presentation to both 
CD4 and CD8 T cells resulting in effective T cell immunity and autoimmune 
pathology (Bennett et al., 1998; Garza et al., 2000; Hawiger et al., 2001), or 
prevention of tolerance to tumours (Diehi et al., 1999; Grohmann et al., 2001; 
Sotomayor et al., 1999). However, others report that administration of agonistic 
CD40 does not prevent tolerance induction (Chung et al., 2004; Sun and Van 
Houten, 2002). One effect of CD40 ligation on APC is the up-regulation of OX40L 
on the surface of the APC (Fillatreau and Gray, 2003). Ligation of 0X40 (up-
regulated on T cells in response to TCR signalling) has been reported to lead to 
elevated T cell expression of survival factors such as Bc!-2 and Bcl-xL (Rogrs et al., 
2001). This chapter describes a series of experiments that tested the requirements for 
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CD 154 expression for tolerance induction, and investigated whether administration 
of agonistic anti-0X40 and anti-CD40 antibodies, prevented peptide-induced 
tolerance. The relevance of this approach was also tested in the disease setting of 
EAE. 
3.2. Approach 
Firstly, the ex vivo recall responses to administration of Ag in CFA (later employed 
to test the induction or prevention of T cell tolerance) were compared in CD40-
deficient, CD154-deficient mice and wild-type (136) mice. In order to induce 
systemic T cell tolerance, a high dose (50Oig) of Ag (either pMOG or pOVA) was 
administered i.v. One of the criteria used to define tolerance is unresponsiveness to 
administration of the Ag in adjuvant, which would normally result in successful T 
cell priming. Throughout this chapter, mice were tolerised by i.v. administration of 
Ag. Some groups of mice received the agonistic antibodies anti-0X40 and anti-
CD40 at the time of i.v. administration of soluble Ag, and two days later, a protocol 
which was adapted from other systems (Diehi et al., 1999; Sotomayor et al., 1999). 
In order to test whether exogenous ligation of CD40 or 0X40 prevented tolerance 
induction, mice were subsequently given Ag in CPA. Tolerance induction would lead 
to diminished proliferation and cytokine production. These responses would be intact 
if tolerance had been prevented. EAE was also used to test the relevance of the 
findings in an autoimmune disease setting. 
The experimental outline of this chapter is shown in Figure 3.1. 
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3.3. Comparison of primary responses in CD40 1 , CD1 54' 
and B6 mice 
Previous studies show that CD40' and CD154' mice are defective in Ag-specific T 
cell responses (Castigli et al., 1994; Grewal et al., 1995; Kawabe et al., 1994; Xu et 
al., 1994). Because the extent of T cell priming can be determined by the route of Ag 
administration and the choice of adjuvant, we compared priming of CD40t CD 154' 
and B6 mice using the Ag and adjuvant subsequently used throughout this series of 
experiments, namely pOVA in CFA and pMOG in CFA. CPA contains 
mycobacterial components that act through TLRs to induce a Th I type response in 
most experimental systems (Schnare et al., 2001). The CD40-CD154 interaction is 
important for the induction of a Thi type response, since ligation of CD40 increases 
IL-12 release by DC, which results in IFN-y production by T cells (Schulz et al., 
2000). The lack of CD 154 or CD40 could therefore have an effect on T cell priming 
using Ag in CFA. 
B6, CD154 and CD40' mice were immunised with pMOG/CFA. Ten days after 
immunisation with pMOG/CFA, cells of the DLN were examined for Ag-specific 
proliferative capacity and cytokine production. B6 mice showed high Ag-specific 
proliferation, high levels of IFN-y, and low levels of IL-4, indicative of a Thi 
response (Fig. 3.2). These results were also applicable to immunisation with 
pOVA/CFA (not shown). While CD40 deficiency led to decreased proliferative 
capacity, proliferation in CD154 mice was comparable to that seen in B6 mice. 
Cytokine production was also impaired differently in the knockouts compared to B6 
control mice (Fig. 3.2). DLN cells from CD40' mice failed to produce considerable 
amounts of IFN-y, but produced some IL-4. CD154 LN cells, on the other hand, 
produced little IFN-y, but large amounts of IL-4, corresponding to a Th2 phenotype 
(Fig. 3.2). 
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Although CD40' mice primed poorly, it was nevertheless possible to make TCL 
after p0 VA/CPA or pMOG/CFA immunisation using DLN from these mice. These 
TCL were assessed for Ag-specific cytokine production after several rounds of 
restimulation with syngeneic B6 APC. Similar to DLN cells from 'mice lacking 
CD 154, TCL cells from CD 154' mice produced little IFN-y, but considerable IL-4 
production, indicative of a Th2 phenotype (Fig. 3.3, even though the background 
levels for IL-4 production were high in both groups, there nevertheless was 
considerable Ag-specific IL-4 production in TCL from CD154' mice). TCL cells 
from CD40' mice, on the other hand, showed considerable IFN-y production after 
several rounds of stimulation, with little IL-4 production (Fig 3.3). This suggests that 
the lack of CD154 on T cells produced a stable Th2 phenotype. The deficits from 
initial priming in the absence of CD40, however, were overcome through 
restimulation in the presence of CD40 on B6 APC, allowing development of a Thi 
phenotype. 
B6 mice thus showed optimal T cell expansion, and displayed a Thi type profile, 
while CD154' mice showed almost optimal T cell expansion, displaying a stable 
Th2 type profile after Ag/CPA immunisation. CD40' mice had reduced T cell 
expansion, with a Th2 type profile, which can be converted to a Thi phenotype 
through restimulation with syngeneic B6 APC. 
3.4. Exogenous ligation of CD40 or 0X40 influences the 
cytokine response in CD1 54/  mice 
The lack of the CD40-CD 154 interaction thus shifts the cytokine response towards a 
Th2 profile. The 0X40-OX40L interaction has been implicated to be important for 
the induction of Th2 type responses (Flynn et al., 1998; Linton et al., 2003). 
Agonistic antibodies to CD40 and 0X40 were used to test if exogenous ligation of 
these two molecules would influence the cytokine profile in CD154 4 mice. Mice 
were immunised with pMOG/CFA on day 0, and some groups received anti-CD40 or 
anti-0X40 antibodies at the same time, and two days later. Ligation of CD40 greatly 
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reduced IL-4 levels relative to those seen in CD154' control mice, but had no 
significant effect on IFN-y levels. Ligation of 0X40 resulted in increased levels of 
both IL-4 and IFN-'y (Fig. 3.4). Isotype control antibodies for anti-CD40 and anti-
0X40 were not available at the time of these experiments. However, administration 
of isotype controls in later experiments did not have the effects seen with 
administration of anti-CD40 or anti-0X40. Exogenous ligation of CD40 thus 
appeared to shut off IL-4 production in CD154' mice without an increase in IFN-y 
production, while exogenous ligation of 0X40 greatly enhanced both IL-4 and WN-1 
production. This experiments remains to be repeated, but indicated a differential 
effect of anti-CD40 and anti-0X40 on cytokine production. 
3.5. CD154 is not required for peptide-induced tolerance 
Previous reports give conflicting results with respect to the importance of CD 154 
during peptide-induced tolerance induction (Kweon et al.,.1999), (Howland et al., 
2000). In order to address this question in the experimental system used here, mice 
received one dose of pOVA i.v. or 3 doses of pMOG i.p., two tolerisation protocols, 
which have both been used extensively by our laboratory and others to effectively 
induce T cell tolerance. 7 days after administration of soluble peptide, mice received 
the same peptide in CFA. Unresponsiveness to this rechallenge with Ag in adjuvant 
would indicate successful tolerance induction. Since profound effects on proliferative 
capacity were observed after i.v. or i.p. administration of both pOVA and pMOG 
(Fig. 3.5), tolerance was induced successfully in the absence of CD 154. CD154 was 
thus not required for peptide-induced tolerance to pOVA or pMOG. 
3.6. Peptide-induced tolerance diminishes cytokine 
responses in both B6 and CD154 mice 
To further investigate the effects of i.v. administration of pOVA on T cell effector 
function, pOVA-specific cytokine ELISAs were carried out 10 days after in vivo 
rechallenge with pOVA in CFA. Both the Thi type response in B6 mice, and the Th2 
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type response in CD154' mice were ablated after administration of soluble pOVA 
(Fig. 3.6). 
3.7. Investigating the roles of CD40 and 0X40 in peptide-
induced tolerance 
Exogenous ligation of CD40 activates APC in vivo, and has previously been reported 
to result in effective immunity against tumours (Diehl et al., 1999; Grohmann et al., 
2001; Sotomayor et al., 1999). Based on the central hypothesis, administration of 
agonistic anti-CD40 should also prevent tolerance induction by administration of 
soluble peptide. Similarly, if agonistic anti-CD40 prevents tolerance through up-
regulation of OX40L on DC, which then binds to 0X40 on activated T cells, 
exogenous ligation of 0X40 should prevent peptide-induced tolerance. In order to 
elucidate the importance of the CD40-CD154 and OX40L-0X40 interactions in the 
experimental system used here, the ability of agonistic anti-CD40 and anti-0X40 to 
prevent induction of tolerance was investigated. 
Since both i.v. and i.p. administration of Ag resulted in tolerance induction, the 
protocol chosen to use in subsequent experiment was i.v. administration of Ag, 
which only required a single dose of 500.tg pOVA, rather than three doses of 200ig 
pOVA. 
3.7.1. Exogenous ligation of CD40 or 0X40 does not convert 
a tolerogenic signal into an immunogenic one 
To test whether administration of agonistic anti-0X40 and anti-CD40 could convert 
tolerance into immunity in the experimental system used, B6 or CD154 mice 
received 200jig of anti-CD40, anti-0X40 or isotype control antibody on the same 
day as i.v. administration of 500ig pOVA and a second dose of antibody two days 
later. Initially, pOVA was not given in CFA at day 7. Instead, ex vivo recall 
responses to a dose range of pOVA were examined 7 days after Ag administration, to 
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test whether administration of these antibodies could result in effective T cell 
priming. Administration of pOVA alone did not result in effective recall responses, 
and neither anti-CD40, nor anti-0X40 administration resulted in effective T cell 
priming in B6 or CD154' mice (Fig. 3.7). 
3.7.2. Exogenous ligation of CD40 or 0X40 prevents 
tolerance induction in B6 and CD1 54' mice 
Although administration of anti-CD40 or anti-0X40 did not result in T cell priming, 
it was possible that administration of these antibodies nevertheless allowed the T 
cells to maintain responsiveness to subsequent in vivo challenge of Ag in adjuvant. 
B6 or CD154' mice therefore received 500tg pOVA i.v. at day -7, with or without 
anti-CD40, anti-0X40 or isotype control antibodies on the same day and two days 
later, followed by administration of 20jig pOVA/CFA on day 0 and examination of 
ex vivo recall responses to a dose range of pOVA on day 10. Ligation of CD40 and 
0X40 in B6 and CD40 in CD154 mice increasedproliferative responses to levels 
comparable to non-tolerised controls, while in CD 154' mice, ligation of 0X40 
further increased the proliferative response (Fig. 3.8). Administration of isotype 
control antibodies did not have this effect. This shows that although ligation of CD40 
or 0X40 did not result in effective T cell priming, it did prevent tolerisation of the T 
cells in bothB6 and CD154' mice. 
3.7.3. Exogenous ligation of CD40 or 0X40 partially prevents 
tolerance induction in the absence of B cells 
Although DC are responsible for the initiation of primary T cell responses in vivo 
(Banchereau et al., 2000), B cells are important in the induction of effective T cell 
immunity. CD40 and 0X40 are both expressed on activated B cells (Banchereau et 
al., 1994; Croft, 2003), but the importance of this expression for successful T cell 
priming remains to be determined (A. Crawford, personal communication). If CD40 
and 0X40 on B cells do not play a role in the prevention of T cell tolerance, ligation 
of CD40 and 0X40 at the time of administration of soluble peptide in iMT mice, 
which lack B cells, should still result in restoration of effective proliferative 
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responses. j.tMT mice thus received 500.tg pOVA i.v. at day -7, with or without anti-
CD40, anti-0X40 or isotype control antibodies on the same day and two days later, 
followed by administration of 20p.g pOVAICFA on day 0 and examination of ex vivo 
recall responses to a dose range of pOVA on day 10. Peptide-induced tolerance to 
pOVA was successfully induced in jiMT mice, indicating that B cells do not play a 
significant role in the induction of tolerance to soluble peptide. Administration of 
both anti-CD40 and anti-0X40 partially prevented tolerance induction as evident 
after immunisation with pOVAICFA (Fig. 3.9), an effect not seen after 
administration of isotype control antibodies. Anti-CD40 and anti-0X40 are therefore 
most likely to act on DC and T cells respectively to prevent tolerance induction, but a 
role for B cells in restoring responsiveness cannot be totally excluded. 
3.8. Induction and prevention of tolerance to EAE 
EAE is a mouse model for multiple sclerosis, and can be induced experimentally in 
mice in various ways (Bhardwaj et al., 1994; Sakai et al., 1988; Zamvil et al). Here, 
EAE was induced in H2b  mice by immunisation with pMOG in CFA. The activation 
of autoreactive CD4 T cells of the ThI functional phenotype after immunisation 
results in induction of EAE, characterised by a paralysis, which typically peaks 
around 2 weeks after immunisation with Ag. By four weeks after Ag administration 
the mice have recovered from the disease. 
To investigate whether i.v. administration of Ag could induce T cell tolerance and 
prevent the induction of EAE, mice received a single dose of 500ig pMOG 7 days 
prior to the induction of EAE. This approach resulted in tolerance and protection 
from EAE (Fig. 3.10). 
3.8.1. Exogenous ligation of 0X40 prevents tolerance 
induction to EAE in 136 mice 
The importance of the CD40-CD 154 interaction in EAE is well-documented 
(Gemtse et al., 1996; Grewal et al., 1996; Samoilova et al., 1997), while the 
importance of the 0X40-OX40L interaction has more recently been described to be 
relevant for development of clinical symptoms in EAE (Ndhlovu et al., 2001; Nohara 
et al., 2001; Weinberg et al., 1999). Since the present study showed that 
administration of anti-0X40 could prevent tolerance induction to a model Ag 
(pOVA), this approach was extended into the EAE setting. 200j.lg of anti-0X40 or 
isotype control antibody was administered i.p. at the time of i.v. administration of 
pMOG (day —7) and two days later. On day 0, EAE was induced by administration of 
pMOG in CPA, and i.p. injections of PTX on days 0 and 2. This experiment was 
carried out once. These preliminary results showed prevention of tolerance induction 
by administration of anti-0X40, with mice developing clinical signs of EAE similar 
to those seen in non-tolerised control mice (Fig. 3.10). 
3.8.2. Exogenous ligation of 0X40 in CD40-deficient mice 
does not lead to induction of EAE 
CD40' mice do not develop clinical signs of EAE (Becher et al., 2001). Since 
ligation of 0X40 results in increased number of Ag-specific T cells, and an increased 
memory T cell population (Gramaglia et al., 2000), we wanted to test whether 
administration of anti-0X40 could overcome the lack of CD154 signalling, and lead 
to priming of self-reactive T cells in CD40' mice, resulting in induction of EAR 
200ig anti-0X40 or isotype control antibody was given to CD40-deficient mice at 
the time of EAE induction, and two days later. However, administration of anti-
0X40 did not restore the induction of EAE (Fig. 3.11). 
3.8.3. CD40 expression on bone marrow-derived cells is 
required for typical EAE disease progression 
Previous reports suggested that CD40 expression in the CNS is of critical importance 
for development of clinical signs of EAE (Becher et al., 2001). Administration of 
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anti-0X40 in CD40' mice did not restore the induction of EAE, which was 
potentially due to the lack of CD40 expression in the CNS. Bone marrow chimeras, 
which lacked expression of CD40 on all bone marrow-derived cells, but not on any 
other cells in the body, were produced, and allowed to reconstitute for 8 weeks, 
before induction of EAE. The absence of CD40 on bm-derived cells was confirmed 
by FACS analysis. The lack of CD40 expression on bone marrow-derived cells 
resulted in greatly decreased severity of disease compared to B6 controls. 
Nevertheless, these mice did develop some signs of disease, in contrast to CD40' 
mice, where the global lack of CD40 totally prevented EAE (Fig. 3.12). 
3.9. Summary 
This chapter investigated the requirement of CD154 on T cells for the induction of 
tolerance, and the potentialto prevent tolerance induction through the administration 
of agonistic antibodies to CD40 and 0X40. It was found that CD 154-deficient mice 
gave Ag-specific ex vivo recall responses, suggesting successful T cell priming upon 
immunisation with Ag. CD40' mice however failed to prime efficiently, shown by a 
considerable decrease in ex vivo recall responses. Immunisation of CD 1541  mice 
with Ag in an adjuvant known to induce a Thi type cytokine profile resulted in a Th2 
type cytokine profile. This Th2 profile could only be partially shifted to a Thi profile 
by exogenous ligation of CD40 at the time of Ag challenge (decreased IL-4 
production, but no increased WN-y production). Exogenous ligation of 0X40 at the 
time of immunisation greatly increased the production of both type I and type 2 
cytokines in CD154' mice. The results indicate a possible quantitative effect of 
0X40 ligation on the immune response, while CD40 ligation has a qualitative effect 
with respect to the cytokine profile observed. 
Intravenous administration of soluble peptide produced Ag-specific T cell 
unresponsiveness in the absence of CD 154 signalling. This T cell tolerance could be 
prevented by exogenous ligation of CD40 or 0X40, in CD154 mice as well as B6 
mice. B6 mice were successfully tolerised against the induction of EAE by iv. 
administration of pMOG, which could similarly be prevented through administration 
of 0X40 at the time of Ag administration. Expression of CD40 in the CNS was 
required for optimal induction of EAE, and exogenous ligation of 0X40 did not 
induce EAE in CD40-deficient mice. It is concluded that although the CD40-CD 154 
interaction is important in T cell responses, CD 154 on T cells is not absolutely 
required for either initiation of T cell immunity or induction of T cell tolerance. 
Nevertheless, the results presented in this chapter indicate that the CD40-CD 154 and 
0X40-OX40L interactions are indeed important checkpoints determining firstly the 
outcome of T cell immunity with respect to tolerance versus immunity, and secondly 
the cytokines produced in response to antigenic challenge. 
3.10. Discussion 
Although, it was originally reported that CD154' mice do not prime effectively 
(Grewal et al., 1996), it has since then been shown that CD154 T cells initially 
expand normally, but cannot sustain a Thi type response (Howland et al., 2000). It 
was shown here that CD154' mice prime normally compared to B6 mice. In the 
experimental system employed, the Ag is emulsified in CFA, which is believed to 
provide a lasting suppl'y of Ag (it remains to be investigated for how long). Although 
it has been shown that in CD 154' mice, Ag-loaded DC failed to migrate out of the 
skin and fewer DC accumulated in the DLN after contact sensitisation (Moodycliffe 
et al., 2000), an Ag depot may explain the effective recall responses seen here after 
immunisation of CD154-deficient mice with Ag in CFA, since such a depot may 
have allowed sufficient numbers of Ag-loaded DC to reach DLN. This Ag depot 
could thus have rescued proliferative responses, but would not rescue CD 154 
signalling to DC. A lack of CD154 signalling to DC would cause decreased IL-12 
production by DC, and result in a Th2 type profile, which was indeed observed in 
this system. 
This same explanation should however hold true for C1340-deficient mice. Instead, 
mice lacking CD40 showed greatly reduced proliferative and cytokine responses. 
CD40 ligation is required for DC migration from the site of Ag administration to 
DLN, as well as during DC-T cell interactions in the DLN (Miga et al., 2001; 
Moodycliffe et al., 2000). A better explanation for the recall responses, which were 
observed in CD154 mice, but not CD40' mice, may thus be the existence of a 
different ligand for CD40, which compensates for the lack of CD 154 at the site of 
CFA injection. This would again allow DC migration to DLN, where they could 
interact with T cells, and in the absence of CD 154, induce a Th2 type response. In 
CD40' mice however, the lack of CD40 would result in ineffective DC migration, 
and thus result in greatly decreased proliferative recall responses. The 70 kDa 
mycobacterial heat shock protein (HSP 70) has been described to bind CD40 and 
result in release of chemokines (Wang et al., 2001). The presence of HSP 70 in CFA 
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might have substituted for the lack of CD154 at the site of CFA injection and 
allowed efficient T cell priming in CD 154' mice,but not in CD40' mice. 
Although conflicting evidence exists with respect to a CD154 requirement for 
tolerance induction (Howland et al., 2000; Kweon et al., 1999), it was shown here 
that CD 154 was not required for peptide-induced tolerance. The results obtained 
agree with previous data, that showed that systemic i.v administration of soluble 
peptide did not require the presence of CD154 (lowland et al., 2000). The 
contrasting results were obtained using a different experimental system, and 
investigated the requirements for mucosal tolerance after orally administered Ag 
(Kweon et al., 1999). Further evidence suggests that tolerance is differentially 
regulated at these different peripheral sites. On the one hand, ligation of CD40 has 
been used extensively to promote anti-tumour immunity (Diehl et al., 1999; 
Grohmann et al., 2001; Sotomayor et al., 1999), and to activate quiescent DC, 
breaking peripheral tolerance in vivo (Hawiger et al., 2001). On the other hand, in 
systems investigating mucosal tolerance, ligation of CD40 was not sufficient to 
prevent tolerance induction, even though it led to upregulation of CD80 and CD86 
on DC, and potentiated the proliferation of Ag-specific T cells in lymphoid organs 
(Chung et al., 2004). Similarly, activation of resident DC through administration of 
Flt3 Ligand, a growth factor that expands DC in vivo, prevented systemic tolerance 
(Pulendran et al., 1998), while it enhanced mucosal tolerance (Viney et al., 1998). It 
may well be that tolerance is differentially regulated at different peripheral sites, 
probably through DC biology. 
Exogenous ligation of CD40 successfully prevented the induction of tolerance 
through i.v. administration of soluble peptide, fitting with data obtained from other 
experimental systems (Diehl et al., 1999; Hawiger et al., 2001). Since one effect of 
CD40 ligation on is the upregulation of OX40L, it appears that the agonistic CD40 
antibody may be exerting its effects through induction of OX40L, allowing 
signalling to T cells and subsequent induction of survival molecules, resulting in 
effective T cell immunity. This is further investigated in the following chapter. 
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Exogenous ligation of 0X40 also prevented the induction of T cell tolerance, 
probably by directly ligating 0X40 on T cells and promoting T cell survival. This 
was similarly suggested in a recent paper investigating the effects of exogenous 
ligation of 0X40 (Bansal-Pakala et al., 2001). Using a T cell adoptive transfer 
system, this group reported successful tolerance induction through a single i.v. dose 
of soluble peptide, illustrated by reduced proliferative capacity upon in vitro 
rechallenge, and lack on IFN-y or IL-4 production, comparable to the data presented 
here. They prevented this tolerance through exogenous ligation of 0X40 at the time 
of administration of soluble peptide. Finally, they also report reversal of tolerance 
through 0X40 ligation at the time of giving peptide in CFA (i.e. at the time of in vivo 
rechallnge with Ag in adjuvant, rather than at the time of administration of soluble 
peptide). This raises the question of the exact timing of the immunogenic effect of 
the anti-0X40 antibody. While anti-0X40 may indeed have acted at the time of 
administration of soluble peptide, promoting T cell survival, without actually 
allowing T cell proliferation (Fig. 3.7), it cannot be excluded that anti-0X40 exerted 
its effects at the time of rechallenge with Ag in adjuvant. Identification of ways to 
reverse peptide-induced tolerance may lead to insights into preventing unwanted 
tolerance against tumours, holding great therapeutic potential, and further 
investigation needs to be carried out. 
The importance of the CD40-CD 154 interaction for the induction of EAE has 
previously been investigated in some detail (Gerritse etal., 1996; Grewal et al., 1996; 
Samoilova et al., 1997). CD40 deficient mice did not develop clinical signs of EAE, 
which correlates with more recently obtained data from a different group (Becher et 
al., 2001). Similarly, this group reported that the lack of CD40 on bone marrow-
derived cells resulted in decreased disease severity, which is also shown in this 
chapter. Exogenous ligation of 0X40 could not induce disease in CD40-deficient 
mice. Unfortunately, the ability of agonistic anti-0X40 to induce disease in mice 
lacking expression of CD40 on bone marrow-derived cells could not be investigated, 
due to time constraints. This antibody greatly enhanced cytokine responses in 
CD 154-deficient mice, inducing large amounts of IFN-y, and also prevented peptide- 
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induced tolerance to pOVA and pMOG. It seems likely therefore, that exogenous 
ligation of 0X40 in CD40-deficient bone marrow chimeras would greatly enhance 
disease scores seen in these mice. This possibility remains to be investigated. 
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Experimental outline of Chapter 3 
Does exogenous ligation of CD40 or 0X40 prevent the induction 
of tolerance? 200 jig anti-CD40, anti-0X40 or isotype control 
antibody was co-administered with 500p.g pOVA on day —6, and 
mice received a second dose of antibody on day —4. 
The EAE model. Tolerance induction and induction of EAE. 
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Figure 3.2: 
Comparison of T cell priming in CD40', CD154' and B6 mice 
after immunisation with pMOG in CFA 
Mice received 100p.g pMOG in CFA on day 0. Draining lymph 
nodes were assessed 10 days later for pMOG-specific proliferative 
responses or by ELISA for pMOG-specific IFN-1 or IL-4 
production. Background levels were as levels seen at lowest 
concentration of Ag in each group. For each cytokine datapoint, the 
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Figure 3.3: 
Cytokine production by TCL derived from CD40' or CD154' 
mice 
Mice received pMOG in CFA. DLN were taken 10 days later, and 
TLC established as described in the materials in methods. pMOG-
specific IL-4 and IFN-y production (A and B respectively) was 
assessed by ELTSA. Background levels were as follows: IL-
4(pg/ml): CD 154 -1- mice 98, CD40' mice 116; IFN-y (ng/ml): 
CD 154-'- mice 0.7, CD40' mice 2). For each datapoint, the SEM 
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Fig. 3.4: 
Exogenous ligation of CD40 or 0X40 influences the cytokine 
response in CD154' mice 
CD154 mice received lOOjig pMOG in CFA at day 0. As 
indicated, some groups also received 200ig anti-0X40 or anti-
CD40 at the time of pMOG in CFA administration and 2 days later. 
Draining lymph nodes were assessed 10 days later by ELISA for 
pMOG-specific IL-4 and TFN-y production to a dose range of 
pMOG (A: 1L-4, B: IFN-y). The effects seen with anti-CD40 and 
anti-0X40 were not found using isotype control antibodies. 
Background levels in each group were below detectable levels. For 
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Fig. 3.5: 
CD154 is not required for peptide-induced tolerance 
Mice received 3 doses of 500tg pMOG or PBS i.p., on days -8, -6 
and —4 (A) or a single dose of 500jig pOVA i.v. on day —7 (B), 
before immunisation with pMOG or pOVA in CFA on day 0. 
Draining lymph nodes were assessed 10 days later for pMOG or 
p0 VA-specific proliferative responses respectively. These data are 
from one of five giving consistent results. Background cpm in each 
group were as follows: pMOG: PBS 3291, peptide-treated CDl54 
mice 2834; pOVA: PBS 2375, peptide-treated CDlS4 mice 6224. 
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Peptide-induced tolerance diminishes cytokine responses in B6 
and CD154' mice 
Mice received 5001g of pOVA i.v. on day —7, before 
administration of pOVA in CFA on day 0. Draining lymph nodes 
were assessed 10 days later by ELISA for p0 VA-specific cytokine 
production. Shown are IFN-y and IL-4 production by B6 mice (A 
and B respectively) and CD 154 -'- mice (C and D). These data are 
from one of three experiments giving consistent results. The 
background cpm for all cytokines was below detectable levels in all 
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Fig. 3.7: 
Exogenous ligation of CD40 or 0X40 does not convert a 
tolerogenic signal into an immunogenic one 
B6 or CD 154 -'- mice received a single dose of 500p.g pOVA i.v. As 
indicated, some groups also received 200p.g anti-0X40 or anti-
CD40 at the time of pOVA administration and 2 days later. 
Draining lymph nodes were assessed 7 days later for proliferative 
responses to a dose range of pOVA (A: B6 mice, B: CD 154 -' - mice). 
Background proliferation was as proliferation observed at iO for 
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Exogenous ligation of CD40 or 0X40 prevents tolerance 
induction in B6or CD154' mice 
B6 or CD154 mice received a single dose of 500ig pOVA i.v. on 
day —7. As indicated, some groups also received 200.1g anti-0X40 or 
anti-CD40 at the time of pOVA administration and 2 days later. Mice 
were then immunised with pOVAJCFA on day 0, and draining lymph 
nodes assessed 10 days later for proliferative responses to a dose 
range of pOVA (A: B6 mice, B: CD154 mice). The effects seen 
with anti-CD40 and anti-0X40 were not found using isotype control 
antibodies. These data are from one of three experiments giving 
consistent results. Background cpm were as follows: B6: PBS 2038, 
pOVA 1530, pOVA+anti-CD40 1214, pOVA+anti-0X40 1483; 
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Exogenous ligation of CD40 or 0X40 partially prevents 
tolerance induction in B cell-deficient mice 
pMT mice received a single dose of 500.tg pOVA i.v. on day —7. 
As indicated, some groups also received 200Ig anti-0X40 or anti-
CD40 at the time of pOVA administration and 2 days later. Mice 
were then immunised with pOVAICFA on day 0, and draining 
lymph nodes assessed 10 days later for proliferative responses to a 
dose range of pOVA. These data are fiom one of two experiments 
giving consistent results. Background levels were as follows: PBS 
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Fig. 3.10: 
Exogenous ligation of 0X40 prevents tolerance induction to 
EAE in B6 mice 
Mice received a single dose of 50Otg pMOG i.v. on day —7. As 
indicated, some groups also received 200tg anti-0X40 at the time 
of pMOG administration and 2 days later. EAE was then induced 
through immunisation with pMOG/CFA on day 0 and PTX was 
given at the same day and 2 days later. Clinical EAE scores were 
assessed daily from day 7-28. The effects seen with anti-0X40 
were not found using an isotype control antibody. These results are 
from one preliminary experiment, and remain to be repeated. (p 
values determined by Mann-Whitney U test were: B6 controls vs. 
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Fig. 3.11: 
Exogenous ligation of 0X40 does not restore induction of EAE 
in CD40' mice 
EAE was induced through immunisation with pMOG/CFA on day 
0. PTX was given at the same day and 2 days later. One group also 
received antiOX40 i.p. at the time of immunisation and 2 days 
later. Clinical EAE scores were assessed daily from day 7-28. (p 
values determined by Mann-Whitney U test were: B6 controls vs. 
CD40' controls: <0.0001, B6 controls vs CD40+anti-OX40: 
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Fig. 3.12: 
CD40 expression on bone marrow-derived cells is required for 
typical EAE disease progression 
Chimeras lacking CD40 expression on all bone marrow-derived 
cells were generated. EAE was induced through immunisation with 
pMOG/CFA on day 0. PTX was given at the same day and 2 days 
later. Clinical EAE scores were assessed daily from day 7-28. (p 
values determined by Mann-Whitney U test were: B6 controls vs. 
CD40 controls: <0.0001, B6 controls vs. CD40chimeras: 
<0.0001), CD40 controls vs. CD40 chimeras: <0.0001) These 
results are from one preliminary experiment. 
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4. CHAPTER 4 - Kinetics of costimulation during the 
induction of T cell tolerance versus immunity 
4.1. Introduction 
The previous chapter illustrated that exogenous ligation of either CD40 or 0X40 
could prevent the induction of T cell tolerance. This suggests that upregulation of 
one or both these costimulatory molecules occurred during tolerance induction, and 
indicates that .molecules known to be important for T cell activation may also play a 
role in T cell tolerance. This chapter investigated at which time-points during this 
process these receptors and their ligands were expressed. Expression of a third 
receptor-ligand pair, namely RANK-RANKL, was also examined. The RANK-
RANKL interaction was reported to be important for DC survival (Cremer et al., 
2002), and treatment of DC with RANKL before transfer into mice enhances their 
survival in the DLN, resulting in enhanced T cell responses (Josien et al., 2000). This 
pair could therefore play a role in the decision between tolerance and immunity. All 
three pairs are thus known to play an important role during T cell activation, but to 
date their expression during the induction of T cell tolerance has not been 
investigated. 
LPS has known effects on DC migration and activation (Reis e Sousa and Germain, 
1999), but most experimental data available stems from histological evaluation with 
regards to DC location, and from in vitro activation of DC. Although it is assumed 
that tolerance induction is the result of peptide presentation by quiescent DC, which 
lack full costimulatory potential (Steinman et al., 2003), few experiments actually 
look at the DC phenotype during the induction of T cell tolerance. Similarly, little ex 
vivo data exists, showing the state of DC activation after LPS administration. The 
• experiments in this chapter were designed to test the view that T cell immunity is the 
result of DC activation through microbial signals, whilst tolerance induction is a 
result of peptide presentation by immature DC, and sets out to reveal possible 
differences in costimulatory molecule expression on T cells during the induction of T 
cell tolerance or immunity. 
4.2. Approach 
Since T cell responses in naïve mice involve a very small number of Ag-specific T 
cells, it was necessary to use an adoptive transfer system to look at the T cell 
phenotype during the induction of tolerance. The use of TCR transgenic T cells from 
OT-Il mice (Barnden et al., 1998) allowed the transfer of a specific number of 
pOVA-reactive T cells into naive B6 hosts, enabling tracking of a defined number of 
Ag-reactive T cells. OT-Il cells express the Va2 and Vj35 TCR chains, and initially, 
the transferred cells were identified using monoclonal antibodies to these TCR 
chains. However, naïve B6 mice have endogenous Va2t Vl35 T cells, which are not 
necessarily p0 VA-reactive. OT-Il mice were therefore crossed with mice expressing 
the congenic marker Ly5. 1 (CD45. 1), and were identified by expression of this 
marker during subsequent FACS analysis (host B6 mice express Ly5.2). UT-Il cells 
were adoptively transferred into naïve hosts, before pOVA was administered in 
tolerogenic, i.e. soluble form, or immunogenic form, i.e. with LPS as adjuvant. At 
various time points after Ag administration, mice were sacrificed, and the transferred 
T cell population in the spleen was analysed by FACS. 
DC constitute about 1% of spleen cells, and gating on splenic DC during FACS 
analysis is difficult due to the heterogeneous level of expression of the CDIIc 
marker. DC were therefore purified before FACS analyses. Although purification 
may result in DC activation, it was necessary in order to examine the phenotype of 
the splenic DC population. A grdup, which received PBS, rather than pOVA in any 
form, was used as a control for possible DC activation and change in surface 
phenotype due to the purification process employed. Any reported changes in 
costimulatory molecule expression are with respect to this control group. 
The experimental outline is shown in Figure 4.1. 
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4.3. Administration of soluble pOVA induces Ag-specific 
tolerance in TCR transgenic T.cells 
The previous chapter shows that i.v. administration of soluble pOVA results in 
pOVA-specific T cell tolerance. In order to look at the phenotype of a defined 
population of T cells, the OT-Il adoptive transfer system was employed in most of 
the subsequent experiments. It was therefore important to test that systemic 
administration of soluble pOVA could similarly induce tolerance after the transfer of 
a large number of Ag-specific T cells. Mice received OT-Il cells on day —1, followed 
by 500p.g pOVA on day 0, and in vivo rechallenge with 20tg pOVA in CFA on day 
7. Greatly reduced T cell ex vivo recall proliferative responses were observed on day 
17, even after transfer of OT-Il cells (Fig. 4.2). Administration of a single dose of 
soluble pOVA could therefore be used in subsequent experiments to investigate the 
phenotype of DC and p0 VA-reactive T cells during the induction of T cell tolerance. 
4.4. Co-administration of LPS (but not CpG) leads to T 
cell immunity 
With the aim to compare T cell phenotype during the induction of T cell tolerance 
compared to the induction of T cell immunity, LPS and CpG were tested as adjuvants 
to prevent the induction of T cell tolerance, since both can be administered i.v. at the 
same time as soluble pOVA. OT-il cells were adoptively transferred into naïve B6 
hosts I day prior to the hosts receiving either 50Oig pOVA, 500Ig pOVA with 51g, 
10tg or 30.tg CpG (5tg has been used by others to induce immunity (Vicari et al., 
2002)), or 500Ig pOVA with 30tg LPS (various doses of LPS have previously been 
shown to induce immunity (Khoruts et al., 1998; Maxwell et al., 2002), and 301g 
was tested, and found to work efficiently to prevent tolerance). Splenic populations 
were assessed 7 days later for proliferative responses to a dose range of pOVA (Fig. 
4.3). Co-administration of pOVA and LPS did not result in tolerance induction, but 
allowed efficient recall responses, while co-administration of pOVA and CpG did 
not result in effective T cell immunity, since responses were similar to those seen 
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with pOVA alone, (Fig. 4.3, shown is pOVA co-administration with 30jig CpG, 
which was the highest dose used. Other doses included 5.p.g and 10tg CpG, which 
also did not prevent the induction of tolerance in this system, results not shown). 
CpG did however have an effect on DC in vitro, as shown through upregulation of 
CD40, CD80 and CD86 on bone manow-derived DC after incubation with 6tgIml 
(1tM) CpG overnight (Fig. 4.4). Other groups have administered CpG 
intratumorally to prevent tolerance against tumours (Vicari et al., 2002). This very 
localised delivery of CpG may explain the ability of CpG to prevent tolerance in that 
system, compared to systemic administration of CpG in the system used here. Since 
administration of pOVA with LPS resulted in effective T cell immunity, this protocol 
was used in subsequent experiments to compare the phenotype of DC and pOVA-
reactive T cells during induction of T cell immunity versus T cell tolerance. 
4.5. Phenotypic analysis of DC and T cells during the 
induction of T cell immunity versus T cell tolerance 
Having established that administration of pOVA alone resulted in T cell tolerance, 
while co-administration of pOVA and LPS induced T cell immunity, experiments 
were carried out to look at the phenotype of T cells and DC during these two 
processes. In all of the subsequent experiments in this chapter, CD4 OT-IT cells 
were purified by positive selection using anti -CD4-conj ugated MACS beads, prior to 
transfer into naïve recipients on day-i. On day 0, mice received the indicated 
administration protocol of pOVA alone or pOVA and LPS, and mice were sacrificed 
at various time points following Ag administration. Spleens were disaggregated, 
before DC were purified by positive selection using anti-CD lic beads. The 
flowthrough of this purification was kept to analyse the transfened T cell population. 
By day 2 after Ag administration, transfened OT-Il cells started to expand in 
numbers. T cells in groups that received pOVA alone consistently showed greater 
expansion at day 2 after Ag administration compared to pOVA+LPS groups. In the 
particular experiment shown (Fig. 4.5), CD4, Ly5.1 OT-Il cells made up 1.65% 
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(pOVA alone) and 0.31% (pOVA+LPS) of total lymphocytes on day 2. By day 3, 
both groups showed significant expansion (4.52% and 3.79% respectively). By day 
4, the p0 VA-specific T cell population in mice that had received pOVA alone started 
to decrease in number (3.19), indicating the induction of tolerance, while in mice that 
had received pOVA+LPS, the T cells continued to expand in numbers (7.18%) (Fig. 
4.5). 
The greater expansion seen at day 2 after administration of p0 VA alone could have 
been due to earlier entry into proliferation phase in this group, or due to greater 
expansion of T cells at these early time points. In order to distinguish between these 
two possibilities, CD4-purified Ly5.1 OT-Il cells were CFSE-labelled before 
adoptive transfer into naïve recipients on day-i. The CFSE profile of OT-Il cells was 
examined at days 1, 2, 3 and 4 after pOVA administration with or without LPS. 
Again, mice that had received pOVA alone showed a greater number of pOVA-
reactive T cells on day 2 than those that had received pOVA+LPS. Overlaying the 
CFSE profiles of groups that had received pOVA or pOVA+LPS allowed 
comparison of the number of cell divisions undergone in each group (Fig. 4.6b). This 
showed that the number of cell divisions in each group was similar at day 2, and the 
difference in T cell numbers are thus not due to earlier entry into cell division after 
administration of pOVA alone. By day 3 post Ag administration, both groups 
showed significant expansion as before (compare Fig. 4.5 and 4.6), but the CFSE 
profiles revealed that the cells had undergone greater numbers of cell division after 
administration of pOVA+LPS, compared to administration of pOVA alone (Fig. 
4.6b). By day 4, pOVA-reactive T cell numbers continued to increase during the 
induction of immunity, while numbers in mice that had been given pOVA alone had 
greatly reduced numbers of p0 VA-reactive T cells (Fig. 4.6). 
Fig. 4.5 and Fig. 4.6 illustrate the variation in percentages of pOVA-reactive cells 
seen between different experiments. These differences are probably due to the 
variations in transferred numbers, cell death after transfer (CFSE-labelled cells are 
more fragile, and prone to dying due to the way they have been prepared), and 
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differences in effectiveness of Ag administration. Nevertheless, the same trend was 
consistently observed in all experiments, and variation between experiments was 
therefore acceptable. 
4.6. Expression of costimulatory molecules on T cells 
during the induction of tolerance or immunity 
The establishment of systemic T cell tolerance takes at least three days (Liu and 
Wraith, 1995), and it was therefore decided to carry out a time course over 4 days, 
looking at the phenotype of T cells and DC during the induction of T cell tolerance 
and immunity. The experimental data obtained from days 3 and 4 were the same in 
all experimental groups unless indicated otherwise, and the results for days 1, 2 and 3 
are therefore shown. 
The transferred T cells were identified during FACS analysis by staining for the 
congenic marker Ly5.1, and gating onto CD4, Ly5.1F  cells. Expression of CD69, 
CD154, 0X40 and RANKL was analysed on this population of cells. CD69 is a 
marker accepted to be expressed very early after T cell stimulation. Since there is no 
evidence that this molecule has costimulatory capacity, it was solely used as a 
marker of T cell activation in these experiments. Although T cells expressed higher 
levels of CD69 after administration of pOVA with LPS (Appendix Fig. 1), the 
marker was expressed after administration of either pOVA alone, or pOVA with 
LPS, indicating successful initial T cell activation in both cases. 
4.6.1. Tolerance is not due to the absence of CD1 54 
expression on T cells 
Mice were sacrificed on days 1, 2 and 3 after Ag administration, and the expression 
profile of CD154 on transferred T cells was investigated at these time-points. CD154 
was expressed on days I and 2 after administration of pOVA and pOVA+LPS (Fig. 
4.7). By day 3, only a small percentage of transferred cells still expressed CD154. 
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CD 154 was expressed on the T cell during the induction of both T cell tolerance and 
immunity, although it appeared to be expressed for longer on T cells during the 
induction of T cell immunity. 
4.6.2. Tolerance is not due to the absence of 0X40 
expression on T cells 
0X40 was found on day I during induction of both T cell tolerance and T cell 
immunity (Fig. 4.8). Interestingly, 0X40 was expressed for longer and at higher 
levels on T cells during the induction of T cell immunity, with some 0X40 
expression still present on day 2 after Ag administration (34.6%). By day 3, neither 
of the two experimental groups showed 0X40 expression on transferred T cells 
compared to the PBS control group. Therefore, both CD154 and 0X40 were 
consistently seen to be expressed for longer during the induction of immunity 
compared to induction of tolerance. 
4.6.3. Tolerance induction results in rapid expression of 
RANKL on T cells 
Similar to CD154 and 0X40, RANKL was expressed on T cells during induction of 
tolerance and immunity (Fig. 4.9). In contrast to CD154 and 0X40 however, 
RANKL was expressed earlier and at higher levels during induction of tolerance 
compared to induction of immunity. This was clearly noticeable when a more 
detailed time course analysis was carried out (Fig. 4.10), with the pOVA group 
beginning to express RANKL by 12 hours, whereas the pOVA+LPS group did not 
express RANKL until 48 hours. Both groups still expressed some RANKL on day 3 
after Ag administration (Fig. 4.9). V 
Although the level of RANKL appeared to vary between experiments (compare Fig. 
4.9 and Fig. 4.10), there was definite up-regulation of RANKL in both experimental 
groups, which was not seen in the PBS control group, and this upregulation was 
consistently observed earlier, and on a greater percentage of T cells after 
administration of pOVA compared to administration of pOVA+LPS. 
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4.7. Expression of costimulatory molecules on DC during 
the induction of tolerance or immunity 
DC purity after isolation was assessed by staining for CD1 Ic, and was consistently 
above 80%. The CD11c population was stained for expression of CD40, OX40L, 
RANK, CD80 and CD86 in conjunction with CD8ct. Even though the percentages of 
CD8a DC appeared to vary between days 1, 2 and 3, this is most likely due to 
variation in staining (Fig. 4.11). There was nevertheless a small, but consistent 
increase in the percentage of CD8a 4  DC in the spleen after administration of pOVA 
alone, and a decrease of CD8c1 1 DC after administration of pOVA+LPS compared to 
the PBS control group on each day (Fig. 4.11). 
Purification of DC in the presence of polymyxin B (which binds LPS and prevents its 
DC-activating properties) (Montoya et al., 2002), and purifying DC by depletion, 
using a cocktail of antibodies against thymocytes, B cells, and granulocytes (Kamath 
et al., 2000), did not change the level of costimulatory molecules displayed on the 
surface of DC compared to the described method of positive selection (Appendix 
Fig. 2). It was therefore chosen to purify DC for phenotyping using positive 
selection. 
Immature DC constitutively express low levels of CD40, CD80 and CD86 (Vremec 
and Shortman, 1997). In order to control for possible activation and upregulation of 
these molecules during the purification procedure, levels of these molecules after Ag 
administration were compared to PBS controls, which were purified in the same way 
as the other experimental groups. Any upregulation of CD40, CD80 and CD86 must 
therefore have been due to events that had happened in vivo, prior to DC isolation. 
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4.7.1. CD40 is upregulated on DC during the induction of T 
cell immunity 
The level of CD40 on DC was not increased in mice that had received pOVA 
compared to PBS controls, but DC from mice that had received pOVA+LPS showed 
increased levels of CD40 on days I and 2 after Ag administration, as indicated by 
median fluorescence values (MF) in each group (Fig. 4.12). No difference in up-
regulation of CD40 could be observed between CD8a and CD8a DC, although in 
all three groups (in the steady state as well as after DC activation) MF values 
indicated slightly higher levels of CD40 on CD8a DC compared to CD8ci. DC (Fig. 
4.13). By day 3, CD40 levels had returned to normal compared to PBS controls. The 
CD1 lc, CD40 b 0  population, which was consistently seen on days I and 2 in the 
group that had received pOVA+LPS, may have consisted of immature DC recruited 
due to the inflammation occurring after administration of LPS, but this was not 
investigated in greater detail. Nevertheless, the administration of adjuvant therefore 
led to increased levels of CD40 on DC during induction of immunity, while during 
the tolerance induction, CD40 levels on DC did not change compared to PBS 
controls. 
4.7.2. OX40L is not detectable on DC during induction of T 
cell tolerance or T cell immunity 
No significant expression of OX40L on DC compared to isotype controls was 
observed during the induction of T cell tolerance or T cell immunity over the 3 days 
time course (Fig. 4.14). The MF values suggested expression of OX40L on DC after 
administration of pOVA+LPS at the day I time-point: However, although this 
increase was consistently observed, it is very small, and it is therefore difficult to 
draw conclusions with respect to OX40L expression from the FACS data obtained. 
4.7.3. RANK is upregulated on DC during the induction of T 
cell immunity 
DC constitutively expressed low levels of RANK. The level of RANK on DC was 
not increased in mice that had received pOVA compared to PBS controls, but DC 
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from mice that had received pOVA+LPS showed increased levels of RANK on day I 
after Ag administration (Fig. 4.15). No difference in upregulation of RANK could be 
observed between CD8I' and CD8a DC (Fig. 4.16), although similar to CD40 
expression, MF values indicated slightly elevated levels of RANK on CD8c DC 
compared to CD8cI DC, in all three experimental groups. By day 2, RANK levels in 
this group were returning to normal, and by day 3, RANK levels had returned to PBS 
controls levels. Interestingly, there was hardly any RANK expression above 
background levels at day 2 after pOVA+LPS administration, while RANKL was 
expressed on the T cells at that time. Fig. 4.10 shows that RANKL expression is 
induced between 24 and 48 hours after pOVA+LPS administration. Although RANK 
expression had decreased to background levels by day 2 (i.e. 48 hours), there 
nevertheless is a time window between day 1 and day 2 where both RANK and 
RANKL could have been expressed. 
4.7.4. CD80 and CD86 are upregulated on DC during the 
induction of T cell immunity 
DC constitutively expressed CD80 and CD86, but similar to data investigating CD40 
expression, CD80 and CD86 were upregulated after administration of pOVA+LPS, 
but stayed at levels seen in PBS controls groups after administration of pOVA alone 
(Figs. 4.17 and 4.18). By day 2, a population of CD80
1ow i cells could be dentifled, 
which was still present at day 3, again similar to the CD40 expression data described 
above. Similarly, a large proportions of cells were present at day 2 and 3 that showed 
intermediate expression of CD86. Nevertheless, it appeared that CD86 stayed up-
regulated for longer, since it was still seen at high levels on a proportion of cells on 
day 3 after Ag administration. 
107 
4.8. Summary of costimulatory molecule expression on T 
cells and DC during the induction of T cell tolerance or 
immunity 
The time course investigating the phenotype of DC and T cells after administration 
of a tolerogenic or immunogenic protocol was repeated many times. Although slight 
variations in the duration and level of costimulatory molecule expression were 
observed, the same trend, summarised in Fig. 4.19, was observed consistently. 
CD154 (Fig. 4.7), 0X40 (Fig. 4.8) and RANKL (Fig. 4.9) were all found to be 
expressed on T cells after administration of pOVA alone or pOVA+LPS. However, 
CD154 and 0X40 were expressed at higher levels andlor for longer during the 
induction of immunity than tolerance, while RANKL was expressed earlier and at 
greater levels during tolerance induction. 
Nevertheless, the data obtained suggests that the expression of costimulatory 
molecules on DC is the deciding factor between tolerance and immunity, since 
increased expression of CD40 (Fig. 4.12), RANK (Fig. 4.15), CD80 and CD86 (Fig. 
4.17 and 4.18) was only ever seen during the induction of T cell immunity. During 
the induction of T cell thlerance, the expression of these molecules was 
indistinguishable from the PBS controls. 
The CD40, CD80 and CD86 profiles after administration of pOVA+LPS showed two 
DC populations at days 2 and 3, expressing different levels of CD40, CD80 and 
CD86 (Fig. 4.12, 4.17 and 4.18). The CD4010  population may suggest recruitment of 
immature DC from the circulation. Interestingly, Fig. 4.13 shows that the CD40b0 
population of CD1 1c cells was mostly CD8a. The significance of these 
observations, if indeed significant at all, remains open for discussion. 
4.9. Co-administration of pOVA and CpG does not alter 
the phenotype of DC, and does not prevent tolerance 
induction 
Even though co-administration of pOVA+CpG did not prevent tolerance induction, it 
did result in upregulation of co-stimulatory molecules in vitro. The phenotype of DC 
was therefore investigated ex vivo after co-administration of pOVA+CpG. 
Expression of CD40, OX40L and RANK did not change on DC in groups that had 
received pOVA+CpG compared to pOVA alone or PBS control groups (Fig 4.20, 
and Appendix Fig. 3-5). Similarly, administration of pOVA+CpG did not change 
expression of 0X40 and RANKL on T cells compared to groups that received pOVA 
alone (Appendix Fig. 6 and 7). Expression of CD 154 on T cells was not investigated 
in these experiments. 
4.10. Administration of agonistic anti-CD40 antibody 
results in induction of OX40L expression on DC 
Administration of agonistic anti-CD40 antibody prevented the induction of tolerance 
(Chapter 3). Successful T cell priming is normally used as a read-out for DC 
activation by the antibody. Here, T cell and DC phenotype were also analysed over a 
4-day time course. At these early time-points, T cell expansion was comparable in 
groups of mice that had received pOVA alone, or pOVA and anti-CD40. Analysis of 
DC phenotype however showed considerable DC activation after CD40 
administration, as illustrated by upregulation of CD80 and CD86 on days 2 and 3 
after Ag administration (Fig. 4.21). Administration of CD40 also induced expression 
of OX40L on days 2 and 3 (Fig. 4.21). Increased expression of CD80 and CD86, and 
expression of OX40L was found at comparable levels in CD8a and CD80 DC (not 
shown). The isotype control shown in Fig. 4.21 for day 2 was taken from the group 
of mice that had received pOVA+anti-CD40. This was because this group had the 
highest background staining at that day. Nevertheless, an upregulation of OX40L 
could be observed in that group on day 2 compared to the control staining. By day 4, 
expression of OX40L, CD80 and CD86 had returned to levels comparable to those in 
PBS controls (not shown). 
4.11. Expression of costimulatory molecules on CD154-
deficient T cells during the induction of T cell tolerance 
- 	or immunity 
It was shown in Chapter 3 that CD 154 on T cells is not essential for induction of T 
cell tolerance. In order to look at the expression of costimulatory molecules on 
CD154' T cells, OT-Il mice were crossed with CD154' mice. These mice did not 
express the congenic marker Ly5.1. Purified CD4 cells from OT II x CD154 mice 
were transferred into naïve CD154 4  recipients, and identified by gating on Va2 and 
V35, the TCR chains expressed by OT-Il mice. This allowed phenotyping of 
CD 154" T cells during the induction of T cell tolerance or immunity. However, 
CD154' mice have endogenous Va2, VI35  T cells (approximately 0.5% of the 
CD4 'T cell population in the spleen), which may not be pOVA-reactive. The 
number of Va2, VI35 increases to 1-1.8% after transfer. By gating on Va2 and V5, 
the FACS data obtained therefore included endogenous as well as transferred T cells. 
The percentage of transferred cells positive for the costimulatory molecule being 
analysed may in reality have been higher than seen on the FACS plots, since 
endogenous Vcx, p0 VA-non-specific T cells will not have been activated by 
administration of pOVA, and will thereby have increased the number of Va2, V05 
T cells, which are costimulatory mo1ecule. 
As with B6 mice, administration of pOVA+LPS induced immunity in CD154 mice 
(Appendix Fig. 8). In essence, the pattern of costimulatory molecule expression on T 
cells and DC during the induction of tolerance and immunity was the same in 
CD154 4-  mice as seen in B6 mice (summarised in Fig. 4.22). In the absence of 
CD154, 0X40 was expressed on T cells during the induction of tolerance and 
immunity (Appendix Fig.9). Similar to results obtained with CD 154-sufficient T 
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cells, 0X40 was expressed on a greater percentage of T cells and for longer after 
administration of pOVA+LPS. OX40L was not seen on any of the experimental 
groups, similar to results obtained in B6 mice (Appendix Fig.12). 
RANKL was expressed on cD I 54 T cells after administration of pOVA and after 
pOVA+LPS (Appendix Fig.10). RANKL expression again appeared at lower levels 
after administration- of pOVA+LPS, similar to results obtained with CD154-
sufficient T cells. CD154 signalling to DC via CD40 has previously been shown to 
induce RANK expression (Anderson et al., 1997). However, RANK expression in 
CD154 was comparable to that observed in B6 mice (compare Fig. 4.15 and 
Appendix Fig. 13), suggesting an LPS-dependent, CD40-CD 154-independent 
pathway of RANK upregulation. The expression of the three receptor-ligand pairs 
during induction of tolerance or immunity in CD154' mice is summarised in Fig. 
4.22. Although the level of RANK on day 2 was only slightly increased compared to 
the other groups (Appendix Fig. 13), this increase was seen consistently on day 2 
after administration of pOVA+LPS, and the summary therefore shows DC to display 
RANK on their surface at that time-point. 
4.12. Expression of costimulatory molecules in B cell-
deficient mice during the induction of T cell tolerance 
or immunity 
B cells have been shown to display MHC-peptide complexes on their surface after 
administration of soluble protein (Zhong et al., 1997). Chapter 3 showed that T cell 
tolerance could be established in the absence of B cells. Expression of the 
costimulatory molecules was investigated by transferring OT-Il cells into B cell 
deficient tMT mice. The expression of the costimulatory molecules during induction 
of tolerance or immunity in B cell-deficient mice is summarised in Fig. 4.23 (the 
expression of CD 154 was not investigated). 
Ill 
Expression of 0X40 on day 1 on pOVA-reactive T cells was comparable to data 
obtained from B6 mice (compare Fig. 4.8 and Appendix Fig. 14). However, 0X40 
was still found at increased levels on day 2, and thus appeared to stay upregulated 
longer in the absence of B cells. Interestingly, the expression of RANKL on T cells 
after administration of pOVA+LPS was negligible, similar to data obtained in 
CD154' mice (Appendix Fig. 15). However, the absence of B cells did not influence 
the levels of expression of CD40, OX40L and RANK on DC during induction of 
tolerance or immunity (Appendix Fig. 16 and 17, OX40L is not shown, since no 
expression was observed). Comparable to results obtained from experiments with B6 
mice, the levels of CD40 and RANK were increased on DC during the induction of 
immunity (Appendix Fig. 16 and 17), indicating that these cells are responsible for 
effective T cell immunity. 
4.13. Histological approach to investigating the expression 
of costimulatory molecules during the induction of 
tolerance of immunity 
Chapter 3 provided evidence for the lack of 0X40-OX40L signalling during 
tolerance, since exogenous ligation of 0X40 can prevent tolerance induction, which 
has also been observed by another group (Bansal-Pakala et al., 2001). During the 
induction of either tolerance or immunity, T cells became activated (Figs. 4.7-4.9), 
indicating definite contact with cells displaying peptide on their surface. These cells 
were likely to. be DC, since similar data was obtained from experiments in B6 
compared to B cell-deficient mice (Fig. 4.23). OX40L is induced through CD40 
ligation (Fig. 4.21). Interestingly, CD 154 was expressed on T cells during both the 
induction of tolerance and immunity (Fig. 4.7), which should have been sufficient to 
allow signaling through CD40, resulting in OX40L expression on DC. Nevertheless, 
only a very small increase of OX40L expression after administration of pOVA+LPS 
was seen, and the expression of OX40L on DC was therefore minimal under 
conditions leading to either tolerance or immunity (Fig. 4.14). Since OX40L 
expression via CD40 signaling requires DC-T cell contact, it was possible that the 
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actual number of DC in contact with T cells and expressing OX40L was too low to 
be detected through FACS analysis. 
In order to investigate expression of OX40L on DC in contact with T cells, and to 
validate the data obtained through FACS analysis, immunofluorescent histology was 
carried out on spleen tissue sections. To identify adoptively transferred T cells, CD4-
purified, Ly5.1 OT-LI cells were fluorescently labelled with CT orange before 
transfer into naïve B6 recipients, and pOVA was administered in tolerogenic (pOVA 
alone) or immunogenic form (pOVA+LPS), as before. Because the intensity of the 
fluorescent dye decreased with cell division, two early time-points, 12 hours and 36 
hours, were initially chosen to look at expression of costimulatory molecules, in 
particular CD154, 0X40 and OX40L. Mice were sacrificed at these two time-points, 
and spleen tissue sections were snap-frozen in liquid nitrogen. These sections were 
firstly stained for Ly5.1, to validate that the fluorescent cells, which could be seen in 
the tissue sections, actually were the Ly5.1 OT-Il cells, that had been transferred. 
Staining for Ly5.1 revealed that at 12 hours after administration of Ag, cells 
identified as CT were indeed Ly5.1 (Fig. 4.24a). However, by 36 hours after Ag 
administration, a large proportion of the Ly5.1 cells could no longer be 
distinguished from background fluorescence (Fig. 4.24b), since the number of Ly5.1 
cells identified through staining was larger than the number of CT cells observed. 
Fluorescently labelling UT-IT cells before transfer was thus an effective technique to 
look at expression of costimulatory molecules at very early time-points, but could not 
be used to look at later time-points. A double-staining protocol, staining for 
expression of Ly5. 1 and the chosen costimulatory marker, must be developed in 
order to look at these later time-points. Although a number of different approaches 
were tested, development of a double-staining protocol proved difficult, and requires 
further optimisation before it can be used effectively. 
Nevertheless, sections were stained for expression of CD69, CD 154, 0X40 and 
OX40L, 12 hours after administration of Ag. Correlating with the FACS data 
obtained from this 12 hours time-point, CD69, CD 154 and 0X40 were found to be 
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expressed on CT cells (i.e. on CD4 OT-Il cells) during both induction of tolerance 
and immunity, while OX40L staining was hardly observed (Fig. 4.25 and Table 
4.26). The percentages of CD69 adoptively transferred cells after administration of 
pOVA was higher than data obtained through FACS analysis (47.1 vs. 37.6%). 
However, after administration of pOVA+LPS, FACS analysis revealed a large 
percentage of pOVA-reactive T cells to be CD69 (81.2%), while 
immunofluorescence shows 66.6% of cells to be CD69. The percentages of CT 
cells showing expression of CD154 was higher than the results obtained through 
FACS analysis (pOVA: 25.7 vs. 15%, pOVA+LPS 27.7 vs. 7.43). This could be due 
to the method of staining. Cells need to be fixed, and intracellularly stained for 
CD 154 expression. Immunofluorescence staining on tissue sections may arguably be 
a more sensitive method of detection, and intracellular staining may not show a large 
enough shift during FACS analysis to accurately show all the CD154 cells. 
Immunofluorescence staining for 0X40 similarly showed a higher percentage of 
cells to be OX40 compared to FACS analysis (pOVA: 27.8 vs. 6.15, pOVA+LPS: 
29.3 vs. 19.3%). Very little immunofluorescent staining for OX40L was observed at 
this early time-point, and was rarely in proximity to CT cells. Unfortunately, it was 
not possible to investigate whether or not OX40L was expressed close to pOVA-
reactive T cells at later time-points. 
The use of a laser scanning cytometer (LSC) would allow quantification of the data 
obtained from OX40L staining, since using the LSC, one can scan tissue sections, 
and the software available allows analysis of the fluorescence observed not only on 
the cells of interest, but also in close proximity to those cells. A collaboration with 
Dr Paul Garside and Angela Grierson in Glasgow was set up, aiming to analyse 
expression of OX40L in close proximity to CT-labelled T cells. However, since very 
little OX40L staining was observed at the 12 hour time-point, and the CT-labelled 
cells could not be identified at later time-points, this approach again required 
development of a double-staining protocol. In an attempt to quantify the data 
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obtained from staining for OX40L, I counted OX40L staining in close proximity to 
transfened T cells. A summary of the histological data is given in Table 4.26. 
4.14. Induction of OX40L on CD8& DC by an unidentified 
compound 
The initial time courses that were performed to investigate DC and T cell phenotype 
used LPS from an unknown source, kindly provided by the lab of Prof. D. Gray, 
11W. Interestingly, these first experiments showed upregulation of OX40L 
specifically on the CD8a subset of CDI1c 1 DC on day 1 (Fig. 4.27), which later 
appeared to become CD8ct 11t  and/or disappeared from the spleen. This upregulation 
was also observed after administration of LPS alone in CD40' mice and CD154 
mice (not shown), pointing towards a pathway of CD40-CD154-independent 
induction of OX40L. It was later realised that the LPS was contaminated, possibly 
with a fungus. Unfortunately, the LPS has since been discarded, and the identity of 
this contaminant, remains a mystery. Nevertheless, the possibility that CD8ct DC 
can specifically upregulate OX40L expression, in a CD40-CD154-independent 
fashion, in response to an unknown (possibly fungally-derived) agent, is intriguing. 
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4.15. Summary 
The expression of three costimulatory receptor-ligand pairs, namely CD40-CD 154, 
0X40-OX40L and RANK-RANKL, was characterised during the tolerisation or 
activation of T cells over a time course of 4 days. T cells expressed CD154, 0X40 
and RANKL during the induction of either tolerance or immunity. CD 154 and 0X40 
were expressed for longer, and on a greater percentage of pOVA-reactive T cells 
during induction of immunity, while RANKL was expressed earlier and on a greater 
percentage of T cells during tolerance induction. DC increased their expression of 
CD40 and RANK only after administration of Ag with LPS, while FACS analysis 
could not detect OX40L during induction of either immunity or tolerance. OX40L 
expression was however observed specifically on CD8f DC in response to an 
unknown, possibly fungally derived compound. 
Induction of tolerance or immunity in CD154' mice was comparable to B6 mice, 
with similar expression of 0X40 on CD 154' T cells, and CD40, OX40L and RANK 
on DC during induction of either tolerance or immunity. In contrast to data from B6 
mice, little RANKL expression was found in CD154' mice after admihistration of 
pOVA and LPS. The absence of B cells had little influence on T cell or DC 
phenotype after Ag administration. Again, no RANKL was detected in response to 
pOVA+LPS. 
Chapter 3 showed that exogenous ligation of anti-CD40 prevented T cell tolerance, 
and it was here further shown that exogenous ligation of CD40 resulted in up-
regulation of CD80, CD86, and most importantly OX40L on DC, re-enforcing the 
idea that the CD40-CD154 and the 0X40-OX40L interactions are pivotal in the 
induction and prevention of T cell tolerance. 
Collectively, it is concluded that presentation of soluble peptide by quiescent or 
immature DC brings about T cell tolerance, while administration of LPS results in 
I 16 
activation of DC as shown by increased expression of costimulatory molecules, 




In recent years, evidence has accumulated suggesting that the activation state of the 
DC determines the outcome of antigenic challenge. Ligation of TLRs is coupled to 
DC activation, leading to increased expression of costimulatory molecules on the DC 
surface, migration into T cell areas, and the induction of effective T cell immunity 
(Reis e Sousa, 2004). The current consensus view suggests that in the absence of 
inflammatory stimuli in vivo, DC play an important role in the maintenance of 
peripheral tolerance (Belz et al., 2002; Hernandez et al., 2001; Scheinecker et al., 
2002; Steinman and Nussenzweig, 2002; Steinman et al., 2000). The ability of DC to 
induce tolerance or immunity appears to depend on their maturation stage 
(Dhodapkar et al., 2001; Jonuleit et al., 2000). Unmanipulated DC in vivo express 
little CD40 (Inaba et al., 1994; Schulz et al., 2000), and DC constitutively take up 
antigens in the periphery and present them to T cells in lymphoid organs in a 
tolerogenic fashion, which can be converted into immunogenic presentation after DC 
activation through CD40 (Hawiger et al., 2001; Maxwell et al., 1999). 
This chapter provided direct evidence for the importance of activation state of DC in 
the decision between tolerance and immunity. Specifically, it showed that 
administration of pOVA and LPS resulted in significant DC activation, illustrated by 
increased expression of CD40, RANK, CD80 and CD86, which resulted in T cell 
immunity. Expression levels of these molecules did not change during the induction 
of tolerance with respect to steady state controls. It is worth noting that the data 
presented did not investigate peptide expression on DC. It has been suggested that 
CD8I DC present peptide to CD4 T cells after s.c. administration of soluble 
peptide (Ingulli et al., 2002; Itano et al., 2003), and that CD8a DC also efficiently 
present processed peptide to CD8 T cells after i.v. administration of protein (Pooley 
et al., 2001). Co-administration of Ag and LPS has been shown to induce DC 
migration from the splenic marginal zone into T cell areas, enhancing expression of 
processed peptides on both CD8ct and CD8cC DC (Reis e Sousa and Germain, 
1999), which express TLR-4 at similar levels (Boonstra et al., 2003). It remains to be 
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investigated which subset of DC presents peptide after i.v. administration, although 
unpublished data from our laboratory suggests that both CD8c and CD8cI (CD4) 
DC do so (S. Anderton, personal communication). 
Administration of Ag and LPS consistently resulted in a small decrease of CD8c( 
DC in the spleen, while administration of Ag alone resulted in an increase of CD8f 
DC in the spleen. The CD8a subset of DC has previously been implicated in down-
regulating CD8 T cell responses (Belz et al., 2002; Kronin et al., 1996). The 
turnover of all subsets in the spleen is between 1.5 and 2.9 days, with the CD80( DC 
showing the fastest turnover rate after administration of LPS (Kamath et al., 2000), 
which agrees with data shown here. Although one may suggest that the decrease in 
CD8ct DC after administration of pOVA and LPS is due to preferential CD8a DC 
death and subsequent loss from the spleen, a mechanism by which the number of 
CD8a DC would increase after administration of soluble Ag alone is more difficult 
to explain. The changes in percentages of CD8a versus CD8cI DC observed here 
are very small, and the significance remains to be investigated. 
Whereas the differences in expression of CD40 and RANK on DC during the 
induction of immunity versus tolerance were very striking, less obvious differences 
were evident in costimulatory molecule expiession by T cells during the two 
processes. The general timing of expansion and subsequent loss of Ag-reactive cells 
after i.v. administration of soluble Ag correlates with previous reports (Kearney et 
al., 1994). These earlier studies compared T cell expansion after i.v. administration 
of Ag without adjuvant to administration of Ag in CFA, while this chapter compared 
administration of soluble peptide alone with co-administration of peptide and LPS. 
Greater T cell numbers were consistently observed at early time-points after 
administration of pOVA alone, compared to co-administration of pOVA and LPS. 
Using a TCR transgenic transfer system, it has been reported that for up to 42 hours 
after administration of Ag, T cells were difficult to detect by flow cytometry, 
although histology data showed that the cells were present in the organs examined 
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(Maxwell et al., 2004). This "loss" of T cells could be overcome by collagenase 
digesting the samples before flow cytometry. This decrease in T cell numbers was 
evident after both administration of Ag alone, and Ag and adjuvant, while in the 
system used here, numbers were lower after administration of Ag and adjuvant. 
Nevertheless, it cannot be excluded that the lower percentage of pOVA-reactive T 
cells found here at early time-points after pOVA+LPS administration compared to 
pOVA alone was due to the isolation procedure used, which did not include a 
collagenase digest. 
Previous data suggests that CD40 ligation acts to greatly enhance RANK expression 
on DC (Anderson et al., 1997). Nevertheless, RANK was found to be expressed at 
similar levels after administration of pOVA+LPS in B6 as well as CD154 mice. 
The levels of RANK expression observed in the steady state of B6 and CD154' mice 
were comparable to those described previously (Williamson et al., 2002). While 
CD154 and 0X40 were found for longer and at higher levels during the induction of 
immunity, RANKL expression was found at higher levels and at earlier time-points 
during the induction of tolerance compared to induction of immunity. RANKL 
expression was barely detectable in CD154' and B cell-deficient mice during the 
induction of immunity, while it was clearly present during the induction of tolerance. 
B cells and CD154 are thus not absolutely required for RANKL expression. 
Identification of a costimulatory molecule with positive correlation with tolerance 
induction was surprising, and it is intriguing to speculate about what significance the 
early RANKL expression during tolerance may have. This is further discussed in 
Chapter 6. 
Chapter 3 highlighted the importance of CD40 ligation as a checkpoint in the 
decision between immunity and tolerance through the successful prevention of 
tolerance induction with anti-CD40, comparable to data obtained in other recent 
studies investigating CD4 T cell tolerance (Hawiger et al., 2001). This chapter 
further shows that exogenous CD40 ligation increased expression of CD80, CD86 
and OX40L on DC. A similar approach (administration of anti-CD40 i.v.), has 
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previously been reported to result in upregulation of CD80 and CD86 (Chung et al., 
2004)., However, this upregulation was already seen by 24 hours after administration 
of antibody, compared to 48 hours in the results shown here, and also employed a 
model of mucosal tolerance, in which administration of anti-CD40 did not prevent 
tolerance induction. The discrepancy in timing may have been due to i.v. versus i.p. 
administration of the antibody, while inability to prevent tolerance may be due to 
differential regulation of tolerance in different peripheral sites. 
Although CD40 ligation resulted in CD80 and CD86 upregulation, its effect on 
OX40L expression was not investigated previously (Chung et al., 2004). OX40L was 
here found to be expressed after exogenous ligation of CD40, but not after 
administration of Ag with LPS. One explanation may be that only DC receiving a 
CD40 signal would upregulate OX40L. After administration of Ag in LPS, only DC 
in contact with the appropriate Ag-reactive (i.e. cD154 4 ) T cells should upregulate 
OX40L, and the number of those DC was too small to be traceable during FACS 
analysis. After administration of anti-CD40 however, a larger number of DC will 
have been given a signal through CD40 and upregulation of OX40L was seen at days 
2 and 3 after ligation. If OX40L is first upregulated at these later time-points after 
CD40 ligation, this would provide an explanation for the lack of OX40L staining on 
histology sections, which was carried out at 12 hours, i.e. at an earlier time-point, 
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Experimental outline of experiments investigating T cell and 
DC phenotypes during the induction of T cell tolerance versus 
the induction of T cell immunity 
Naive mice received a transfer of p0 VA-reactive T cells. One day 
later, mice were tolerised or immunised with pOVA, and the 
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Tolerance induction in, naïve B6 mice versus B6 mice after 
adoptive transfer of p0 VA-reactive cells 
Naïve B6 mice received a single dose of 500jig pOVA or PBS 
i.v. on day 0, followed by 20 jig pOVA/CFA on day 7, and 
lymphoid populations (draining lymph nodes shown here) assessed 
10 days later for proliferative responses to a dose range of pOVA'. 
B6 mice received Ly5.1 OT-Il cells one day prior to 
administration of pOVA i.v. Mice received a single dose of 500 jig 
pOVA or PBS i.v. on day 0, followed by 20 jig pOVA/CFA on day 
7, and lymphoid populations (draining lymph nodes shown here) 
were assessed on day 17 for proliferative responses to a dose range 
of pOVA. Background cpm were as those seen with iO jiM 
pOVA. 














Co-administration of LPS (but not CpG) leads to T cell 
immunity 
B6 mice received Ly5. 1 1 OT-Il cells on day –1, one day prior to 
administration of pOVA. Mice received either 500 jig pOVA, PBS, 
500 jig pOVA with 30 jig CpG, or 500 jig pOVA with 30jig LPS (all 
i.v.) day 0, and splenic populations were assessed 7 days later for 
proliferative responses to a dose range of pOVA. Background cpm 
were as follows: PBS 2304, pOVA 2932, pOVA+CpG 2818, 
pOVA+LPS 6245. These data are from one of two experiments 
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Phenotype of DC after overnight culture with CpG 
B6 bone marrow cells were growti for 7 days 111 the presence of 
GM-CSF. cultured with 6ig/inl CpG overnight at 37°C, and 
stained for CD40, OX40L, CD80 and CD86. Filled histograms are 
CDI 1c cells stained with an isotype control antibody. These data 
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Expansion of p0 VA-reactive CD4 T cells after administration 
of pOVA or pOVA+LPS 
B6 mice received Ly5.lTh OT-Il cells one day prior to 
administration of pOVA, pOVA+LPS or PBS. 
On days 2, 3 and 4 post Ag administration, spleen cells were 
analysed by FACS for Ly5. I and CD4 expression. Percentages of 
total cells that were CD4. Ly5.l. are shown. These data are from 
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Fig. 4.6: 
CFSE profile of p0 VA-reactive CD4 1 T cells after 
administration of pOVA or pOVA+LPS 
B6 mice received CFSE-labelled Ly5.1 OT-Il cells one day prior 
to administration of pOVA, pOVA+LPS or PBS. 
On days 2, 3 and 4 post Ag administration, spleen cells were 
analysed by FACS for Ly5.1 and CD4 expression. A: CFSE 
profiles and percentages of total cells that are CD4, Ly5.P, are 
shown. B: The overlay allows comparison of number of cell 
divisions undergone after administration of pOVA or pOVA+LPS. 
These data are from one of three experiments giving consistent 
trends for division of p0 VA-reactive cells. 
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Tolerance is not due to the absence of CD 154 on T cells 
B6 mice received Ly5. 1 OT-lI cells one day prior to 
administration of pOVA, pOVA+LPS or PBS. 
On days 1, 2 and 3 post Ag administration, spleen cells were 
analysed by FACS for CD154 expression by Ly5.l CD4 OT-lI 
cells (filled histograms are Ly5.1 CD4 UT-lI cells stained with 
streptavidin-APC alone). Percentages of Ly5. l CD4 UT-Il cells 
positive for CD 154 are shown on each graph. These data are from 
one of two experiments giving consistent results. 
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Fig. 4.8: 
Tolerance is not due to the absence of 0X40 on T cells 
B6 mice received Ly5. 1 0T-I1 cells one day prior to 
administration of pOVA, pOVA+LPS or PBS. 
On days 1,2 and 3 post Ag administration, spleen cells were 
analysed by FACS for 0X40 expression by Ly5.l C134 OT-lI 
cells (filled histograms are Ly5.l CD4 OT-Il cells stained with 
streptavidin-APC alone). Percentages of Ly5. I + CD4 OT-Il cells 
positive for 0X40 are shown on each graph. These data are from 
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Fig. 4.9: 
Tolerance induction results in rapid expression of RANKL on T 
cells 
B6 mice received Ly5. 1 1 UT-TI cells one day prior to 
administration of pOVA, pOVA+LPS or PBS. 
On days 1, 2 and 3 post Ag administration, spleen cells were 
analysed by FACS for RANKL expression by Ly5. I + CD4 OT-! I 
cells (filled histograms are Ly5.I CD4 UT-Il cells stained with 
streptavidin-APC alone). Percentages of Ly5. I + CD4 UT-Il cells 
positive for RANKL are shown on each graph. These data are from 
one of four experiments giving consistent results. 
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Detailed time course analysis of RANKL expression on 1 cells 
during induction of tolerance versus immunity 
B6 mice received Ly5. I + OT-Il cells one day prior to 
administration of pOVA. pOVA+LPS or PBS. 
12, 18,24 and 48 hours post Ag administration, spleen cells were 
analysed by FACS for RANKL expression by Ly5. l CD4 OT-Il 
cells (filled histograms are Ly5.1 CD4 01-11 cells stained with 
streptavidin-APC alone). Percentages of Ly5. V CD4 OT-Il cells 
positive for RANKL are shown on each graph. These data are 
from one of two experiments giving consistent results. 
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CD8a expression on DC after administration of pOVA, 
pOVA+LPS or PBS 
B6 mice received Ly5.l UT-TI cells one day prior to 
administration of pOVA, pOVA+LPS or PBS. On days 1, 2 and 3 
post Ag administration, CDI 1c DC were purified from the spleen. 
CD1Ic cells were analysed by FACS for CD8a expression on 
days 1, 2 and 3. Percentages shown are CD8W DC vs. CD8cc 
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Fig. 4.12: 
CD40 expression is upregulated on DC during the induction of 
immunity 
B6 mice received Ly5.1 OT-Il cells one day prior to 
administration of pOVA, pOVA+LPS or PBS. 
On days 1, 2 and 3 post Ag administration. CDI lc DC were 
purified from the spleen. CD! lc cells were analysed by FACS for 
CD40 expression on days 1,2 and 3 (filled histograms are CDI 1c 
cells stained with an isotype control antibody). Median 
fluorescence values of CD40 stained DC are shown on each graph. 

























CD40 expression on CD8a versus CD8a DC during the 
induction of tolerance or immunity 
B6 mice received Ly5. 1 OT-il cells one day prior to 
administration of pOVA. pOVA+LPS or PBS. 
On days I and 2 post Ag administration, CDI Ic DC were purified 
from the spleen. CDI 1c cells were analysed by FACS for CD8a 
and CD40 expression on days 1 and 2 (filled histograms are 
CD1 1c cells stained with an isotype control antibody). Median 
fluorescence values of CD40 stained DC are shown on each graph. 






















OX40L expression is not detectable on DC during the induction 
of tolerance or immunity 
B6 mice received Ly5. I + OT-H cells one day prior to 
administration of pOVA or pOVA+LPS. 
On days 1,2 and 3 post Ag administration, CD1lc DC were 
purified from the spleen. CD1 1c cells were analysed by FACS for 
OX40L expression on days 1, 2 and 3 (filled histograms are 
CD1 lc cells stained with an isotype control antibody). Median 
fluorescence values of OX40L stained DC are shown on each 
graph. These data are from one of several experiments giving 
consistent results. 
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RANK expression is upregulated on I)C during the induction of 
immunity 
B6 mice received Ly5.l OT-Il cells one day prior to 
administration of pOVA or pOVA+LPS. 
On days 1.2 and 3 post Ag administration, CDI lc DC were 
purified from the spleen.CDI 1c cells were analysed by FACS for 
RANK expression on days 1,2 and 3 (filled histograms are CDI lc 
cells stained with an isotype control antibody). Median 
fluorescence values of RANK stained DC are shown on each 
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Fig. 4.16: 
RANK expression on CD8ocl versus CD8 DC during the 
induction of tolerance or immunity 
B6 mice received Ly5.l OT-Il cells one day prior to 
administration of pOVA or pOVA+LPS. 
On days I and 2 post Ag administration. CDI lc DC were purified 
from the spleen.CD1 lc cells were analysed by FACS for CD8cx 
and RANK expression on days 1 and 2 (filled histograms are 
CD1 1c cells stained with an isotype control antibody). Median 
fluorescence values of RANK stained DC are shown on each graph. 
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Fig. 4.17: 
CD80 expression is upregulated on DC during the induction of 
immunity 
B6 mice received Ly5. I + OT-lI cells one day prior to 
administration of pOVA, pOVA+LPS or PBS. 
On days 1,2 and 3 post Ag administration, CDI lc DC were 
purified from the spleen. CDI lc cells were analysed by FACS for 
CD80 expression on days 1,2 and 3 (filled histograms are CDI lc 
cells stained with an isotype control antibody). Median 
fluorescence values of CD80 stained DC are shown on each graph. 
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Fig. 4.18: 
CD86 expression is upregulated on DC during the induction of 
immunity 
B6 mice received Ly5. 1 OT-lI cells one day prior to 
administration of pOVA, pOVA+LPS or PBS. 
On days 1,2 and 3 post Ag administration. CDI lc DC were 
purified from the spleen. CD1 1c cells were analysed by FACS for 
CD86 expression on days 1, 2 and 3 (filled histograms are CDI 1c 
cells stained with an isotype control antibody). Median 
fluorescence values of CD86 stained DC are shown on each graph. 
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Summary of costimulatory molecule expression on DC and T 
cells during induction of tolerance or immunity 
B6 mice received Ly5.1 OT-Il cells one day prior to administration 
of pOVA, pOVA+LPS or PBS. 
On days 1, 2 and 3 post Ag administration, CDI lc DC were 
purified from the spleen, and CD! 1c cells were analysed by FACS 
for CD40, OX40L and RANK expression. Spleen cells were also 
analysed by FACS for CD 154, 0X40 and RANKL expression on 
Ly5. V CD4 OT-Il cells. These data are a summary from four 
experiments giving consistent trends of the timing of expression of 
these costimulatory molecules. 
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Summary of costimulatory molecule expression on DC and T 
cells after i.v. administration of pOVA alone, or pOVA+CpG 
B6 mice received Ly5. V OT-Il cells one day prior to administration 
of pOVA, pOVA+CpG or PBS. 
On days 1, 2 and 3 post Ag administration, CD! I cl DC were 
purified from the spleen, and CD11c cells were analysed by FACS 
for CD40, OX40L and RANK expression on days 1, 2 and 3. Spleen 
cells were also analysed by FACS for 0X40 and RANKL 
expression by Ly5. V CD4 OT-Il cells. These data are a summary 
from three experiments giving consistent trends of the timing of 
expression of these costimulatory molecules. Expression of CD 154 
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Expression of CD80, CD86 and OX40L after administration of 
agonistic anti-CD40 Ab 
B6 mice received Ly5. 1 1 OT-Il cells one day prior to 
administration of pOVA or pOVA+200ig anti-CD40. 
On days 1.2 and 3 post Ag administration, CDI lc DC were 
purified from the spleen, and cells were analysed by FACS for 
OX40L. CD80 or CD86 expression on days 1, 2 and 3. Filled 
histograms are DC from mice that received pOVA+antiCD40. 
stained with streptavidin-APC alone. These data are from one of 
two experiments where administration of anti-CD40 successfully 
prevented the induction of T cell tolerance. 
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Summary of costimulatory molecule expression on DC and 
CD154-deficient T cells during induction of tolerance or 
immunity 
CD 154' mice received CD154'xOT-II cells one day prior to 
administration of pOVA, pOVA+LPS or PBS. 
On days 1, 2 and 3 post Ag administration, CD11c DC were 
purified from the spleen, and CD! 1c cells were analysed by FACS 
for CD40, OX40L, RANK. Spleen cells were also analysed by 
FACS for 0X40 and RANKL expression by Va2, V35 OT-Il 
cells. These data are a summary from three experiments giving 
consistent trends of the timing of expression of these costimulatory 
molecules. 
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Summary of costimulatory molecule expression on DC and T 
cells during induction of tolerance or immunity in B cell 
deficient mice 
.tMT mice received OT-fl cells one day prior to administration of 
pOVA, pOVA+LPS or PBS. 
On days 1, 2 and 3 post Ag administration, CD11c DC were 
purified from the spleen, and CDL 1c cells were analysed by FACS 
for CD40, OX40L and RANK expression. Spleen cells were also 
analysed by FACS for 0X40 and RANKL expression by Ly5.1 
CD4 OT-Il cells. These data are a summary from two experiments 
giving consistent trends of the timing of expression of these 
costimulatory molecules. Expression of CD 154 was not investigated 





Identification of CT orange-labelled cells during induction of 
tolerance of immunity 
B6 mice received CT orange-labelled, Ly5. V OT-Il cells one day 
prior to administration of pOVA, pOVA+LPS or PBS. 
12 and 36 hours post Ag administration, mice were sacrificed, 
samples of the spleen were snap-frozen in liquid nitrogen. CT 
orange-labelled cells are shown in red, and sections were stained for 
Ly5.1 (shown in green). Shown are samples from mice 12 hours (A) 
and 36 hours (B) after administration of p0 VA alone. These results 
are from one preliminaiy experiment. 
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Fig. 4.25a: 	 - 
CD69 and CD154 expression 12 hours after administration of Ag 
B6 mice received CT orange-labelled, Ly5.1 OT-Il cells one day 
prior to administration of p0 VA, pOVA+LPS or PBS. 
12 post Ag administration, mice were sacrificed,and samples of the 
spleen were snap-frozen in liquid nitrogen. CT orange-labelled cells 
are shown in red, and sections were stained for CD69 and CDI 54 as 
indicated (in green). Corresponding FACS analysis is shown in 
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Fig. 4.25b: 
0X40 and OX40L expression 12 hours after administration of Ag 
B6 mice received CT orange-labelled, Ly5. V OT-lI cells one day 
prior to administration of pOVA, pOVA+LPS or PBS. 
12 post Ag administration, mice were sacrificed,and samples of the 
spleen were snap-frozen in liquid nitrogen. CT orange-labelled cells 
are shown in red, and sections were stained for 0X40 and OX40L as 
indicated (in green). Corresponding FACS analysis for 0X40 is 
shown in lower right corners of pictures. These results are from one 
preliminaiy experiment. 
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PBS 3/19 15.8 3/36 8.3 4/61 6.6 0/51 0 
pOVA 16/34 47.1 18/70 25.7 20/72 27.8 0/93 0 
pOVA+LPS 14/21 66.6 33/119 27.7 34/1 16 29.3 1/62 0 
Fig. 4.26: 
Summary of expression of costimulatory molecules as seen 
through histology 
B6 mice received CT orange-labelled, Ly5. 1 1 OT-TI cells one day 
prior to administration of pOVA, pOVA+LPS or PBS. 
12 hours post Ag administration, mice were sacrificed, samples of 
the spleen were snap-frozen in liquid nitrogen. Tissue sections were 
stained for CD69, CD 154, 0X40 and OX40L. Pictures were taken, 
and CT cells were analysed for expression of these markers. The 
numbers shown are marker cells out of CTI cells (or in the case of 
OX40L, very little OX40L staining was observed), and percentage 
of marker cells calculated from these counts are shown in bold. 
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Fig. 4.27: 
Induction of OX40L on CI)8u' DC by an unidentified compound 
B6 mice received Ly5.1 OT-lI cells one day prior to administration 
of pOVA, pOVAi-contaminated LPS or PBS. Shown are days I and 2 
only. 
On days 1,2 and 3 post Ag administration, CDI 1c DC were 
purified from the spleen. CD1 1c cells were analysed by FACS for 
OX40L expression on days 1,2 and 3 (filled histograms are CDI lc 
cells stained with streptavidin-APC alone). Median fluorescence 
values of OX40L stained DC are shown on each graph. Shown are 
days I and 2. 
CD8a expression is examined in the pOVA+contaminated LPS 
group on OX40L cells or OX40U (filled histograms are from 
OX40L, empty lines OX40L). These data are from one of three 
experiments giving consistent results. 
149 
5. CHAPTER 5 - Systemic administration of antigen-
loaded C1340-deficient DC mimics peptide-induced 
tolerance 
5.1. Introduction 
The previous chapters provided evidence for the importance of the CD40-CD154 
interaction in the induction of T cell immunity. Administration of pOVA and LPS, 
leading to effective immunity, resulted in increased expression of CD40 on DC. 
Exogenous ligation of CD40 induced expression of CD80, CD86 and OX40L on DC, 
and prevented the induction of T cell tolerance. This indicates that low levels of 
CD40 during tolerance induction, and the possible subsequent lack of CD40-CD154 
interaction, may have been responsible for the induction of tolerance. In order to 
determine whether the predominant effect of CD40 ligation was through 
upregulation of CD80/86, a system was needed in which CD80 and CD86 were 
expressed at high levels on DC, while CD40 was either present or absent. If signals 
downstream of the CD40-CDI 54 interaction other than CD80ICD86 (for example 
OX40L) were crucial for induction of immunity, the lack of CD40 should override 
the presence of CD80/CD86, and result in the induction of tolerance. 
Previous studies, which addressed the importance of CD40 using s.c. administration 
of Ag-loaded CD40-deficient or —sufficient DC, concluded that, whilst CD40' DC 
failed to lead to productive T cell immunity, T cell tolerance was also not evident 
(Miga et al., 2001). However a key factor for the induction of effective T cell 
tolerance with soluble Ag is the use of a systemic route (Anderton, 2001), 
implicating the spleen to be important in this process. One would therefore have 
predicted that the previous study using the subcutaneous route would not lead to a 
global tolerogenic effect. This chapter describes a series of experiments, in which 
CD40-deficient splenic DC (spDC) were administered i.v., testing the hypothesis that 
a lack of CD40 on DC in the spleen would induce Ag-specific T cell tolerance. 
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5.2. Approach 
Throughout these experiments, B6 and CD40-deficient mice were used as sources of 
DC. These DC were loaded with Ag ex-vivo, before being used to activate T cells 
either in vitro or in vivo. Initially, pMOG was used to load the DC, but with the 
arrival of the OT-Il adoptive transfer system in the lab, pOVA was used in most of 
the subsequent experiments, allowing the analysis of Ag-specific T cells. Early 
experiments, which were repeated with both pMOG and pOVA (without prior 
adoptive transfer of T cells), showed corresponding results, irrespective of the Ag 
used. The relevance of the findings from the adoptive transfer system were tested 
using the EAE model. 
The experimental outline of this chapter is shown in Figure 5.1. 
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5.3. Comparison of T cell activation by bone marrow-
derived DC and splenic DC in vitro 
Using spleens from B6 and CD40-deficient mice as sources of DC, the consequences 
of the lack of CD40 expression by DC on the kinetics of T cell activation and 
expansion were examined. In order to show the viability and Ag-presenting capacity 
of spDC after purification, in vitro T cell activation by spDC and bone marrow-
derived DC (bm-DC) from B6 mice were compared. SpDC were purified by positive 
selection using anti-CD 1 ic-conjugated MACS beads, and bm-derived DC were 
grown from bm of B6 or CD40' mice for 7 days in the presence of GM-CSF. DC 
were loaded with pOVA in the presence of LPS for 2hrs, and cultured with Ag-
specific T cells for 2 days. At lower DC:T cell ratios (i.e. fewer DC per T cell), bm-
derived and spDC induced similar levels of T cell proliferation. At higher DC:T cell 
ratios, spDC induced more T cell proliferation compared to bm-derived DC (Fig. 
5.2). The chosen method of purification for DC from the spleen thus left DC able to 
effectively present pOVA to Ag-specific T cells. 
Although bm-derived DC can easily be obtained in larger numbers, spDC were used 
in subsequent experiments, since the spleen is arguably the most important organ for 
induction of systemic T cell tolerance, and DC from the spleen are very likely to be 
involved in this process. DC are very potent initiators of immune responses. Only 
low numbers are needed to carry out in vitro or in vivo experiments, therefore, the 
rarity of DC in the spleen (approximately 1% of total spleen cells) did not present a 
problem in this series of experiments. 
5.4. B6 and C1340' splenic DC have similar phenotypic 
characteristics 
So as to exclude the possibility that subsequent results were due to variation in 
expression of other costimulatory molecules or in the proportions of DC subsets, the 
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surface phenotype of splenic DC isolated from B6 or CD40' mice was analysed. The 
DC were treated as for subsequent use in T cell activation studies, i.e. positive 
selection using anti-CD I Ic-conjugated beads and cultured in the presence of LPS for 
2 hrs. Similar percentages of CD8cx and CD4 DC subsets were found in each DC 
population (Fig. 5.3, bottom panel). Similar levels of CD80, CD86 and MHC class II 
were also found on the two DC populations (Fig. 5.3 top and middle panel). A large 
proportion of the DC displayed a mature phenotype, as illustrated by CD80, CD86 
and MHC class II expression, suggesting that the procedure used resulted in 
significant DC activation (Fig. 5.3). The only difference between CD40-sufficient 
and CD40-deficient DC is the level of CD40, and subsequent differences in ability to 
activate Ag-reactive T cells are therefore likely to be due to the presence or absence 
of CD4O. 
5.5. Comparing the ability of B6 and CD40' splenic DC to 
induce T cell activation and expansion in vitro 
The previous chapters have highlighted the importance of CD40-CD154 during T 
cell activation and tolerance. In an attempt to develop an in vitro model of T cell 
unresponsiveness, experiments were designed to test whether CD40' DC could 
activate a primary T response in vitro. 
5.5.1. CD40' spDC are able to induce T cell activation and 
expansion in vitro 
OT-Il mice were crossed with CD40' mice and CD4 T cells were purified from 
these OT II x CD40' mice, by positive selection using anti-CD4-conjugated MACS 
beads. This use of CD4 cells from OT II x CD40' mice ensured that any 
contaminating CD4 DC would be CD40 4 . The purified CD4 cells were CFSE-
labelled, and cultured with pOVA-pulsed DC (purified from B6 or CD40' mice and 
loaded with 50tM pOVA in the presence of LPS) in a 10:1 T cell:DC ratio. The 
CFSE profile was assessed after 2, 3, 4, and 5 days of culture (Fig. 5.4), together 
with expression of CD69, CD25, 0X40 and RANKL on p0 VA-reactive T cells (Fig. 
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5.5). CD69 and CD25 were used as markers of T cell activation, and together with 
the costimulatory molecules 0X40 and RANKL, expression of this set of molecules 
was investigated to reveal possible differences in the ability of B6 or CD40' DC to 
direct the outcome of T cell activation. 
Stimulation with CD40' spDC consistently led to a lower percentage of T cells 
entering division at early time-points (day 3 of culture) compared with cultures using 
B6 DC (Fig. 5.4). By day 3 of the experiment shown, about twice as many T cells 
had undergone cell division when stimulated with B6 DC, compared with those 
stimulated with CD40' DC (Fig. 5.4, middle panel). This was reflected in the 
percentages of T cells showing upregulation of CD69 and CD25 at days 2 and 3, and 
in the percentages of T cells showing upregulation of 0X40 and RANKL on day 3 
(Fig. 5.5). The results shown are gated on live cells, but.it  must be mentioned that 
cultures with CD40' DC had greater numbers of dead cells at later time-points, i.e. 
day 5, presumably from T cells that had not divided in response to Ag stimulation. 
Although down-regulation of levels of CD69, CD25, 0X40 and RANKL expression 
occurred more rapidly after stimulation with CD40' DC compared to B6 DC (Fig. 
5.5), those T cells that had entered the proliferative cycle had undergone similar 
numbers of cell divisions in both groups, irrespective of the DC used for stimulation 
(Fig. 5.4, overlays). In summary, these experiments suggest that CD40' DC were 
less efficient at triggering initial CD4 T cell expansion in vitro, but that this defect 
was overcome with time, possibly due to other costimulatory molecules, 
compensating for the lack of CD40 on CD40' DC. 
5.5.2. Varying the number of B6 and CD40' spDC does not 
differentially affect their ability to induce T cell 
expansion in vitro 
The number of DC presenting pOVA to Ag-specific T cells had a great effect on T 
cell proliferation (Fig. 5.2). To ensure that the lack of CD40 on DC is not overcome 
by the number of DC present during T cell stimulation, the number of DC was 
decreased from the previous 10:1 ratio, while the number of T cells was kept 
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constant, at 4x10 4  per well. The T cell:DC ratios were decreased 5 and 10 fold, 
giving 50:1 and 100:1 T cell:DC ratios, and DC were co-cultured with T cells as 
before. This reduction in DC number did not show any additional effects of CD40 
deficiency on DC, neither with respect to T cell expansion (Fig. 5.6), nor T cell 
costimulatory molecule expression (Fig. 5.7). The difference in the ability of B6 and 
CD40' DC to stimulate T cells, which was observed at higher DC numbers, was still 
seen at lower numbers of DC. The overall percentages of T cells undergoing cell 
division and showing upregulation of.costimulatory molecules (CD69 and 0X40 are 
shown in Fig. 5.7, but the same effect was seen for CD25 and RANKL) was 
decreased after culture with CD40' DC, but T cells stimulated by CD40-deficient 
DC underwent the same number of cell divisions as those stimulated by B6 DC. The 
presence of CD40 on DC is therefore not crucial for efficient T cell activation in 
vitro. 
5.6. CD40-deficient splenic DC induce abortive T cell 
activation and subsequent unresponsiveness in vivo 
The previous chapter showed that T cells go through a phase of activation before 
reaching a tolerant state in vivo. The above data shows the ability of CD40-deficient 
DC to activate T cells in vitro, but did not provide evidence for unresponsiveness to 
rechallenge. 
5.6.1. CD40' spDC do not support sustained Ag-specific T 
cell activation in vivo 
In order to test whether activation by CD40' DC renders T cells unresponsive to 
rechallenge with the same Ag, DC from CD40 4  or B6 mice were purified as before, 
and pulsed in vitro with pOVA, prior to i.v. administration to naïve B6 mice (initially 
without adoptive transfer of pOVA-reactive T cells). After six days, peripheral LN 
and spleen cells were examined for ex vivo recall responses to pOVA. Ag-specific 
proliferation was observed in lymphoid populations taken from mice that had 
received p0 VA-pulsed B6 DC, but not those that had received CD40' DC (Fig. 5.8). 
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Exogenous ligation of 0X40 prevented the induction of tolerance (Chapter 3) and 
0X40 is upregulated on the T cell during both induction of tolerance and immunity 
(Chapter 4). Since one effect of CD40 ligation is the upregulation of OX40L on DC 
(Chapter 4), which signals to T cells via 0X40, resulting in upregulation of the 
survival factors BcI-2 and Bcl-xL (Rogers et al., 2001), one could reason that 
provision of 0X40-signalling using an agonistic anti-0X40 monoclonal antibody 
might overcome the deficit in T cell activation seen after CD40' DC administration. 
However, no pOVA-reactive proliferative response in lymphoid populations from 
mice treated using this approach could be detected (Fig. 5.8), which correlated with 
data shown in Chapter 3, where provision of anti-0X40 at the time of primary Ag 
administration did not result in effective T cell responses (Fig. 3.7). 
5.6.2. CD40' spDC induce unresponsiveness to subsequent 
rechallenge with Ag in adjuvant in vivo 
Primary in vivo stimulation with Ag-loaded CD40' DC resulted in a lack of T cell 
responsiveness when T cells were restimulated in vitro. However, a more rigorous 
assessment of potential tolerance induction required analysis of T cell reactivity upon 
subsequent in vivo rechallenge with Ag in adjuvant. Mice therefore received pOVA-
loaded DC as before, and were then immunised with pOVA in CFA 6 days after 
administration of DC. Recall proliferative responses to a dose range of pOVA were 
tested 10 days after challenge with pOVA in CFA. Lymphoid populations from mice 
that initially received CD40' DC were clearly impaired in their ability to proliferate 
to pOVA in vitro compared with those from mice that had received B6 DC, or from 
control mice that received no DC (Fig. 5.9). In this setting, the provision of anti-
0X40 at the time of CD40' DC administration allowed in vitro recall responsiveness 
to be evident after immunisation with pOVA in CFA. Again, this is reminiscent of 
data obtained in Chapter 3, where T cells responded to in vivo rechallenge with Ag in 
adjuvant after previous tolerisation (Fig. 3.10). The absence of CD40 on DC 
rendered T cells unresponsive, but this unresponsiveness could be rescued by 
exogenous ligation of 0X40. 
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5.6.3. CD40' spDC induce abortive T cell activation in vivo 
A lack of T cell responsiveness may reflect an absence of Ag-reactive cells or their 
functional inactivation. To address this issue, the expansion and phenotypic changes 
of pOVA-specific T cells were followed in vivo using the OT-Il adoptive transfer 
system. Naïve B6 mice received CFSE-labelled OT-Il T cells on day —I, followed on 
day 0 by an i.v. injection of pOVA-pulsed B6 or CD40' DC as described above. 
Flow cytometry revealed similar changes in the levels of CD69 expression by 
transferred OT-Il T cells in the first three days after administration of either B6 or 
CD40' DC. However, although CD40' DC induced T cell proliferation in vivo, this 
was not sustained past three days after DC administration (Fig. 5.10). OT-Il T cell 
numbers were greatly reduced at the day 4 time-point in the spleens of mice that 
received CD40' DC, compared with a continued T cell expansion from day 3 to 4 in 
mice that received B6 DC (Fig. 5.10). 
5.6.4. Reduced. IL-2 and IFNy production and reduced 
proliferative capacity after exposure to Ag-loaded 
CD4O spDC 
The data presented above showed that the number of Ag-reactive T cells rapidly 
decreased after exposure to Ag on CD40' DC (Fig. 5.10). To determine whether 
disruption of CD40 signalling not only influenced survival of Ag-specific T cells, but 
also affected T cell effector function, i.e. T cell cytokine-producing capacity, 
intracellular cytokine production by OT-Il T cells 6 days after DC administration 
was measured. Lymphoid cells received mitogenic stimulation with PMA and 
ionomycin for 4 hours before intracellular cytokine production was determined by 
FACS staining. Production of both IL-2 and IFN-y was clearly evident after 
administration of B6 DC. Fewer OT-Il cells were producing IL-2 and IFN-y, 
however, after CD40' DC administration, although the percentages of Ly5.lt CD4 
T cells producing IL-2 and IFN-1 were still much higher than in PBS controls (Fig. 
5.1 lb and 5.1lc). Production of IL-4 and IL-lO was minimal after administration of 
either DC group (Fig. 5.1ld and 5.1le). Consistent with earlier findings using B6 
mice without OT-Il transfer (Fig. 5.8), it was found that lymphoid populations from 
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mice harbouring OT-Il T cells showed a greatly reduced proliferative capacity upon 
in vitro culture with pOVA after CD40' DC administration compared with those 
from mice receiving B6 DC (Fig. 5.12). The response in the CD40' DC group 
showed a low level of proliferation mirroring that seen in control mice that received 
PBS rather than DC (Fig. 5.12). 
5.6.5. CD40' spDC induce unresponsiveness in the adoptive 
transfer model 
The results obtained using the adoptive transfer system correlated with those from 
naive B6 mice. After transfer of OT-Il cells, mice received DC and were immunised 
with pOVA/CFA on day 6. Ten days after immunisation, diminished in vitro recall 
proliferative responses to pOVA and a decreased frequency of pOVA-reactive T 
cells in mice that received CD40' DC were found in DLN (Fig. 5.13a and b). 
Collectively, the data looking at T cell expansion in response to Ag encounter on DC 
lacking CD40 suggest that administration of CD40' DC results in an abortive 
activation of Ag-reactive T cells, with the remaining cells being less able to produce 
IL-2, WN-y, or to proliferate in response to Ag. 
5.7. Administration of CD40-deficient spDC protects from 
CNS autoimmune pathology 
The data thus far had indicated that exposure to Ag in the absence of the 
CD40:CD154 interaction induced a transient T cell activation followed by a 
substantial loss in Ag-reactive T cell numbers. Those T cells that did persist had a 
reduced ability to proliferate and produce cytokines. The net effect of these processes 
was to render the mouse relatively unresponsive to subsequent immunogenic 
challenge in vivo. To determine the significance of this unresponsiveness in a 
pathogenic setting, the capacity of autoantigen-loaded CD40' DC to modulate the 
development of pMOG-induced EAE was tested. Mice received either B6 or CD40' 
DC that had been loaded in vitro with the 50.tM pMOG and 6 days later EAE was 
induced by immunization with pMOG/CFA. Both 136 and CD40' DC consistently 
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conferred a degree of protection against EAE compared to mice that did not receive 
DC. However, CD40' DC clearly gave a more pronounced protection than B6 DC 
(Fig. 5.14). 
5.8. Inducing tolerance through administration of CD40' 
bone marrow-derived DC gives inconsistent results 
Although the spleen is arguably the most important organ for induction of T cell 
tolerance, as previously mentioned, it was decided to investigate the tolerogenic 
potential of bm-derived CD40' DC in a similar fashion to spDC as shown above. 
Human blood-derived monocytes, which are currently used in many clinical trials for 
enhancing immune responses to tumours (Bocchia et al., 2000), show similar 
characteristics to bm-DC (Shortman and Liu, 2002). DC in which ReIB function is 
inhibited lack CD40 expression (Martin et al., 2003). If bm-DC lacking CD40 have 
the same tolerogenic potential as CD40' spDC, the possible therapeutic benefits 
associated with blood-derived monocytes, which could be differentiated into DC 
lacking CD40, and could be grown for each patient individually, are considerable. 
5.8.1. 136 and CD404 bone marrow-derived DC have similar 
phenotypic characteristics 
After one week of in vitro culture with GM-CSF, bm-DC from B6 or CD40' mice 
were cultured in the presence of LPS for 2 hrs. DC were then stained for DC subset 
markers CD8cx and CD4, and their relative maturity assessed by staining for the 
costimulatory molecules CD80, CD86 and CD40, as well as by staining for MHC 
class II expression. Bone marrow-derived cells were CD8oC and CD4, and both B6 
and CD40' DC displayed similar surface levels of CD80, CD86 and MHC class II 
(Fig. 5.15). 
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5.8.2. Bone marrow-derived CD404 DC do not support Ag-
specific T cell proliferation in vivo 
DC grown from CD40' or B6 mice were pulsed in vitro with pMOG in the presence 
of LPS, prior to i.v. administration to naïve 136 mice. After six days, peripheral LN 
and spleen cells were examined for in vitro recall responses to pMOG. Ag-specific 
proliferation was observed in lymphoid populations taken from mice that had 
received pMOG-pulsed B6 DC, but not those that had received CD40' DC (Fig. 
5.16), consistent with findings using spDC (Fig. 5.8). 
5.8.3. Bone marrow-derived CD40' DC inconsistently induce 
unresponsiveness in vivo 
As with spDC, the above findings indicated a lack of T cell responsiveness as a result 
of primary in vivo stimulation with Ag-loaded bm-derived CD40' DC. However, 
rechallenge with Ag in adjuvant, which consistently resulted in decreased pOVA-
specific proliferation in after administration with CD40' spDC, gave inconsistent 
results when bm-derived CD40' DC were used (Fig. 5.17). In one experiment, 
administration of CD40' DC gave an Ag-non-specific reduction in T cell 
proliferation, while in a separate experiment, administration of both 136 and CD40' 
DC resulted in a modest decrease in proliferative responses to pMOG (Fig. 5.17). 
Even several repeats of the experiment did not lead to clarification whether or not 




The experiments described in this chapter tested the prediction that Ag presentation 
by DC lacking CD40 would drive Ag-reactive T cell towards unresponsiveness. It 
was shown that CD40 expression on spDC was neither necessary for T cell 
proliferation in vitro, nor was it crucial for initial T cell expansion in vivo. However, 
it was essential for sustaining in vivo T cell expansion past day 3 after DC 
administration, after which a decrease in Ag-specific T cells was observed. This 
correlated with a decreased proportion of T cells producing IL-2 and JFN-y when 
stimulated by CD40' spDC. Importantly these deficits were evident even though the 
CD40' DC had elevated expression of other costimulatory molecules (CD80, 
CD86), and this effect is most likely due to the lack of CD40 on DC, disrupting 
further down-stream events (other than CD80/CD86). Reduced proliferative recall 
responses were found after administration of CD40' spDC, even after rigorous 
assessment of tolerance by administration of Ag in a strong adjuvant. Similar to data 
obtained in chapter 3, exogenous ligation of 0X40 did not rescue responsiveness 
during initial T cell priming, but allowed effective recall responses after rechallenge 
in the presence of a strong adjuvant. Using EAE, it was shown that administration of 
CD40-deficient DC conferred effective protection against the development of 
autoimmune pathology. From these data, it is concluded that the systemic 
administration of CD40-deficient spDC leads to inhibition of T cell activation and a 
deletional form of tolerance that is reminiscent of that seen following administration 
of soluble Ag. 
The chapter concludes by exploring the potentially similar tolerogenic effects of 
CD404 bm-derived DC. Although the initial results appeared promising, and CD40' 
bm-derived DC did not support T cell proliferation in vivo, and more rigorous 
assessment of tolerogenic potential gave inconsistent results. Nevertheless, this 




Presentation of peptide-MHC complexes by resting DC is generally accepted to be 
the key to T cell tolerance induction (Steinman and Nussenzweig, 2002). The finding 
that administration of Ag-loaded, CD40-deficient splenic DC resulted in T cell 
tolerance further highlighted the importance of CD40-CD 154 during the decision 
between tolerance and immunity. This fits with data obtained in Chapters 3 and 4, 
which showed that activation of DC by CD40 prevented tolerance induction, and that 
expression levels of CD40 were increased during the induction of immunity 
compared to tolerance induction (Chapter 4). The system used in this chapter 
provided a tool to specifically look at the impact of CD40-deficiency during T cell 
activation. The finding that CD40' DC induced initial T cell expansion, but were 
unable to sustain this expansion compared to their CD40-sufficient counterparts, is 
consistent with an earlier study that gave DC by a s.c. route (Miga et al., 2001). This 
previous study, however, did not report any unresponsiveness in the Ag-reactive T 
cells that persisted after CD40' DC administration. The obvious difference between 
these two studies is that the route of DC administration. In our series of experiments, 
it was deliberately chosen to give DC i.v., allowing access to the spleen, based on 
previous experience that systemic delivery is most effective at inducing T cell 
tolerance with peptide (Anderton et al., 1998). Inefficient T cell priming after s.c. 
injection of CD40' DC has been reported to be associated with accelerated loss of 
DC from the draining lymph node. Studies of tolerance induction with peptides 
indicate that, whilst establishment of a fully unresponsive state takes 4 to 5 days (Liu 
and Wraith, 1995), the key events that initiate the tolerogenic program probably 
occur within hours of TCR recognition (Hoyne et al., 1996; Zell et al., 2001)., This 
being the case, it could be argued that the issue of how many days B6 versus CD40' 
DC persist in the spleen after i.v. administration is unlikely to be the key to the T cell 
unresponsiveness observed. 
The results clearly show that CD40 DC provoked a proliferative burst in Ag- 
reactive T cells that lasts for three days. This is reminiscent of the data obtained in 
Chapter 4, showing that pOVA-reactive T cells underwent several rounds of cell 
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division after administration of soluble peptide before becoming tolerant. The soluble 
peptide was most likely presented by resting DC, expressing lower levels of CD40, 
compared to DC after administration of Ag and LPS. Therefore the initial 
proliferation seen using DC which completely lacked expression of CD40, fits with 
other experimental systems that lead to T cell tolerance. Even though the percentage 
of cells producing IL-2 and IFN-y is reduced after administration of CD40' DC, it is 
still greatly increased compared to PBS controls. However, the proliferative 
responses were greatly reduced after administration of CD40' DC compared to PBS 
controls, suggesting proliferative unresponsiveness, but not a complete lack of 
effector function. This has previously been observed after administration of soluble 
peptide (Malvey et al., 1998), and is again reminiscent of tolerance induction by 
soluble peptide explored in previous chapters. 
The results. suggest that the decreased IL-2 production in T cells stimulated with 
CD40' DC leads to an abortive immune response, and T cell death. This is 
supported by the sudden decrease in Ag-reactive T cells 4 days after priming with 
CD40' DC. Consistent with inducing a form of deletional tolerance, administration 
of CD40' DC protected from EAE. This matches a recent report in which 
administration of Ag-loaded RelW DC, which also lack CD40' expression, induced 
Ag-specific T cell tolerance (Martin et al., 2003). However, this study reported the 
induction of an IL-tO producing regulatory T cell population. It is unlikely that this 
explains the protection against EAE we observe, since CD40' DC did not induce an 
IL-lO producing T cell population in our OT-Il adoptive transfer system. 
Interestingly, although pOVA-pulsed B6 DC did not appear to result in decreased 
proliferative capacity upon rechallenge, giving pMOG-pulsed B6 DC prior to EAE 
induction consistently gave some protection from disease. Similar data have been 
obtained using LPS-treated, pMOG-pulsed, bone marrow-derived DC (S. Anderton, 
unpublished observations). T cells can become exhausted upon repeated Ag-
stimulation (Lenardo et al., 1999), resulting in reduced capacity to respond to 
rechallenge. Administration of B6 DC and subsequent challenge with a strong 
adjuvant such as CFA may therefore drive some high avidity self-reactive T cells 
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into activation-induced cell death, reducing the ability to induce disease. 
Alternatively, LPS-treated DC could have expanded an already existing population 
of T reg, which has been observed in other systems (Yamazaki et al., 2003), which 
then conferred some protection against autoimmune pathology. 
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Experimental outline for experiments of chapter 5 
C134 pOVA-reactive OT-TI cells were CFSE labelled and co-
cultured with LPS-treated, pOVA-loaded B6 or CD40 DC, and 
analysed by FACS on days 1,2,3,4,5 and 6. 
Some mice received CFSE-labelled, CD4 UT-IT cells on day-i, 
before LPS-treated, p0 VA-loaded B6 or CD40 DC on day 0. In the 
case of an adoptive transfer, mice were sacrificed on I ,2,3 and 4 for 
time course analysis of expression of costimulatory markers. In 
either case, mice were tested for pOVA-specific recall responses on 
day 6, or received pOVAICFA on day 6 and were tested for pOVA-
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Figure 5.2: 
Comparison of T cell activation by bone marrow-derived and 
splenic DC in vitro 
CD4-purified OT-Il cells were co-cultured with bm-derived DC 
(A) or splenic DC (B), and assessed for pOVA-specific 
proliferative responses. Figures in the legend refer to numbers of 
DC/well. 4x104 T cells/well were used. Background levels ranged 
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Figure 5.3: 
Splenic DC from B6 and CD40' mice display similar phenotypic 
characteristics 
Spleens were treated with collagenase and DNAse, DC were purified 
as described in materials and methods, cultured with LPS for 2 hours 
at 37°C, and stained for MHC class II, CD40. CD80, CD86, CD8a 
and CD4. CD1 lc DC were analysed for expression of these 
molecules. These data are from one of two experiments giving 
consistent results. 
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Figure 5.4: 
B6 and CD40' spDC show similar T cell activation capacities in 
vitro 
CFSE-labelled CD4 OT-Il T cells were cultured with Ag-loaded 
splenic DC (10:1 T/DC ratio) and analysed at the times indicated. 
These data are from one of three experiments giving consistent 
results. 
I.r. 
B6 DC CD40 DC 
C'J 	'12 	 €09 	75 
>.H - 
I- 
392 	!_ 	774 
CD 
8 	14 
J1, 10'  
- 	 9 53 





7' 	10 	10 	15 	tO' 	17' 
B6 DC CD40 DC 
2i 	is€ A72 
767 — 








j 1 55 
17 	10' 	10' 	10' 	¶0' 7 	tO' 	10- 	0 









58.3 	0.17 	10 16 01 	:7' 






wlI 	10'4 	3,97 
>,•' 11 ' 	 tO' 
101 	 , T 11 '0 	tO' 10 	10 	10'iO' 10' IV 	1) 







Comparing costimulatory molecule expression induced by B6 and 
CD4O spDC 
CFSE-labelled CD4 OT-Il T cells (4x10 4 cells per well) were 
cultured with Ag-loaded splenic DC (4x10 3 DC per well). At the 
indicated time-points T cells were sampled and expression of CD69. 
CD25, 0X40 and RANKL analysed. Percentages shown on graphs 
refer to percentages of cells in top left and right, and bottom left 
quadrants. These data are from one of three experiments giving 
consistent results. 
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Figure 5.6: 
Varying, the number of B6 and CD40' spDC does not 
differentially affect their ability to induce T cell expansiOn in vitro 
CFSE-labelled CD4 OT-Il T cells (4x10 4 cells per well) were 
cultured with varying numbers of Ag-loaded splenic DC (50/1 or 
100/1 TIDC ratios) and analysed at the times indicated. Numbers 
shown on graphs refer to percentages of divided cells. These data are 
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Figure 5.7: 
Comparing costimulatory molecule expression induced by varying 
numbers of B6 and CD40' spDC 
CFSE-labelled CD4 OT-Il T cells (4x10 4 cells per well) were 
cultured with varying numbers of Ag-loaded splenic DC. At the 
indicated time-points T cells were sampled and expression of CD69, 
CD25. 0X40 and RANKL analysed. Shown are the expression of 
CD69 and 0X40. Percentages shown on graphs refer to percentages of 
cells in top left and right, and bottom left quadrants.These data are 
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Figure 5.8: 
CD40' spDC do not support Ag-specific T cell proliferation in 
vivo 
B6 or CD40 DC were purified and loaded with pOVA as described 
in materials and methods, before i.v. transfer into naïve B6 recipients. 
Six days after DC transfer, splenic lymphoid populations were tested 
for proliferative responses to a dose range of pOVA. These data are 
from one of three experiments giving consistent results. 
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Figure 5.9: 
CD40' spDC administration leads to T cell unresponsiveness in 
vivo 
B6 or CD40 DC were purified and loaded with pOVA as described 
in materials and methods, before transfer into naïve B6 recipients on 
day 0. Mice were immunised on day 6 with pOVA/CFA and draining 
lymph nodes assessed 10 days later for proliferative responses to a 
dose range of pOVA. As indicated some groups also received anti-
0X40 at the time of DC administration and 2 days later. The effects 
seen with ant1 70X40 were not found when using an isotype control 
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Figure 5.10: 
CD40' spDC do not support sustained T cell expansion in vivo 
B6 mice were seeded with CFSE-labelled OT-Il cells one day prior to 
administration of DC. On days 1,3 and 4 post DC administration, 
lymphoid cells (spleen shown here) were analysed by FACS for CFSE 
profile and CD69 expression by V5+Va2+ OT-lI cells (filled lines 
are V5+Va2+ cells that were stained with streptavidin-APC alone). 


































Reduced cytokine production after administration of Ag-loaded 
CD4O spDC 
B6 mice were given Ly5.1 OT-Il cells one day prior to 
administration of DC. Lymphoid populations (spleen shown here) 
were analysed on day 6. UT-lI cells were identified by gating on 
CD4, Ly5.l cells (A, percentages of CD4 cells that were Ly5. 1* 
shown) and counterstained for IL-2 (B), or IFN-y (C, percentages 
of CD4Ly5.1 cells that were cytokine-positive shown). These 
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Figure 5.11d,e: 
Reduced cytokine production after administration of Ag-loaded 
CD4O spDC 
B6 mice were given Ly5.1 UT-Il cells one day prior to 
administration of DC. Lymphoid populations (spleen shown here) 
were analysed on day 6. OT-lI cells were identified by gating on 
CD4, Ly5.1 cells as in Fig. 51 la-c, and counterstained for IL-4 
(D), or IL-lO (E, percentages of CD4Ly5.1 cells that were 
cytokine-positive shown). These data are from one of three 
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Figure 5.12: 
Reduced T cell proliferation after administration of Ag-loaded 
CD401 spDC 
B6 mice were given Ly5.1 UT-IT cells one day prior to 
administration of DC on day 0. B6 or CD40 DC were purified and 
loaded with pOVA as described in materials and methods, before 
transfer into naïve B6 recipients. Six days after DC transfer, splenic 
lymphoid populations were tested for proliferative responses to a dose 
























CD40 spDC induce unresponsiveness to subsequent rechallenge 
in vivo after adoptive transfer of Ag-specific T cells 
B6 mice were given Ly5.1 OT-Il cells one day prior to 
administration of DC on day 0 as before (Fig. 5.12). Mice were 
immunised with pOVA in CFA on day 6 and in vitro recall responses 
to pOVA in the DLN were assessed on day 16. These data are from 
one of several experiments giving consistent results. 
OT-IT cells were identified by gating on CD4, Ly5. l cells on day 
16. Percentages of OT-Il cells in DLN are shown. 
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Figure 5.14: 
CD40' spDC protect from autoimmune CNS pathology 
Mice received pMOG-loaded B6 or CD40 DC 6 days prior to 
induction of EAE with pMOG in CFA. (p values determined by 
Mann-Whitney U test were: PBS vs. B6: 0.0025, PBS vs. CD40 
+pMOG: <0.0001, B6 vs. CD40+pMOG: <0.0001.) These data are 
from one of two experiments giving consistent results. 
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Figure 5.15: 
Bm-DC from B6 and CD40' mice display similar phenotypic 
characteristics 
B6 and CD40 bone marrow cells were grown for 7 days in the 
presence of GM-CSF, cultured with LPS for 2 hours at 37°C, and 
stained for MHC class II, CD40, CD80, CD86, CD8a and CD4. 
CD1 1c DC were analysed for expression of these molecules. These 
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Figure 5.16: 
CD40' bmDC do not support Ag-specific T cell proliferation in 
vivo 
B6 or CD40 DC were grown and loaded with pMOG as described in 
materials and methods, before transfer into naïve B6 recipients. Six 
days after DC transfer, splenic lymphoid populations were tested for 
proliferative responses to a dose range of pMOG. These data are from 
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Figure 5.17: 
Bone marrow-derived CD40' DC inconsistently induce 
unresponsiveness in vivo 
136 or CD40 1 DC were grown and loaded with pMOG as described in 
materials and methods, before transfer into naïve B6 recipients on day 
0. Mice were immunised on day 6 with pMOG/CFA and draining 
lymph nodes assessed 10 days later for proliferative responses to a 
dose range of pMOG. Shown are two examples of the inconsistent 
results obtained. 
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6. CHAPTER 6— Conclusions and Discussion 
This thesis tested the hypothesis that the CD40-CD154 and the 0X40-OX40L 
interactions are pivotal in the decision between T cell tolerance and T cell immunity. 
The results can be summarised as follows: 
Exogenous ligation of both CD40 and 0X40 prevented the induction of T cell 
tolerance after administration of a tolerogenic stimulus. 
• The activation state of the DC, illustrated by the expression levels of CD40 
and RANK was the primary factor in the decision between tolerance and 
immunity. Increased levels of CD40 and RANK resulted in effective 
immunity, while during the induction of tolerance, CD40 and RANK levels 
on DC remained at steady-state levels. 
• Exposure to spDC lacking expression of CD40 resulted in T cell tolerance 
reminiscent of that induced by administration of soluble peptide, and 
effectively protected mice from autoimmune pathology. 
From these results, it can be concluded that the CD40-CD 154 interaction plays a 
pivotal role in the decision between tolerance and immunity. A lack of this 
interaction leads to tolerance, probably also due to subsequent lack of the 0X40-
OX40L interaction, while signalling through CD40 leading to DC activation results 
in T cell immunity. 
am 
6.1. Which molecules constitute the checkpoint in the 
decision between tolerance and immunity? 
Both peptide-induced tolerance and tolerance to peripherally expressed auto-Ag 
involve an initial phase of T cell activation and proliferation (Huang et al., 2003; 
Kearney et al., 1994). This implicates the costimulatory molecules, that are important 
for sustained T cell activation, as key players in the immunity versus tolerance 
checkpoint. The idea that regulation of CD40 expression might represent a general 
mechanism of maintaining peripheral tolerance is an attractive one, and is supported 
by an increasing amount of data. Interference with the CD40:CD40L interaction 
using blocking anti-CD40L prevents effective T cell priming, sometimes leading to a 
tolerant state (Buhlmann et al., 1995; Honey et al., 1999; Tang et al., 1997). Ligation 
of CD40 on the other hand can induce effective immune responses in a number of 
systems (Diehi et al., 1999; Grohmann et al., 2001; Hawiger et al., 2001; Sotomayor 
et al., 1999). 
In accord with the data obtained in other systems (Diehi et al., 1999; Grohmann et 
al., 2001; Hawiger et al., 2001; Sotomayor et al., 1999), the results presented here 
show that exogenous stimulation of CD40 can prevent the induction of tolerance 
(Chapter 3), and ligation of CD40 leads to upregulation of OX40L, CD80 and CD86 
by DC (Chapter 4). Conversely, administration of splenic DC lacking CD40 induces 
T cell deletion and subsequent tolerance, and protects from development of 
autoimmune pathology (Chapter 5). These results support a model of tolerance 
induction in which failure to provide sufficient ligation of CD40 on DC uncouples 
downstream T cell:DC dialogue involving other members of the TNF and TNF-
receptor families. Efficient CD40 ligation drives the upregulation of OX40L. by the 
DC (Fillatreau and Gray, 2003), allowing ligation of 0X40 that is upregulated by the 
T cell following activation through the TCR. 0X40 signalling results in 
accumulation of the anti-apoptotic proteins Bcl-2 and Bcl-xL promoting T cell 
survival (Rogers et al., 2001). Moreover, exogenous ligation of 0X40 on T cells also 
prevented the induction of tolerance, in this study (Chapter 3) and another (Bansal- 
Pakala et al., 2001), further supporting the hypothesis that the CD40-CD154 and 
0X40-OX40L interactions are pivotal in the decision between tolerance and 
immunity. 
A role for the CD28/CTLA-4-CD80/CD86 interaction in this decision has previously 
been suggested. CD28' mice prime poorly (Linsley and Ledbetter, 1993), and T 
cells lacking CD28 fail to expand upon immunisation (Howland et al., 2000). The 
CD28-CD80/CD86 interaction is thus crucial for initial T cell activation. Since a T 
cell has to become activated and go through several rounds of division in order to 
become tolerant, those costimulatory molecules which are important for initial T cell 
activation are unlikely to determine the outcome of the immune responsç, suggesting 
that the initial interaction between CD28 and CD80/86 is not disrupted en route to 
tolerance. 
However, a role for CTLA-4 for the induction of tolerance cannot be excluded. 
Expression of CD80 and CD86 increased during the induction of immunity, similar 
to levelsof CD40 (Chapter 4). CD80/CD86 bind to CTLA-4 on activated T cells, and 
it is accepted that CTLA-4 plays a role in the maintenance of peripheral tolerance. 
CTLA-4-deficient mice develop lymphoproliferative diseases, suggesting CTLA-4 
plays a role in limiting autoimmune responses. In some systems, T cells lacking 
CTLA-4 can be tolerised (Frauwirth et al., 2000; Frauwirth et àl., 2001), while in 
others, CTLA-4 was required for tolerance induction (Greenwald et al., 2001; Perez 
et al., 1997). Most data investigating CD4 T cell tolerance suggests that CTLA-4 is 
required for inhibition of proliferation of the activated T cell and subsequent 
tolerance, suggesting that CD80/CD86 signalling to the T cell via CTLA-4 is 
required for tolerance induction. CD80 and CD86 levels increased during immunity, 
but were found at basal levels during tolerance induction. All activated T cells 
upregulate CTLA-4 after activation (Oosterwegel et al., 1999), and signalling 
through CD80 and CD86 acts as a negative regulator for T cell activation. It is 
possible that basal CD80 and CD86 signalling via CTLA-4 in the absence of positive 
signals to the T cell results in tolerance induction. During the induction of immunity, 
the positive signals outweight the negative signals and en effective immune response 
is initiated. Data on the expression of CTLA-4 during tolerance induction in vivo 
exists, showing that CTLA-4 expression peaked 2 days after i.n. administration of 
soluble peptide, and had decreased to basal levels by day 6 (Metzler et al., 1999). 
CD80 and CD86 expression was highest at day I after i.v. Ag administration in the 
system used here, and decreased to basal levels by day 4. It will be important to 
investigate the timing of expression of CTLA-4 in our system in order to further 
comment on the precise role of CTLA-4 in the induction of tolerance. 
Nevertheless, it was shown here that the absence of CD40 on DC, even in the 
presence of high levels of CD80 and CD86 resulted in T cell tolerance (Chapter 5). 
This indicates that tolerance can be induced in the presence of strong CD28 
signalling (i.e. tolerance probably arises from disruption of other CD40-dependant 
costimulatory events such as 0X40-OX40L signalling). Although CD80 and CD86 
signalling via CTLA-4 may have a role in tolerance induction, the absence of CD40 
has a far greater effect on the outcome of the immune response. If the main effect of 
lack of CD40 signalling is a lack of OX40L upregulation, experiments using DC 
from OX40L-deficient mice should also induce tolerance. These mice have recently 
been acquired, allowing us to further test our hypothesis in the near future. Others 
have shown that the presence of CD80 and CD86 on immunising APC is required for 
the induction of T cell immunity (Lohr et al., 2003), and the presence of basal CD80 
and .CD86 expression is required for maintenance of peripheral tolerance and the T 
reg population (Lohr et al., 2003; Paust et al., 2004). A picture emerges where CD80 
and CD86 are important in the maintenance of peripheral tolerance, possibly through 
inducing T reg populations and/or through interactions with CTLA-4. CD40 ligation 
on the other hand, leads to DC activation and upregulation of costimulatory 
molecules on the DC, and acts as a "master regulator" for the decision between 
immunity and tolerance. 
6.2. Ligation of CD40 versus provision of LPS in the 
prevention of tolerance 
It has previously been suggested that LPS provides a qualitatively different signal 
from CD40 and/or 0X40 costimulation (Maxwell et al., 2002). The data presented 
here provides further evidence that although ligation of CD40 or provision of LPS 
both lead to prevention of tolerance, they do so in different manners. Provision of 
agonistic anti-CD40 has previously been shown to not only enhance immune 
responses (Maxwell et al., 1999), but also to convert tolerogenic Ag presentation by 
DC into immunogenic presentation in some systems (Hawiger et al., 2001), and to 
induce effective tumour immunity in others (Diehi et al., 1999; Grohmann et al., 
2001). It has also been shown that an effective CD8 T cell response develops after 
administration of soluble Ag and anti-CD40 (Lefrancois et al., 2000). However, it 
was shown here that co-administration of soluble Ag and anti-CD40 did not by itself 
result in effective CD4 T cell immunity (Chapter 3). Nonetheless, exogenous 
ligation of CD40 appeared to prevent the tolerance program, and subsequent 
immunisation with Ag/CFA thus allowed efficient recall responses. 
Exogenous ligation of CD40 induced OX40L expression. 0X40 was expressed at 
high levels on day 1 after administration of soluble Ag and anti-CD40, and at lower 
levels on day 2, while OX40L was expressed on day 2 and 3 after administration of 
soluble Ag and anti-CD40. This gives a time window in which the T cell could have 
received a survival signal from the DC, preventing induction of tolerance. In 
contrast, co-administration of LPS and soluble Ag led to effective T cell immunity, 
as has been shown in other systems (Maxwell et al., 2002). Administration of LPS 
increased expression of CD80, CD86, CD40 and RANK, but expression of OX40L 
could not be detected. Whether this was simply due to practical limitation in our 
FACS and histological approaches remains to be investigated. Nevertheless, 
upregulation of all the other costimulatory molecules at a time when their ligands 
were also present on the T cells allowed effective T cell activation. 
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Although early data suggested that CD40 ligation of DC alone was optimal to induce 
DC maturation and licensing to induce an effective T cell response (Mackey et al., 
1998), more recent studies show that co-ligation of TLR and CD40 is necessary to 
induce IL-12 p70 production (i.e. functional IL-12) in vitro or in vivo (Schulz et al., 
2000). Co-ligation of CD40 and TLR also enhances the frequency of peptide-reactive 
CD8 T cells by more than tenfold (Quezada et al., 2004). The importance of 
combined TLR and CD40 signalling becomes evident when considering the 
histological impact of TLR ligation on DC migration. LPS administration induces 
rapid DC migration from the splenic marginal zone into PALS (De Smedt et al., 
1996), and once in the T cell area, DC have a short half life unless they receive 
CD154 signalling (Miga et al., 2001). This may explain why, although CD40 ligation 
activated DC in vivo and induced increased or de novo expression of CD80, CD86 
and OX40L, subsequent TLR ligation through components found in CFA seemed to 
be necessary to induce an effective immune response. This again raises the question 
of when the administered antibodies are having their effects, which remains to be 
investigated. 
6.3. RANKL: An indication for retrograde signalling 
inducing T cell tolerance? 
While Chapter 5 shows that the lack of CD40 led to tolerance, Chapter 3 shows that 
provision of CD40 and 0X40 signals (i.e. providing a signal that was lacking) could 
prevent tolerance. Chapter 4, on the other hand, suggests that tolerance may be more 
than just the absence of signalling from the DC. The early and increased expression 
of RANKL by T cells heading for tolerance was a surprising finding, and it is 
intriguing to speculate what the significance of this tolerance-specific effect may be. 
It could be that RANKL might have been expressed early on T cells during the 
induction of tolerance because a signal from the DC is missing, which is needed to 
control the correct timing of RANKL expression. It is clear from the data presented 
here as well as other studies of tolerance induction with soluble Ag, that transient T 
cell proliferation is intrinsic to the tolerance program (Hoyne et al., 1996; Switzer et 
al., 1998). Tolerance may therefore be an active choice of the immune system, rather 
than just a lack of costimulatory signalling. Another possibility is thus the existence 
of a second receptor for RANKL on the DC. Retrograde signalling from the DC to 
the T cell could (possibly in the absence of other signals, such as CD 154 or 0X40) 
deliver negative signals to the T cell resulting in tolerance - an exciting option. 
The existence of a second receptor for RANKL was therefore investigated. 
Incubation of DC with a recombinant RANKL with a histidine tag, followed by 
incubation with a PE-conjugated anti-histidine antibody, was used in an attempt to 
identify a possibly second receptor for RANKL. Unfortunately, this approach did not 
result in staining on DC known to express RANK, and was therefore not used any 
further. A RANKL fusion protein has already been shown to enhance mucosal 
tolerance induction in vivo, and incubation with DC isolated from the spleen or 
mesenteric lymph nodes (MLN) showed differential DC cytokine production in 
response to RANKL, even though both sets of DC expressed similar levels of RANK 
(Williamson et al., 2002). Splenic DC showed IL-12 production, while MLN DC 
showed IL-10 production (Williamson et al., 2002), which was interpreted to show 
differential responsiveness to RANKL. However, it may be that MLN DC, although, 
very likely predisposed to inducing tolerance rather than immunity due to their 
surroundings, might express a second receptor to RANKL, which further promotes 
tolerance rather than immunity. A RANK fusion protein, which has been used 
previously to look at its effects on osteoclastic bone resorption (Oyajobi et al., 2001), 
may further elucidate whether or not signalling through RANKL could indeed give 
tolerogenic signals to T cells. 
6.4. Lessons learned from comparing in vitro and in vivo 
Although the in vitro requirements for T cell activation have been studied 
extensively, the initiation •of an immune response in vivo takes place within a 
complex microenvironment, in which the interplay between DC and T cells is 
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restricted by anatomical constraints. Data obtained from in vitro experiments may 
therefore not always directly correlate with those from in vivo models, which is 
further illustrated by results presented here. Chapter 4 showed the timing of 
expression of CD 154, 0X40 and RANKL on T cells after administration of soluble 
Ag with or without LPS. CD154 expression had previously been investigated in vitro 
after CD3 stimulation, and was found to peak at 6-8 hours, returning to resting levels 
between 24 and 48 hours (Roy et al., 1993). In vivo however, expression was found 
at day I (approximately 18 hours after Ag administration), but levels stayed 
increased until at least 48 hours. 
A greater contrast between in vitro and in vivo findings were observed looking at 
expression of 0X40. 0X40 was reported to be upregulated later than CD154, 
peaking at 3-4 days after initial T cell activation in vitro (Gramaglia et al., 1998). As 
clearly shown in Chapter 4, 0X40 was upregulated in vivo within 24 hours of Ag 
administration, but had disappeared again by day 3. Similarly, RANKL was 
suggested to act sequentially after CD154, having been found to peak in expression 
48 hours after in vitro T cell stimulation, and remaining high in expression until 96 
hours (Josien et al., 1999). In the system used here, RANKL was found to be 
expressed at day I after administration of Ag alone, and at day 2 after administration 
of Ag and LPS, and had greatly decreased in expression by day 3 (i.e. well before 96 
hours). These differences show that the actual in vivo expression of costimulatory 
molecules greatly differs from in vitro experiments, and probably also varies when 
different immunisation routes are used. Intravenous administration of soluble Ag 
allows almost immediate access of Ag for uptake and/or binding to DC, while s.c. 
administration of Ag/CFA is likely to require DC activation at the site of CFA 
administration, and subsequent migration to DLN, before efficient T cell activation. 
Chapter 5 describes attempts to design an in vitro model to investigate the 
importance of CD40 on DC for T cell priming. Stimulating T cells in vitro with B6 
or CD40' DC showed CD69 expression over period of several days, and 0X40 and 
RANKL expression peaked by day 3 after stimulation, and was still found by day 4 
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(not shown). In vivo however, CD69 expression peaked at day 1, and by day 4, a 
large proportion of T cells activated by CD40' DC had disappeared. The findings of 
in vitro experiments may give an indication of the requirements for T cell activation 
in vivo, but testing of in vitro findings in an in vivo setting is essential. Nevertheless, 
there are of course potential benefits to the development of appropriate in vitro 
models of T cell activation versus tolerance, particularly considering animal welfare, 
and further research should be conducted in an effort to increase the validity of such 
models. 
Identification of the molecules and pathways that drive the T cell response towards 
tolerance rather than immunity is crucial for future design of therapy. A number of 
human trials have shown the effectiveness of administration of allergen peptides to 
reduce allergy symptoms (Norman et al., 1996; Oldfield et al., 2002). Mouse studies 
have already indicated the therapeutic potential of targeting costimulatory molecules 
in either preventing disease or inducing effective immunity. The results presented in 
this thesis provide important information on the kinetics of the basic molecular 
interactions leading to immunity versus tolerance in vivo. These data will hopefully 
contribute to the rational design of therapies that either boost or block immune 
responses, and which may allow treatment of autoimmunity, allergy or tumours in 
the future. 
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Appendix Fig. 1: 
CD69 expression on T cells after administration of pOVA, 
pOVA+LPS or PBS 
B6 mice received Ly5. 1 1 OT-IT cells one day prior to 
administration of pOVA, pOVA+LPS or PBS. 
On days 1, 2 and 3 post Ag administration, spleen cells were 
analysed by FACS for CD69 expression by Ly5.l CD4 OT-Il 
cells (filled histograms are Ly5.1 CD4 OT-Il cells stained with 
streptavidin-APC alone). Percentages of Ly5. V CD4 OT-TI cells 
positive for CD69 are shown on each graph. These data are from 
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Dynal beads purification 
Appendix Fig. 2: 
DC phenotype after purification in the presence of polymyxin, 
or or after negative selection using Dyna!  beads 
DC were purified from naïve B6 mice, either by positive selection 
in the absence (full lines) or the presence of polymyxin (dotted 
lines) or by negative selection using Dynal beads (dashed lines). 
CD1 1c DC were analysed for expression of CD40, CD80 and 
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Appendix Fig. 3: 
CD40 expression on DC after administration of pOVA, 
pOVA+CpG or PBS 
B6 mice received Ly5. 1 1 OT-Il cells one day prior to 
administration of pOVA, pOVA+CpG or PBS. 
On days 1, 2 and 3 post Ag administration, CD1 I cl DC were 
purified from the spleen. CD1 1c cells were analysed by FACS for 
CD40 expression on days 1, 2 and 3 (filled histograms are CDI 1c 
cells stained with an isotype control antibody). Median 
fluorescence values of CD40 stained DC are shown on each graph. 
These data are from one of several experiments giving consistent 
results. 
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OX40L expression on DC after administration of pOVA, 
pOVA+CpG or PBS 
B6 mice received Ly5. 1 1 OT-Il cells one day prior to 
administration of pOVA, pOVA+CpG or PBS. 
On days1, 2 and 3 post Ag administration,CD11c DC were 
purified from the spleen. CD11c cells were analysed by FACS for 
OX40L expression on days 1, 2 and 3 (filled histograms are 
CD1 1c cells stained with an isotype control antibody). Median 
fluorescence values of OX40L stained DC are shown on each 
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Appendix Fig. 5: 
RANK expression on DC after administration of pOVA, 
pOVA-1-CpG or PBS 
B6 mice received Ly5.1 UT-TI cells one day prior to 
administration of pOVA, pOVA+CpG or PBS. 
On days 1, 2 and 3 post Ag administration, CD1 lc DC were 
purified from the spleen. CD1 I cl cells were analysed by FACS for 
RANK expression on days 1, 2 and 3 (filled histograms are CDllc 
cells stained with an isotype control antibody). Median 
fluorescence values of RANK stained DC are shown on each graph. 
These data are from one of several experiments giving consistent 
results. 
219 




















10° 	10' 	102 	101 	10' 	100 	1 01 	102 	10' 	10' 	100 	10' 	102 	10' 	10' 
100 
1 ::k 50 
 40- J 20 
100 	10' 	102 	10' 	10' 	100 	10 1 	102 	100 	10' 	10° 	10' 	10' 	10' 	10' 
(3 	100 	 ioc 	 100 
0.. W4 	 _______ 
10° 	10' 	102 	103 	10' 	100 	10° 	102 	103 	10' 	100 
	1 01 	102 	10' 	104  
0X40 	10 
Appendix Fig. 6: 
0X40 expression on T cells after administration of pOVA, 
pOVA+CpG or PBS 
B6 mice received Ly5. 1 1 OT-Il cells one day prior to administration 
of pOVA, pOVA+CpG or PBS. 
On days 1, 2 and 3 post Ag administration, spleen cells were 
analysed by FACS for 0X40 expression by Ly5. 1 CD4 OT-Il 
cells (filled histograms are Ly5.1 CD4 OT-Il cells stained with 
streptavidin-APC alone). Percentages of Ly5. V CD4 OT-Il cells 
positive for RANKL are shown on each graph. These data are from 
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Appendix Fig. 7: 
RANKL expression on T cells after administration of pOVA, 
pOVA+CpG or PBS 
B6 mice received Ly5.1 OT-Il cells one day prior to administration 
of pOVA, pOVA+CpG or PBS. 
On days 1, 2 and 3 post Ag administration, spleen cells were 
analysed by FACS for RANKL expression by Ly5.1 CD4 OT-Il 
cells (filled histograms are Ly5.1 CD4 OT-Il cells stained with 
streptavidin-APC alone). Percentages of Ly5. 1 CD4 OT-Il cells 
positive for RANKL are shown on each graph. These data are from 














Appendix Fig. 8: 
Administration of pOVA+LPS leads to successful priming in 
CD154' mice 
Naïve CD154 mice received a single dose of 500tg pOVA, 
pOVA+50pg LPS, or PBS i.v. on day 0. Spleen were assessed 5 
days later for proliferative responses to a dose range of pOVA. 
Background levels were as follows: pOVA: 4862, pOVA+LPS: 
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Appendix Fig. 9: 
Tolerance of CD154' T cells is not due to the absence of 0X40 
on T cells 
CD 154-1- mice received CD154'xOT-ll cells one day prior to 
administration of pOVA, pOVA+LPS or PBS. 
On days 1, 2 and 3 post Ag administration, spleen cells were 
analysed by FACS for 0X40 expression by Va2, Vl35  CD4 OT-
II cells (filled histograms are V(x2, V05 CD4 OT-TI cells stained 
with streptavidin-APC alone). Percentages of Va2, Vi35  CD4 
OT-II cells positive for 0X40 are shown on each graph. These data 
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Appendix Fig. 10: 
Tolerance of CD154' T cells is not due to the absence of 
RANKL on T cells 
CD154 mice received CD154'xOT-H cells one day prior to 
administration of pOVA, pOVA+LPS or PBS. 
On days 1, 2 and 3 post Ag administration, spleen cells were 
analysed by FACS for RANKL expression by Va2t VF35 CD4 
OT-TI cells (filled histograms are V(x2, VI35  CD4 OT-IT cells 
stained with streptavidin-APC alone). Percentages of Va2, V1 35 
C134 OT-il cells positive for RANKL are shown on each graph. 



















601 ñ A 
100 	10' 	102 	103 	10' 	100 	10' 	102 	103 	10' 	100 	101 	102 	10' 	10' 
	
¶ 1E A A 
51.7 
1E 
 A 1 
1 





- 	100 	10' 	102 	10' 	10' 	100 	10' 	102 	101 	10' 	10° 	10' 	102 	103 	10' 
CD4O 	10 
Appendix Fig 11: 
CD40 expression is upregulated on DC during the induction of 
immunity in CD154' mice 
CD 154' mice received CD154xOT-H cells one day prior to 
administration of pOVA, pOVA+LPS or PBS. 
On days 1, 2 and 3 post Ag administration, CDl1c DC were 
purified from the spleen. CDI Ic cells were analysed by FACS for 
CD40 expression on days 1, 2 and 3 (filled histograms are CDI Ic 
cells stained with an isotype control antibody). Median 
fluorescence values of CD40 stained DC are shown on each graph. 
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OX40L expression on DC during the induction of tolerance or 
immunity in CD154' mice 
CD 154 -1- mice received CD154xOT-ll cells one day prior to 
administration of pOVA, pOVA+LPS or PBS. 
On days 1, 2 and 3 post Ag administration, CD1 lc DC were 
purified from the spleen. CD11c cells were analysed by FAGS for 
OX40L expression on days 1, 2 and 3 (filled histograms are 
CD1 1c cells stained with an isotype control antibody). Median 
fluorescence values of OX40L stained DC are shown on each 
graph. These data are from one of several experiments giving 
consistent results. 
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Appendix Fig. 13: 
RANK expression is upregulated on DC during the induction of 
immunity in CD154 mice 
CD154 mice received CD154'xOT-ll cells one day prior to 
administration of pOVA, pOVA+LPS or PBS. 
On days 1, 2 and 3 post Ag administration, CDllc DC were 
purified from the spleen. CD1 lc cells were analysed by FACS for 
OX40L expression on days 1, 2 and 3 (filled histograms are 
CDI lc cells stained with an isotype control antibody). Median 
fluorescence values of RANK stained DC are shown on each graph. 
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Appendix Fig. 14: 
Tolerance in B cell-deficient mice in not due to the absence of 
0X40 on T cells 
pMT mice received Ly5.1 OT-Il cells one day prior to 
administration of pOVA, pOVA+LPS or PBS. 
On days 1, 2 and 3 post Ag administration, spleen cells were 
analysed by FACS for 0X40 expression by Ly5.1 + CD4 OT-Il 
cells (filled histograms are Ly5. V CD4 OT-Il cells stained with 
streptavidin-APC alone). Percentages of Ly5. V CD4 UT-Il cells 
positive for 0X40 are shown on each graph. These data are from 
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Appendix Fig. 15: 
Tolerance in B cell-deficient mice is not due to the absence of 
RANKL on T cells 
.tMT mice received Ly5. 1 1 OT-Il cells one day prior to 
administration of pOVA, pOVA+LPS or PBS. 
On days 1, 2 and 3 post Ag administration, spleen cells were 
analysed by FACS for RANKL expression by Ly5.P CD4 OT-IT 
cells (filled histograms are Ly5.l CD4 OT-Il cells stained with 
streptavidin-APC alone). Percentages of Ly5.l CD4 OT-JI cells 
positive for RANKL are shown on each graph. These data are from 
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Appendix Fig. 16: 
CD40 expression is upregulated on DC during the induction of 
immunity in B cell-deficient mice 
.tMT mice received Ly5. 1 1 OT-Il cells one day prior to 
administration of pOVA, pOVA+LPS or PBS. 
On days 1, 2 and 3 post Ag administration, CD1lc DC were 
purified from the spleen. CD1 lc cells were analysed by FACS for 
CD40 expression on days 1, 2 and 3 (filled histograms are CDI lc 
cells stained with an isotype control antibody). Median 
fluorescence values of CD40 stained DC are shown on each graph. 
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Appendix Fig. 17: 
RANK expression is upregulated on DC during the induction of 
immunity in B cell-deficient mice 
i.MT mice received Ly5.1 OT-Il cells one day prior to 
administration of pOVA, pOVA+LPS or PBS. 
On days 1, 2 and 3 post Ag administration, CDllc DC were 
purified from the spleen. CDI 1c cells were analysed by FACS for 
RANK expression on days 1, 2 and 3 (filled histograms are CDI lc 
cells stained with an isotype control antibody). Median 
fluorescence values of RANK stained DC are shown on each graph. 
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Systemic administration of antigen-loaded CD40-
deficient dendritic cells mimics soluble antigen 
administration 
Kristin Hochweller and Stephen M. Anderton 
ICAPB, University of Edinburgh, Edinburgh, GB 
The decision to mount a T cell response to antigen (Ag) is dependent on the cellular context 
in which the Ag is presented. Activated dendritic cells (DC) are potent stimulators of immune 
responses, an ability which is linked to their high expression of several costimulatory mole-
cules. In contrast, resting DC have been implicated in the generation of self tolerance, pre-
sumably due to their reduced costimulatory capacity. However, the precise molecular basis 
for the choice between Ag-induced immunity and unresponsiveness remains unclear. We 
show here thét CD40 plays an important role in this decision. Systemic administration of Ag-
loaded, CD40-deficient DC failed to induce a productive primary T cell expansion and ren-
dered mice relatively unresponsive to subsequent immunization with Ag in adjuvant. Using a 
TCR-transgenic T cell transfer system, we found that CD40 DC triggered an initial T cell 
activation that could not be sustained, resulting in loss of Ag-reactive T cells and reduced 
cytokine production by those T cells that did persist. Furthermore, administration of CD40 
DC that had been loaded with a central nervous system autoantigen was found to protect 
mice from autoimmune pathology. These data implicate the CD40:CD40L interaction as a 
key checkpoint in the development of T cell immunity rather than tolerance. 





The adaptive immune response is dependent on com-
plex interactions between APC and CD4 T cells. In vitro 
and in vivo studies have shown that dendritic cells (DC) 
are the most efficient APC at activating naive T cells [1]. 
This capacity is linked to the ability of DC to sense 
pathogen-derived molecular triggers or inflammatory 
mediators, resulting in DC "activation" as characterized 
by increased expression of MHC and costimulatory mol-
ecules. Experimental provision of protein or peptide anti-
gens in the absence of DC activation (by in vivo adminis-
tration of soluble Ag) fails to induce sustained T cell acti-
vation, but instead leads to T cell tolerance [2, 3]. The 
consensus view is that the activation state of the DC is 
crucial in determining the outcome of antigenic chal-
lenge, i.e. the development of either productive T cell 
immunity or tolerance. Resting and activated DC show 
marked differences in their expression of various costim-
ulatory molecules [4]. Notably, CD40 is expressed at 
[DOl 10.1 002/eji.200324782] 
Abbreviations: pOVA: 323-339 peptide of OVA B6: 
C57BL16 
very low levels by resting DC, but is rapidly up-regulated 
upon activation [5, 6]. Ligation of CD40 leads to further 
DC maturation and up-regulation of CD80, CD86 and 
OX40L which all serve to boost T cell activation and 
expansion [7-10]. 
Experiments using CD40- or CD40L-deficient mice have 
shown clear defects in T cell priming in vivo when this 
interaction is absent [11-13]. This has led to the view that 
ineffective DC stimulation through CD40 may, at least in 
part, account for T cell tolerance that results from admin-
istration of Ag in the absence of adjuvant. Consistent 
with this, triggering CD40 using agonistic anti-CD40 in 
vivo has been shown in several studies to convert a tole-
rogenic antigenic stimulus into an immunogenic one 
[14-16]. If the CD40:CD40L interaction is truly a critical 
checkpoint in the immunity versus tolerance decision, 
then administration of Ag-loaded CD40-deficient DC 
should lead to Ag-specific T cell tolerance reminiscent of 
that induced by soluble Ag. Previous studies that have 
addressed this by administration of DC s.c. concluded 
that, whilst CD40 DC failed to lead to productive T cell 
immunity, T cell tolerance was also not evident [17]. 
However, a key factor for the induction of effective T cell 
tolerance with soluble Ag is the use of a systemic route 
[3]. We would therefore have predicted that the previous 
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study using the sub-cutaneous route would not lead to a 
global tolerogenic effect. 
To re-address this question we have administered Ag-
loaded CD40-sufficient or -deficient DC i.v. and 
assessed their influence on the fate of Ag-reactive T cells 
by using TCR-transgenic transfer systems and by moni-
toring the development of CD4 T cell-mediated CNS 
autoimmunity. We show that CD40 expression was not 
necessary for initial T cell expansion in vivo, but was 
essential for sustaining this expansion past day 3 after 
DC administration. This correlated with a decreased pro-
portion of T cells producing IL-2 and IFN-y when using 
CD40 DC. Importantly these deficits were evident even 
though the CD40 DC had elevated expression of other 
costimulatory molecules (CD80, CD86). Furthermore, 
using EAE, we show that this approach conferred effec-
tive protection against the development of autoimmune 
pathology. From these data, we conclude that the sys-
temic administration of CD40-deficient DC leads to inhi-
bition of T cell activation and deletional tolerance that is 
reminiscent of that seen following administration of solu-
ble Ag. 
2 Results 
2.1 Wild-type and CD40 splenic DC have 
similar phenotypic characteristics 
Using wild-type and CD40 mice as sources of DC, we 
have examined the consequences of the lack of CD40 
expression by DO on the kinetics of T cell activation and 
expansion. In order to exclude the possibility that subse-
quent results were due to variation in expression of other 
costimulatory molecules or in the proportions of DC sub-
sets, we analyzed the surface phenotype of splenic DC 
isolated from C57BLJ6 (136) or CD40 mice. These two 
DC populations expressed similar levels of CD80 and 
CD86 immediately after purification (Fig. 1). Similar per-
centages of CD8a and CD4 DC subsets were also 
found in each population. A large proportion of DC dis-
played a mature phenotype, as illustrated by MHC class 
II expression and high levels of CD40 on B6 cells, sug-
gesting that the purification procedure we used resulted 
in significant DC activation. 
2.2 CD40-deficient splenic DC induce T cell 
activation and expansion in vitro 
We next tested whether CD40 DC could activate a pri-
mary T cell response in vitro using OT-Il T cells that rec-
ognize the 323-339 peptide of OVA (pOVA) [18]. CD4 
OT-Il T cells (from OT-llxCD40r' mice to avoid contami- 
,°, _J 'S. 	 •,S. 	i . 	 ., 
MHCII CD4O 
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Fig. 1. Splenic DC from B6 and CD40 display similar phe-
notypic characteristics. Spleens were treated with collage-
nase and DNase, DC were purified as described in Sect. 4, 
cultured with LPS for 2 h at 37°C, and stained for CD80, 
CD86, CD40, OX40L, MHC class II, CD8a and CD4. 
nating CD40' cells) were CFSE-Iabeled, and cultured 
with pOVA-pulsed DC from B6 or CD40 mice. The 
CFSE profile was assessed after 2, 3, 4, and 5 days of 
culture, together with expression of CD69 and CD25 
(Fig. 2). Stimulation with CD40 4 DC consistently led to a 
lower percentage of T cells undergoing division at early 
time points (days 2 and 3 of culture) compared with cul-
tures using B6 DC. This was reflected in the percentages 
of T cells showing up-regulation of CD69 and CD25 at 
these time points (Fig. 2). However, those T cells that had 
entered the proliferative cycle had undergone similar 
numbers of cell divisions in both groups, irrespective of 
the DC used for stimulation. Moreover, although down-
regulation of levels of CD69 expression occurred more 
rapidly after stimulation with CD40 DC compared to B6 
DC, by day 5 of culture, a similar number of T cells in 
both sets of cultures had undergone substantial cell divi-
sion (Fig. 2). In summary, these experiments suggest that 
CD40 DC were less efficient at triggering initial CD4 T 
cell expansion in vitro, but that this defect was overcome 
with time, possibly due to costimulation via CD80 and 
CD86, which were displayed at similar levels on both B6 
and CD40 DC (Fig. 1). Experiments using a range of 
DC numbers indicated that these modest differences in T 
cell activation were no more pronounced when DC num-
bers were limiting (data not shown). 
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Fig. 2. B6 and CD40 DC show similar T cell activation 
capacities in vitro. CFSE-labeled CD4 OT-Il T cells were cul-
tured with Ag-loaded splenic DC. At the indicated time 
points T cells were sampled and expression of CD69 and 
CD25 analyzed. These data are from one of three experi-
ments giving consistent results. Left hand panels: solid line: 
CD40 DC, dotted line: B6 DC. Percentages of T cells that 
had undergone one or more division(s) were: day 2, B6: 
35.7%, CD40: 25.8%; day 3, 136: 78.7%, CD40: 57.2%. 
Percentages of T cells expressing activation markers are 
shown. 
2.3 CD40-deficient splenic DC induce abortive T 
cell activation and subsequent 
unresponsiveness in vivo 
Since CD40 DC appeared capable of supporting pri-
mary T cell expansion in vitro, we continued by testing 
their ability to initiate productive T cell immunity in vivo. 
DC from CD40 or B6 mice were pulsed in vitro with 
pOVA, prior to i.v. administration to naive B6 mice. After 
6 days, peripheral LN and spleen cells were examined 
for in vitro recall responses to pOVA. Ag-specific prolifer-
ation was observed in lymphoid populations taken from 
mice that had received pOVA-pulsed B6 DC, but not 
those that had received CD404 DC (Fig. 3A). One effect 
of CD40 ligation is the up-regulation of OX40L on the 
surface of DC [10]. Ligation of 0X40, (up-regulated on 
the I cell in response to TCR signaling) has been 
reported to lead to elevated T cell expression of survival 
factors such as Bcl-2 and Bcl-xL [19] and to prevent 
peripheral I cell tolerance induction [20]. We therefore 
reasoned that provision of 0X40-signalling using an ago-
nistic anti-0X40 monoclonal antibody might overcome 
the deficit in T cell activation seen after CD40 DC 
administration. However, we found no pOVA-reactive 
proliferative response in lymphoid populations from mice 
treated using this approach (Fig. 3A). 
The above findings indicated a lack of I cell responsive- 
ness as a result of primary in vivo stimulation with Ag- 
loaded CD40 DC. However, a more rigorous assess- 
50- 
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Fig. 3. CD404 DC administration leads to T cell unrespon-
siveness in vivo. B6 or CD40 DC were purified and loaded 
with pOVA as described in Sect. 4, before transfer into naive 
B6 recipients. Six days after DC transfer, splenic lymphoid 
populations were tested for proliferative responses to a dose 
range of pOVA (A). Further groups of mice were immunized 
on day 6 with pOVNCFA and draining lymph nodes 
assessed 10 days later for proliferative responses to a dose 
range of pOVA (B). As indicated some groups also received 
anti-0X40 at the time of DC administration and 2 days later. 
The effects seen with anti-0X40 were not found when using 
an isotype control antibody. These data are from one of 
three experiments giving consistent results. 
ment of potential tolerance induction requires analysis of 
I cell reactivity upon subsequent in vivo rechallenge with 
Ag in adjuvant. We therefore immunized mice with pOVA 
in CFA 6 days after administration of DC. Lymphoid pop-
ulations from mice that initially received CD40 DC were 
clearly impaired in their ability to proliferate to pOVA in 
vitro compared with those from mice that had received 
B6 DC (Fig. 313), or from control mice that received no 
DC. In this setting, the provision of anti-0X40 at the time 
of CD40 DC administration allowed in vitro recall 
responsiveness to be evident after immunization with 
pOVA in CFA. 
A lack of T cell responsiveness may reflect an absence of 
Ag-reactive cells or their functional inactivation. To 
address this issue we followed the expansion and phe-
notypic changes of pOVA-specific T cells in vivo using a 
transfer system in which naive B6 mice were seeded with 
CFSE-labeled OT-Il T cells. One day after transfer, the 
recipient mice received an i.v. injection of pOVA-pulsed 
86 or CD40 DC as described above. Flow cytometry 
revealed similar changes in the levels of CD69 expres-
sion by 01-I1l cells in the first 3 days after administration 
of either B6 or CD40 DC. However, although CD40 
DC induced T cell proliferation in vivo, this was not sus-
tained past 3 days after DC administration (Fig. 4). OT-Il 
T cell numbers were greatly reduced at the day 4 time 
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Fig. 4. CD40 DC do not support sustained T cell expansion 
in vivo. B6 mice were seeded with CFSE-labeled OT-Il cells 
1 day prior to administration of DC. On days 1, 3 and 4 post-
DC administration, lymphoid cells (spleen shown here) were 
analyzed by FACS for CFSE profile and CD69 expression by 
V135 Vci2  OT-Il cells (filled lines are Vi5Va2  cells that were 
stained with streptavidin-allophycocyanin alone). These 
data are from one of several experiments giving consistent 
results. 
point in the spleens of mice that received CD40 DC, 
compared with a continued T cell expansion from day 3 
to 4 in mice that received B6 DC (Fig. 4). 
2.4 Reduced IL-2 and IFN-y production and 
reduced proliferative capacity as a result of 
exposure to Ag-loaded C1340 DC 
The above data indicated a more rapid loss of Ag-
reactive cells after exposure to Ag on CD40 DC. To 
determine whether disruption of CD40 signaling also had 
an influence on T cell cytokine-producing capacity, we 
measured intracellular cytokine production by OT-Il T 
cells 6 days after DC administration. We did not detect 
production of IL-10 and production of lL-4 was minimal 
after administration of either DC group (data not shown). 
Production of both lL-2 and IFN-y was clearly evident 
after administration of B6 DC. Fewer OT-Il cells were pro-
ducing IL-2 and IFN-y, however, after CD40 DC admin-
istration (Fig. 5B, C). Consistent with our earlier findings 
using B6 mice without OT-Il transfer (Fig. 3), we found 
that lymphoid populations from mice harboring OT-Il T 
cells showed a greatly reduced proliferative capacity 
upon in vitro culture with pOVA after CD40 DC admin-
istration compared with those from mice receiving B6 
DC. The response in the CD40 DC group showed a low 
level of proliferation mirroring that seen in control mice 
that received PBS rather than DC (Fig. 5D). 
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Fig. 5. Reduced T cell proliferation and cytokine production 
after administration of Ag-loaded CD40 DC. B6 mice were 
given Ly5.1' OT-Il cells 1 day prior to administration of DC. 
Lymphoid populations (spleen shown here) were analyzed 
on day 6. OT-ll cells were identified by gating on CD4Ly5.1' 
cells (A, percentages of CD4 cells that were Ly5.1 shown) 
and counterstained for lL-2 (B), or IFN-y (C, percentages of 
CD4Ly5.1 cells that were cytokine-positive shown). (D) 
Proliferation in response to a dose range of pOVA. Further 
groups of mice were immunized with pOVA in CFA on day 6 
and in vitro recall, responses to pOVA were assessed 
10 days later (E). These data are from one of several experi-
ments giving consistent results. 
As above, we then immunized mice with pOVNCFA 
6 days after they had received DC. Ten days after immu-
nization, we found diminished in vitro recall proliferative 
responses to pOVA and a decreased frequency of pOVA-
reactive T cells in mice that received CD40 DC, remi-
niscent of tolerance induced by soluble peptides 
(Fig. 5E). These data suggest that administration of 
CD40" DC results in an abortive activation of Ag-
reactive T cells, with the remaining cells being less able 
to produce lL-2, IFN-?, or to proliferate in response to 
Ag. 
2.5 Administration of CD40-d6ficient DC protects 
from CNS autoimmune pathology 
Our data thus far had indicated that exposure to Ag in 
the absence of the CD40:CD40L interaction induced a 
transient T cell activation followed by a substantial loss 
in Ag-reactive T cell numbers. Those T cells that did per-
sist had a reduced ability to proliferate and produce 
cytokines. The net effect of these processes was to ren-
der the mouse relatively unresponsive to subsequent 
immunogenic challenge in vivo. To determine the signifi-
cance of this unresponsiveness in a pathogenic setting, 
we tested the capacity of autoantigen-loaded CD40 
DC to modulate the development of EAE induced with 
the p35-55 peptide of myelin oligoden1rocyte glycopro-
tein (MOG) [21]. Mice received either B6 or CD40 DC 
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Fig. 6. CD40' DC protect from autoimmune CNS pathology. 
Mice received p35-55-loaded B6 or CD40 DC 7 days prior 
to induction of EAE with p35-55 in CFA. p values determined 
by Mann-Whitney U test were: PBS vs. B6: p=0.0025, PBS 
vs. CD40' + p35-55: p<0.0001, B6 vs. CD40 + p35-55: 
p<0.0001). These data are from one of two experiments giv-
ing consistent results. 
that had been loaded in vitro with the p35-55 peptide 
and 6 days later EAE was induced by immunization with 
p35-55/CFA. Both B6 and CD40 DC consistently con-
ferred a degree of protection against EAE compared to 
mice that did not receive DC. However, CD401 DC 
clearly gave a more pronounced protection than B6 DC 
(Fig. 6). 
3 Discussion 
Presentation of peptide-MHC complexes by resting DC 
is generally accepted to be the key to I cell tolerance 
induction [22]. The rapid activation and proliferation of 
Ag-reactive I cells that is consistently reported after sol-
uble peptide administration [23-25] suggests that the ini-
tial interaction between CD28 and CD80/86 is not dis-
rupted on route to tolerance. This is consistent with 
reports that the CD28-CD80/86 interaction is required for 
initial T cell activation, but that other receptor-ligand 
interactions are important in sustaining T cell expansion 
[26]. In contrast, exogenous stimulation of CD40 (using 
agonistic anti-CD40) can convert an Ag-specific inter-
vention that would otherwise lead to tolerance into one 
that produces immunity [14, 15]. If CD40 truly is a crucial 
checkpoint between tolerance and immunity, administra-
tion of Ag-loaded APC that lack CD40 ought to lead to I 
cell tolerance. Alloantigen-specific tolerance has been 
reported after iv. injection of either CD40 B cells into 
wild-type allogeneic hosts [27], or CD40' allogeneic B 
cells into CD40L hosts [28]. However, the ability of 
CD40 DC to induce T cell tolerance after systemic 
administration had not been formally tested. Our data 
show that this approach leads to an abortive activation 
of Ag-reactive T cells that ultimately leads to an unre-
sponsive state similar to that seen after systemic admir,- 
istration of peptide in solution. Moreover, administration 
of p35-55-loaded CD40 DC rendered mice resistant to 
subsequent attempts to induce EAE. 
Previous studies have shown that ligation of CD40 leads 
to up-regulation of CD80 and CD86 by DC [7]. It is impor -
tant to note that the splenic DC used for this study 
expressed high levels of both CD80 and CD86. We do 
not therefore believe that the failure of the CD40 DC to 
provoke a sustained T cell expansion in vivo stems from 
insufficient CD28 signaling. Instead our results support a 
model of tolerance induction in which failure to provide 
sufficient ligation of CD40 on DC uncouples downstream 
T ceII:DC dialogue involving other members of the TNF 
and TNF receptor families. Efficient CD40 ligation drives 
the up-regulation of OX40L by the DC [10], allowing liga-
tion of 0X40 that is up-regulated by the T cell following 
activation through the TCR. 0X40 signaling results in 
accumulation of the anti-apoptotic proteins BcI-2 and 
BcI-xL promoting T cell survival [19]. Moreover, exoge-
nous ligation of OX40 on T cells can override the tolero-
genic program that follows soluble peptide administra-
tion, allowing T cells to remain Ag-responsive ([20], and 
our own unpublished observations). We found here that 
administration of Ag-loaded CD40 DC under the cover 
of agonistic anti-0X40 did not lead to an expansion of 
Ag-reactive T cells. However, provision of anti-0X40 did 
allow for the development of a productive immune 
response upon subsequent immunization with Ag/CFA. 
Therefore 0X40 signaling appears to prevent the toler -
ance program, but does not in itself promote full T cell 
responsiveness. 
Our finding that CD40 DC were unable to support a 
sustained I cell expansion compared with their CD40-
sufficient counterparts is consistent with an earlier study 
in which DC were administered by a s.c. route [17]. This 
previous study, however, did not report any unrespon-
siveness in the Ag-reactive I cells that persisted after 
CD40 DC administration. The obvious difference 
between these two studies is that we deliberately chose 
to give our DC i.v., allowing access to the spleen, based 
on our previous experience that systemic delivery is 
most effective at inducing T cell tolerance with peptide 
[29]. Inefficient I cell priming after s.c. injection of 
CD40 DC has been reported to be associated with their 
accelerated loss from the draining lymph node. Studies 
of tolerance induction with peptides indicate that, whilst 
establishment of a fully unresponsive state takes 4 to 
5 days [30], the key events that initiate the tolerogenic 
program probably occur within hours of TCR recognition 
[25, 31]. This being the case, we would argue that the 
issue of how many days B6 versus CD40 DC persist in 
the spleen after i.v. administration is unlikely to be the 
key to the T cell unresponsiveness we observe. 
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Our results suggest that the decreased IL-2 production 
in T cells stimulated with CD40 DC leads to an abortive 
immune response, and T cell death. This is supported by 
the sudden decrease in Ag-reactive T cells 4 days after 
priming with CD404 DC. Consistent with inducing a 
form of deletional tolerance, administration of CD404 
DC protected from EAE. This matches a recent report in 
which administration of Ag-loaded RelB DC, which , 
also lack CD404 expression, induced Ag-specific T cell 
tolerance [32]. However, this study reported the induc-
tion of an IL-i 0-producing regulatory T cell population. It 
is unlikely that this explains the protection against EAE 
we observe, since CD404 DC did not induce an IL-b-
producing T cell population in our OT-Il adoptive transfer 
system. Interestingly, although pOVA-pulsed B6 DC did 
not appear to result in decreased proliferative capacity 
upon rechallenge, giving p35-55-pulsed B6 DC prior to 
EAE induction consistently gave some protection from 
disease. T cells can become exhausted upon repeated 
Ag-stimulation [33], resulting in reduced capacity to 
respond to rechallenge. Administration of B6 DC and 
subsequent challenge with a strong adjuvant such as 
CFA may therefore drive some high avidity self-reactive T 
cells into activation-induced cell death, reducing the 
ability to induce disease. Bone marrow-derived CD40 
DC also lead to T cell unresponsiveness in vivo (data not 
shown), suggesting the use of cultured "tolerogenic" DC 
as a possible therapeutic approach in man. 
Various mechanisms exist in the periphery in order to 
maintain T cell tolerance, and avoid autoimmune dis-
eases. The idea that regulation of CD40 expression 
might represent a general mechanism of maintaining 
peripheral tolerance is an attractive one, and is sup-
ported by an increasing amount of data. Interference 
with the CD40:CD40L interaction using blocking anti-
CD40L prevents effective T cell priming, sometimes 
leading to a tolerant state [28, 34, 35]. Recent data have 
shown that in the absence of inflammatory stimuli/n vivo, 
DC play an important role in the maintenance of periph-
eral tolerance [22, 36-38]. The ability of DC to induce tol-
erance or immunity appears to depend on their matura-
tion stage [39, 40]. Unmanipulated DC in vivo express lit-
tle CD40 [6, 41], and DC constitutively take up Ag in the 
periphery and present them to T cells in lymphoid organs 
in a tolerogenic fashion, which can be converted into 
immunogenic presentation after DC activation through 
CD40 [14, 16]. Our results clearly show that CD40 DC 
provoke a proliferative burst in Ag-reactive T cells that 
lasts for 3 days. Several studies using the transfer of 
TCR-transgenic T cells into hosts that also express a 
transgenic Ag have shown an initial T cell expansion 
prior to the development of unresponsiveness [42-44]. 
This presumably is due to presentation of Ag by resting 
DC in the lymphoid organs draining the organ that 
expresses the transgenic Ag. Also it is clear from studies 
of tolerance induction with soluble Ag (another situation 
in which the Ag should be presented by resting DC) that 
transient T cell proliferation is intrinsic to the tolerance 
program [24, 25]. Therefore the initial proliferation we see 
using CD404 DC fits with other experimental systems 
that lead to T cell tolerance. 
In summary we show that the systemic administration of 
Ag-loaded CD40 DC leads to abortive T cell activation 
and subsequent unresponsiveness reminiscent of that 
seen after systemic administration of soluble peptide Ag. 
This approach was robust enough to provide effective 
protection against CNS autoimmunity. These data pro-
vide insights into the effects of DC that may lead to the 
use of costimulation-deficient DC as a future therapeutic 
approach. 
4 Materials and methods 
4.1 Mice, Ag, immunizations and reagents 
C57BL/6 (1216), CD40 (1­12b) [45], B6 Ly5.1 congenic mice 
and OT-Il mice expressing an Abrestricted,  transgenic 
pOVA-reactive TCR [18] were bred at the Institute of Cell, 
Animal and Population Biology, University of Edinburgh. 0T-
IIxCD40 mice were generated by back-crossing OT-Il with 
CD40 mice. Similarly, OT-IIxLy5.1 mice were generated by 
crossing OT-Il mice with Ly5.11 mice. Sex-matched, 6-8-
week-old mice were used for all experiments. 
Peptides (pOVA and p35-55) were synthesized by the 
Advanced Biotechnology Centre, Imperial College London. 
For experiments analyzing T cell activation, mice were 
immunized s.c. with 20 jig pOVA emulsified in CFA (Sigma, 
Poole, GB). After 10 days, spleens and draining inguinal and 
popliteal LN were removed, disaggregated and used as a 
source of primed lymphoid populations. Tissue culture 
medium was RPMI 1640 medium containing 2 mM L-
glutamine, 5x10 M 2-ME, 100 ig/ml penicillin, 100 U/mI 
streptomycin (all from Gibco, Life Technologies, Paisley, GB) 
(RPM I) supplemented with a source of serum. The OX-86 
hybridoma, that produces anti-0X40, and the MAC-49 iso-
type control hybridoma were obtained from the European 
Collection of Cell Culture (ECACC, Wiltshire, GB). 
4.2 Isolation of DC and naive T cell populations 
CD4 T cells were isolated by positive selection from LN and 
spleen of naive OT-IIxCD40 mice using anti-CD4-
conjugated MACS beads (Miltenyi Biotec, Bisley, GB), 
according to the manufacturers instructions. Splenic DC 
were isolated from naive B6 or CD40 mice by initial diges-
tion in 10 ml RPMI without serum, supplemented with 
2.4 mg/mI collagenase D (Worthington Biochemical) and 
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1 mg/mI DNase (Sigma) for 30 min at 37°C. CD11c cells 
were isolated by positive selection using anti-CD11c-
conjugated MACS beads (Miltenyi Biotec), according to the 
manufacturers instructions, with a consistent purity of 
>85% CD1 1 c*  as confirmed by flow cytometry. 
4.3 In vitro assays of primary T cell activation 
Ag-loaded DC were prepared by incubation with 50 iM 
pOVA in RPMI plus 1% normal mouse serum at 37°C for 2 h 
in the presence of 0.1 tg/ml LPS (Sigma). Naive OT-
llxCD40 T cells were labeled with 5 .tM CFSE (Molecular 
Probes), prior to culture with pOVA-loaded DC (4x10 4 T cells 
+ 4x103 DC per well) in 96-well flat-bottom plates (Becton 
Dickinson) using RPMI + 5% FCS. Cells were harvested for 
FACS analysis as described in the figure legends. 
4.4 Cell transfers 
DC were purified from naive B6 or CD40 mice as 
described above and pulsed with either pOVA or p35-55 
(50 tM) in the presence of LPS as above for 2 h prior to i.v. 
injection into B6 recipients (500 5 DC/mouse). Some mice 
also received 200 tg anti-0X40 on the day of DC injection 
and 2 days later, as indicated. For T cell transfers, single cell 
suspensions were prepared from LN of naive OT-Il or OT-
llxLy5.1 donor mice. In some cases, LN cells from naive OT-
II mice were labeled with CFSE as above before 5x10 6 cells 
were injected i.v. into syngeneic B6 recipients. 
4.5 Flow cytometric analysis 
All samples were incubated with the 2.4.G2 anti-Fc receptor 
antibody to prevent nonspecific binding via Fc receptors, 
prior to incubations with other antibodies. All samples were 
collected on a Becton Dickinson FACScan (Mountain View, 
CA) flow cytometer and analyzed using FlowJo Software 
(TreeStar, USA). All antibodies were obtained from BD Phar-
Mingen (Oxford, GB) unless stated otherwise. DC purity was 
assessed with FITC-conjugated anti-CD1 1 c. Costimulatory 
molecules on DC were identified using biotinylated primary 
antibodies specific for CD80, CD86, CD40, or OX40L, fol-
lowed by streptavidin-allophycocyanin conjugate. 
In experiments involving transfer of OT-Il LNC the pOVA-
reactive I cells were identified using biotinylated anti-V5 
followed by allophycocyanin- or FITC-conjugated streptavi-
din and PE-conjugated anti-Va2. Transferred OT-lIxLy5.1 
cells were identified using allophycocyanin-conjugated anti-
CD4 together with FITC-conjugated anti-Ly5.1 . T cell activa-
tion was assessed using biotinylated anti-CD69, anti-CD25, 
or anti-0X40, all followed by allophycocyanin-conjugated 
streptavidin. 
Intracellular cytokine production was measured ex vivo in 
splenocytes by flow cytometric staining as described [46]. 
Briefly, splenocytes were stimulated with PMPiionomycin in 
the presence of GolgiStop (BD PharMingen) for 4 h at 37°C, 
before staining with biotinylated anti-V05 followed by 
allophycocyanin-conjugated streptavidin, and FITC-
conjugated anti-Vcz2, or al lophycocyan i n-conju gated anti-
CD4 together with FITC-conjugated anti-Ly5.1, as indicated. 
Cells were then fixed for 20 min on ice, washed with cyto-
perm wash buffer (BD PharMingen) and stained with PE-
conjugated anti-IL-2, anti-IL-4, anti-IL-lO or anti-IFN-y for 
30 min on ice. 
4.6 Recall proliferation assays 
Lymphoid cell suspensions were cultured in 96-well flat-
bottom microtiter plates (Becton Dickinson) at 600 5 LN 
cells/well or 8x10 5 spleen cells/well using X-vivo15 serum-
free medium (BioWhittaker, Maidenhead, GB) supplemented 
with 2 mM L-glutamine and 5x10 5 M 2-ME. Cultures were 
stimulated with a dose range of pOVA or p35-55 for 48 h 
prior to addition of rH]dThd (0.5 iCi/well). After a further 
18 h, cultures were harvested and dThd incorporation mea-
sured using a liquid scintillation j-counter 1alIac). Results 
are expressed as mean cpm of triplicate cultures. In some 
experiments, spleen cells were labeled with CFSE as above 
and stimulated for 72 h with 1 tM pOVA before flow cyto-
metric assessment of proliferation. 
4.7 Induction and assessment of EAE 
EAE was induced with s.c. injection of 100 ig p35-55 in a 
total of 100 jil CFA containing 1 mg heat-killed Mycobacte-
rium tuberculosis (50 I into each hind leg). Mice also 
received 200 ng pertussis toxin (ECACC) i.p. in 0.5 ml PBS 
on the same day and 2 days later. Clinical signs of EAE were 
assessed using the following scoring index: 0, no signs; 1, 
flaccid tail: 2, impaired righting reflex and/or impaired gate; 
3, partial hind leg paralysis; 4, total hind leg paralysis; 5, hind 
and fore leg paralysis; 6, moribund or dead. Differences in 
total disease burden between groups were determined 
using the Mann-Whitney U test. 
Acknowledgements: We thank Dr. A. MacDonald for help-
ful comments in the preparation of this manuscript. This 
work was supported by grants from the Medical Research 
Council UK and the Weilcome Trust. S.M.A. is an MRC 
research fellow. 
References 
1 Banchereau, J. and Steinman, A. M., Dendritic cells and the 
control of immunity. Nature 1998. 392:245-252. 
2 Jenkins, M. K., Khoruts, A., Ingulli, E., Mueller, D. L, 
McSorley, S. J., Reinhardt, R. L, Itano, A. and Pape, K. A., In 
vivo activation of antigen-specific CD4 I cells. Annu. Rev. Immu-
no!. 2001. 19: 23-45. 
0 2004 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim 	 www.eji.de 
Eur. J. Immunol. 2004.34: 990-998 
	
T cell tolerance in the absence of CD40 	997 
3 Anderton, S. M., Peptide-based immunotherapy of autoimmu-
nity: a path of puzzles, paradoxes and possibilities. Immunology 
2001. 104:367-376. 
4 Flores-Romo, L, In vivo maturation and migration of dendritic 
cells. Immunology 2001 102: 255-262. 
5 Vremec, D. and Shortman, K., Dendritic cell subtypes in mouse 
lymphoid organs: cross-correlation of surface markers, changes 
with incubation, and differences among thymus, spleen, and 
lymph nodes. J. Immunol. 1997. 159: 565-573. 
6 Inaba, K., Witmer-Pack, M., Inaba, M., Hathcock, K. S., 
Sakuta, H., Azuma, M., Yagita, H., Okumura, K., Linsley, P. S., 
Ikehara, S. et al., The tissue distribution of the 87-2 costimulator 
in mice: abundant expression on dendritic cells in situ and during 
maturation in vitro. J. Exp. Med. 1994. 180:1849-1860. 
7 Yang, Y. and Wilson, J. M., CD40 ligand-dependent T cell acti-
vation: requirement of 137-CD28 signaling through CD40. Science 
1996. 273:1862-1864. 
8 Brocker, T., Guibranson Judge, A., Flynn, S., Riedinger, M., 
Raykundalia, C. and Lane, P., CD4 T cell traffic control: in vivo 
evidence that ligation of 0X40 on CD4 T cells by 0X40-ligand 
expressed on dendritic cells leads to the accumulation of CD4 T 
cells in B follicles. Eur. J. Immunol. 1999. 29: 1610-1616. 
9 CelIa, M., Scheidegger, D., Palmer-Lehmann, K., Lane, P., 
Lanzavecchia, A. and Alber, G., Ugation of CD40 on dendritic 
cells triggers production of high levels of interleukin-12 and 
enhances T cell stimulatory capacity: T-T help via APC activation. 
J. Exp. Med. 1996. 184: 747-752. 
10 Fillatreau, S. and Gray, D., T cell accumulation in B cell follicles 
is regulated by dendritic cells and is independent of B cell activa-
tion. J. Exp. Med. 2003. 197:195-206. 
11 Xu, J., Foy, T. M., Laman, J. D., Elliott, E. A., Dunn, J. J., 
Waldschmidt, T. J., Elsemore, J., Noelle, R. J. and Flavell, R. 
A., Mice deficient for the CD40 ligand. Immunity 1994. 1: 
423-431. 
12 Grewal, I. S., Xu, J. and Flavell, R. A., Impairment of antigen-
specific T cell priming in mice lacking CD40 ligand. Nature 1995. 
378: 617-620. 
13 Castigli, E., Alt, F. W., Davidson, L., Bottaro, A., Mizoguchi, E., 
Bhan, A. K. and Geha, R. S., CD40-deficient mice generated by 
recombination-activating gene-2-deficient blastocyst comple-
mentation. Proc. NatI. Acad. Sci. USA 1994. 91: 12135-12139. 
14 Hawiger, D., Inaba, K., Dorsett, Y., Guo, M., Mahnke, K., 
Rivera, M., Ravetch, J. V., Steinman, R. M. and Nussenzweig, 
M. C., Dendritic cells induce peripheral T cell unresponsiveness 
under steady state conditions in vivo. J. Exp. Med. 2001. 194: 
769-780. 
15 Diehl, L., den Boer, A. T., Schoenberger, S. P., van der Voort, E. 
I., Schumacher, T. N., Melief, C. J., Offringa, A. and Toes, A. E., 
CD40 activation in vivo overcomes peptide-induced peripheral 
cytotoxic T-lymphocyte tolerance and augments anti-tumor vac-
cine efficacy. Nat. Med. 1999. 5: 774-779. 
16 Maxwell, J. R., Campbell, J. D., Kim, C. H. and Vella, A. T., 
CD40 activation boosts T cell immunity in vivo by enhancing T 
cell clonal expansion and delaying peripheral T cell deletion. J. 
Immunol. 1999. 162: 2024-2034. 
17 Miga, A. J., Masters, S. A., Durell, B. G., Gonzalez, M., 
Jenkins, M. K., Maliszewskl, C., Kikutani, H., Wade, W. F. and 
Noelle, R. J., Dendritic cell longevity and T cell persistence is 
controlled by CD154-CD40 interactions. Eur. J. Immunol. 2001. 
31: 959-965. 
18 Barnden, M. J., Allison, J., Heath, W. R. and Carbone, F. R., 
Defective 7CR expression in transgenic mice constructed using 
cDNA-based alpha- and beta-chain genes under the control of 
heterologous regulatory elements. Immunol. Cell Biol. 1998. 76: 
34-40. 
19 Rogers, P. R., Song, J., Gramaglia, I., Killeen, N. and Croft, M., 
0X40 promotes Bcl-xL and Bcl-2 expression and is essential for 
long-term survival of CD4 T cells. Immunity 2001. 15: 445-455. 
20 Bansal-Pakala, P., Jember, A. G. and Croft, M., Signaling 
through 0X40 (CD1 34) breaks peripheral T cell tolerance. Nat. 
Med. 2001. 7:907-912. 
21 Mendel, I., Kerlero de Rosbo, N. and Ben-Nun, A., A myelin oh-
godendrocyte glycoprotein peptide induces typical chronic 
experimental autoimmune encephalomyelitis in H-2b mice: fine 
specificity and T cell receptor V beta expression of encephalito-
genicT cells. Eur. J. Immunol. 1995. 25: 1951-1959. 
22 Steinman, A. M. and Nussenzweig, M. C., Avoiding horror 
autotoxicus: the importance of dendntic cells in peripheral T cell 
tolerance. Proc. NatI. Acad. Sd. USA 2002. 99: 351-358. 
23 Keamey, E. A., Pape, K. A., Loh, D. Y. and Jenkins, M. K., Visu-
alization of peptide-specific T cell immunity and peripheral toler-
ance induction in vivo. Immunity 1994. 1: 327-339. 
24 Swier, S. K., Wallner, B. P., Bnner, T. J., Sunshine, G. H., 
Bourque, C. A. and Luqman, M., Bolus injection of aqueous 
antigen leads to a high density of T cell-receptor ligand in the 
spleen, transient T cell activation and anergy induction. Immunol-
ogy 1998. 94: 51 3-522. 
25 Hoyne, G. F., Askonas, B. A., Heizel, C., Thomas, W. A. and 
Lamb, J. R., Regulation of house dust mite responses by intrana-
sally administered peptide: transient activation of CD4 T cells 
precedes the development of tolerance in vivo. Int. Immunol. 
1996. 8: 335-342. 
26 Howland, K. C., Ausubel, L. J., London, C. A. and Abbas, A. K., 
The roles of CD28 and CD40 ligand in I cell activation and toler-
ance. J. Immunol. 2000. 164: 4465-4470. 
27 Hollander, G. A., Castigli, E., Kulbacki, R., Su, M., Burakoff, S. 
J., Gutierrez-Ramos, J. C. and Geha, R. S., Induction of 
alloantigen-specific tolerance by B cells from CD40-deficient 
mice. Proc. NatI. Acad. Sci. USA 1996. 93: 4994-4998. 
28 Buhlmann, J. E., Foy, T. M., Aruffo, A., Crassi, K. M., Ledbet-
ter, J. A., Green, W. R., Xu, J. C., Shultz, L. D., Roopesian, D., 
Flavell, R. A. et al., In the absence of a CD40 signal, B cells are 
tolerogenic. Immunity 1995. 2: 645-653. 
29 Anderton, S. M., Burkhart, C., Liu, G. Y., Melzler, B. and 
Wraith, D. C., Antigen-specific tolerance induction and the 
immunotherapy of experimental autoimmune disease. Novartis 
Found. Symp. 1998. 215: 120-131; discussion 131-126, 
186-190. 
30 Liu, G. Y. and Wraith, D. C., Affinity for class II MHC determines 
the extent to which soluble peptides tolenze autoreactive T cells 
in naive and primed adult mice - implications for autoimmunity. 
Int. Immunol. 1995. 7: 1255-1263. 
31 Zell, T., Khoruts, A., Ingulli, E., Bonnevier, J. L., Mueller, D. L. 
and Jenkins, M. K., Single-cell analysis of signal transduction in 
CD4 T cells stimulated by antigen in vivo. Proc. NatI. Acad. Sd. 
USA 2001. 98:10805-10810. 
32 Martin, E., O'Sullivan, B., Low, P. and Thomas, R., Antigen-
specific suppression of a primed immune response by dendritic 
cells mediated by regulatory T cells secreting interleukin-lO. 
Immunity 2003. 18: 155-167. 
33 Lenardo, M., Chan, K. M., Homung, F., McFarland, H., Siegel, 
R., Wang, J. and Zheng, L, Mature T lymphocyte apoptosis-
immune regulation in a dynamic and unpredictable antigenic 
environment. Annu. Rev. Immunol. 1999. 17: 221-253. 
© 2004 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim 	 www.eji.de 
998 	K. Hochweller and S. M. Anderton 
	
Eur. J. Immunol. 2004.34:990-998 
34 Honey, K., Cobbold, S. P. and Waldmann, H., CD40 ligand 
blockade induces CD4 T cell tolerance and linked suppression. 
J. Immunol. 1999. 163: 4805-4810. 
35 Tang, A., Judge, T. A. and Turka, L.A., Blockade of CD40-CD40 
ligand pathway induces tolerance in murine contact hypersensi-
tivity. Eur. J. Immuno!. 1997. 27: 3143-3150. 
36 Hernandez, J., Aung, S., Redmond, W. L and Sherman, L. A., 
Phenotypic and functional analysis of C08(+) T cells undergoing 
peripheral deletion in response to cross-presentation of self-
antigen. J. Exp. Med. 2001. 194: 707-718. 
37 Belz, G. T., Behrens, G.M., Smith, C. M., Miller, J. F., Jones, C., 
Lejon, K., Fathman, C. G., Mueller, S. N., Shortman, K., 
Carbone, F. R. and Heath, W. R., The CD8alpha(+) dendritic cell 
is responsible for inducing peripheral self-tolerance to tissue-
associated antigens. J. Exp. Med. 2002. 196:1099-1104. 
38 Scheinecker, C., McHugh, R., Shevach, E. M. and Germain, R. 
N., Constitutive presentation of a natural tissue autoantigen 
exclusively by dendritic cells in the draining lymph node. J. Exp. 
Med. 2002. 196: 1079-1090. 
39 Dhodapkar, M. V., Steinman, A. M., Krasovsky, J., Munz, C. 
and Bhardwaj, N., Antigen-specific inhibition of effector T cell 
function in humans after injection of immature dendritic cells. J. 
Exp. Med. 2001. 193: 233-238. 
40 Jonuleit, H., Schmitt, E., Schuler, G., Knop, J. and Enk, A. H., 
Induction of interleukin 10-producing, nonproliferating CD4(+) T 
cells with regulatory properties by repetitive stimulation with allo-
geneic immature human dendritic cells. J. Exp. Med. 2000. 192: 
1213-1222. 
41 Schulz, 0., Edwards, D. A., Schito, M., Aliberti, J., Manick-
asingham, S., Sher, A. and Reis e Sousa, C., CD40 triggering of 
heterodimeric lL-12 p70 production by dendritic cells in viva 
requires a microbial priming signal. Immunity 2000. 13:453-462. 
42 Morgan, D. J., Kreuwel, H. T. and Sherman, L.A., Antigen con-
centration and precursor frequency determine the rate of CD8' T 
cell tolerance to peripherally expressed antigens. J. Immunol. 
1999. 163: 723-727. 
43 Huang, C. T., Huso, D. L., Lu, Z., Wang, T., Zhou, G., Kennedy, 
E. P., Drake, C. G., Morgan, D. J., Sherman, L. A., Higgins, A. 
D., Pardoll, D. M. and Adler, A. J., CD4 T cells pass through an 
effector phase during the process of in viva tolerance induction. 
J. Immuno!. 2003. 170: 3945-3953. 
44 Tanchot, C., Barber, D. L., Chiodetti, L. and Schwartz, R. H., 
Adaptive tolerance of CD4 T cells in vivo: multiple thresholds in 
response to a constant level of antigen presentation. J. Immunol. 
2001. 167:2030-2039. 
45 Kawabe, T., Naka, T., Yoshida, K., Tanaka, T., Fujiwara, H., 
Suematsu, S., Yoshida, N., Kishimoto, T. and Kikutani, H., The 
immune responses in CD40-deficient mice: impaired immuno-
globulin class switching and germinal center formation. Immunity 
1994. 1:167-178. 
46 Openshaw, P., Murphy, E. E., Hosken, N. A., Maino, V., Davis, 
K., Murphy, K. and O'Garra, A., Heterogeneity of intracellular 
cytokine synthesis at the single-cell level in polarized T helper 1 
and Thelper2 populations. J. Exp. Med. 1995.182:1357-1367. 
Correspondence: Stephen M. Anderton, University of Edin-
burgh, ICAPB, King's Buildings, West Mains Road, Edin-
burgh EH9 3JT, GB 
Fax: +44-131-650-7322 
e-mail: steve.anderton@ed.ac.uk  
0 2004 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim 	 www.eji.de 
